

**PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS
OF USING THE SAME**

RELATED APPLICATIONS

This application claims priority to U.S.S.N. 60/262,454 (Attorney Ref.: 21402-250), filed January 18, 2001; U.S.S.N. 60/272,920 (Attorney Ref.: 21402-250G1), filed March 2, 2001; U.S.S.N. 60/284,549 (Attorney Ref.: 21402-250G2), filed April 18, 2001; U.S.S.N. 60/303,229 (Attorney Ref.: 21402-250G3), filed July 5, 2001; U.S.S.N. 60/262,892 (Attorney Ref.: 21402-251), filed January 19, 2001; U.S.S.N. 60/263,605 (Attorney Ref.: 21402-252), filed January 23, 2001, U.S.S.N. 60/269,098 (Attorney Ref.: 21402-252A), filed February 15, 2001, U.S.S.N. 60/264,159 (Attorney Ref.: 21402-254), filed January 25, 2001, U.S.S.N. 60/265,517 (Attorney Ref.: 21402-259), filed January 31, 2001, U.S.S.N. 60/271,855 (Attorney Ref.: 21402-259B) filed February 27, 2001, U.S.S.N. 60/267,057 (Attorney Ref.: 21402-266), filed February 7, 2001, and U.S.S.N. 60/286,287 (Attorney Ref.: 21402-250G2 REV), filed April 25, 2001, each of which is incorporated by reference in its entirety.

FIELD OF THE INVENTION

The invention relates to polynucleotides and the polypeptides encoded by such polynucleotides, as well as vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using the same.

BACKGROUND OF THE INVENTION

The present invention is based in part on nucleic acids encoding proteins that are new members of the following protein families: delta serrate ligand receptors, protein kinases, G-protein coupled receptors (GPCR), ankyrin repeat containing proteins, TNF intracellular domain interacting proteins, secretory proteins and dual specificity phosphatases. More particularly, the invention relates to nucleic acids encoding novel polypeptides, as well as vectors, host cells, antibodies, and recombinant methods for producing these nucleic acids and polypeptides.

SUMMARY OF THE INVENTION

The invention is based in part upon the discovery of nucleic acid sequences encoding novel polypeptides. The novel nucleic acids and polypeptides are referred to herein as NOVX, or

NOV1, NOV2, NOV3, NOV4, NOV5, NOV6, NOV7, NOV8, and NOV9 nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as "NOVX" nucleic acid or polypeptide sequences.

5 In one aspect, the invention provides an isolated NOVX nucleic acid molecule encoding a NOVX polypeptide that includes a nucleic acid sequence that has identity to the nucleic acids disclosed in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29. Protein phosphorylation is a fundamental process for the regulation of cellular functions. The coordinated action of both protein kinases and phosphatases controls the levels of phosphorylation and, hence, the activity of specific target proteins. One of the predominant roles of protein phosphorylation is in signal transduction, where extracellular signals are amplified and propagated by a cascade of protein phosphorylation and dephosphorylation events. Eukaryotic protein kinases are enzymes that belong to a very extensive family of proteins which share a conserved catalytic core common with both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. In the N-terminal extremity of the catalytic domain there is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. In the central part of the catalytic domain there is a conserved aspartic acid residue which is important for the catalytic activity of the enzyme. In some embodiments, the NOVX nucleic acid molecule will hybridize 10 under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule that includes a protein-coding sequence of a NOVX nucleic acid sequence. The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, 15 analog or derivative thereof. For example, the nucleic acid can encode a polypeptide at least 80% identical to a polypeptide comprising the amino acid sequences of SEQ ID NOS:2, 4, 6, 8, 10, 12, 20 14, 16, 18, 20, 22, 24, 26, 28 and 30. The nucleic acid can be, for example, a genomic DNA 25 fragment or a cDNA molecule that includes the nucleic acid sequence of any of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29.

Also included in the invention is an oligonucleotide, *e.g.*, an oligonucleotide which includes at least 6 contiguous nucleotides of a NOVX nucleic acid (*e.g.*, SEQ ID NOS:1, 3, 5, 7, 30 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29) or a complement of said oligonucleotide. Also included in the invention are substantially purified NOVX polypeptides (SEQ ID NOS:2, 4, 6, 8,

10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30). In certain embodiments, the NOVX polypeptides include an amino acid sequence that is substantially identical to the amino acid sequence of a human NOVX polypeptide.

5 The invention also features antibodies that immunoselectively bind to NOVX polypeptides, or fragments, homologs, analogs or derivatives thereof.

In another aspect, the invention includes pharmaceutical compositions that include therapeutically- or prophylactically-effective amounts of a therapeutic and a pharmaceutically-acceptable carrier. The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or an antibody specific for a NOVX polypeptide. In a further aspect, the invention includes, in one or more containers, a therapeutically- or prophylactically-effective amount of this pharmaceutical composition.

In a further aspect, the invention includes a method of producing a polypeptide by culturing a cell that includes a NOVX nucleic acid, under conditions allowing for expression of the NOVX polypeptide encoded by the DNA. If desired, the NOVX polypeptide can then be recovered.

15 In another aspect, the invention includes a method of detecting the presence of a NOVX polypeptide in a sample. In the method, a sample is contacted with a compound that selectively binds to the polypeptide under conditions allowing for formation of a complex between the polypeptide and the compound. The complex is detected, if present, thereby identifying the 20 NOVX polypeptide within the sample.

The invention also includes methods to identify specific cell or tissue types based on their expression of a NOVX.

25 Also included in the invention is a method of detecting the presence of a NOVX nucleic acid molecule in a sample by contacting the sample with a NOVX nucleic acid probe or primer, and detecting whether the nucleic acid probe or primer bound to a NOVX nucleic acid molecule in the sample.

30 In a further aspect, the invention provides a method for modulating the activity of a NOVX polypeptide by contacting a cell sample that includes the NOVX polypeptide with a compound that binds to the NOVX polypeptide in an amount sufficient to modulate the activity of said polypeptide. The compound can be, *e.g.*, a small molecule, such as a nucleic acid, peptide,

polypeptide, peptidomimetic, carbohydrate, lipid or other organic (carbon containing) or inorganic molecule, as further described herein.

Also within the scope of the invention is the use of a therapeutic in the manufacture of a medicament for treating or preventing disorders or syndromes including, *e.g.*, trauma,

5 regeneration (in vitro and in vivo), viral/bacterial/parasitic infections, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, stroke, Tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, multiple sclerosis, Ataxia-telangiectasia, leukodystrophies, behavioral disorders, addiction, anxiety, pain, actinic keratosis, acne, hair growth diseases, alopecia, pigmentation disorders, endocrine disorders, connective tissue disorders, such as severe neonatal Marfan syndrome, dominant ectopia lentis, familial ascending aortic aneurysm, isolated skeletal features of Marfan syndrome, Shprintzen-Goldberg syndrome, genodermatoses, contractual arachnodactyly, inflammatory disorders such as osteo- and rheumatoid-arthritis, inflammatory bowel disease, Crohn's disease; immunological disorders, AIDS; cancers including but not limited to lung cancer, colon cancer, neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer, leukemia or pancreatic cancer; blood disorders; asthma; psoriasis; vascular disorders, hypertension, skin disorders, renal disorders including Alport syndrome, immunological disorders, tissue injury, fibrosis disorders, bone diseases, Ehlers-Danlos syndrome type VI, VII, type IV, S-linked cutis laxa and Ehlers-Danlos syndrome type V, osteogenesis imperfecta, neurologic diseases, brain and/or autoimmune disorders like encephalomyelitis, neurodegenerative disorders, immune disorders, hematopoietic disorders, muscle disorders, inflammation and wound repair, bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, treatment of Albright hereditary osteodystrophy, angina pectoris, myocardial infarction, ulcers, benign prostatic hypertrophy, 20 arthrogryposis multiplex congenita, osteogenesis imperfecta, keratoconus, scoliosis, duodenal atresia, esophageal atresia, intestinal malrotation, pancreatitis, obesity systemic lupus erythematosus, autoimmune disease, emphysema, scleroderma, allergy, ARDS, neuroprotection, fertility Myasthenia gravis, diabetes, obesity, growth and reproductive disorders hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host, 25 adrenoleukodystrophy, congenital adrenal hyperplasia, endometriosis, xerostomia, ulcers, cirrhosis, transplantation, diverticular disease, Hirschsprung's disease, appendicitis, arthritis,

5 ankylosing spondylitis, tendinitis, renal artery stenosis, interstitial nephritis, glomerulonephritis, polycystic kidney disease, erythematosus, renal tubular acidosis, IgA nephropathy, anorexia, bulimia, psychotic disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease and/or other pathologies and disorders of the like.

10 The therapeutic can be, *e.g.*, a NOVX nucleic acid, a NOVX polypeptide, or a NOVX-specific antibody, or biologically-active derivatives or fragments thereof.

15 For example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The polypeptides can be used as immunogens to produce antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding NOVX may be useful in gene therapy, and NOVX may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

20 The invention further includes a method for screening for a modulator of disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like. The method includes contacting a test compound with a NOVX polypeptide and determining if the test compound binds to said NOVX polypeptide. Binding of the test compound to the NOVX polypeptide indicates the test compound is a modulator of activity, or of latency or predisposition to the aforementioned disorders or syndromes.

25 Also within the scope of the invention is a method for screening for a modulator of activity, or of latency or predisposition to disorders or syndromes including, *e.g.*, the diseases and disorders disclosed above and/or other pathologies and disorders of the like by administering a test compound to a test animal at increased risk for the aforementioned disorders or syndromes. The test animal expresses a recombinant polypeptide encoded by a NOVX nucleic acid. Expression or activity of NOVX polypeptide is then measured in the test animal, as is expression or activity of the protein in a control animal which recombinantly-expresses NOVX polypeptide and is not at increased risk for the disorder or syndrome. Next, the expression of NOVX polypeptide in both the test animal and the control animal is compared. A change in the activity

of NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of the disorder or syndrome.

In yet another aspect, the invention includes a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide, a NOVX nucleic acid, or both, in a subject (e.g., a human subject). The method includes measuring the amount of the NOVX polypeptide in a test sample from the subject and comparing the amount of the polypeptide in the test sample to the amount of the NOVX polypeptide present in a control sample. An alteration in the level of the NOVX polypeptide in the test sample as compared to the control sample indicates the presence of or predisposition to a disease in the subject. Preferably, the predisposition includes, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like. Also, the expression levels of the new polypeptides of the invention can be used in a method to screen for various cancers as well as to determine the stage of cancers.

In a further aspect, the invention includes a method of treating or preventing a pathological condition associated with a disorder in a mammal by administering to the subject a NOVX polypeptide, a NOVX nucleic acid, or a NOVX-specific antibody to a subject (e.g., a human subject), in an amount sufficient to alleviate or prevent the pathological condition. In preferred embodiments, the disorder, includes, e.g., the diseases and disorders disclosed above and/or other pathologies and disorders of the like.

In yet another aspect, the invention can be used in a method to identify the cellular receptors and downstream effectors of the invention by any one of a number of techniques commonly employed in the art. These include but are not limited to the two-hybrid system, affinity purification, co-precipitation with antibodies or other specific-interacting molecules.

NOVX nucleic acids and polypeptides are further useful in the generation of antibodies that bind immuno-specifically to the novel NOVX substances for use in therapeutic or diagnostic methods. These NOVX antibodies may be generated according to methods known in the art, using prediction from hydrophobicity charts, as described in the “Anti-NOVX Antibodies” section below. The disclosed NOVX proteins have multiple hydrophilic regions, each of which can be used as an immunogen. These NOVX proteins can be used in assay systems for functional analysis of various human disorders, which will help in understanding of pathology of the disease and development of new drug targets for various disorders.

The NOVX nucleic acids and proteins identified here may be useful in potential therapeutic applications implicated in (but not limited to) various pathologies and disorders as indicated below. The potential therapeutic applications for this invention include, but are not limited to: protein therapeutic, small molecule drug target, antibody target (therapeutic, 5 diagnostic, drug targeting/cytotoxic antibody), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, tissue regeneration in vivo and in vitro of all tissues and cell types composing (but not limited to) those defined here.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention 10 belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel nucleotides and polypeptides encoded thereby.

20 Included in the invention are the novel nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to herein as "NOVX nucleic acids" or "NOVX polynucleotides" and the corresponding encoded polypeptides are referred to as "NOVX polypeptides" or "NOVX proteins." Unless indicated otherwise, "NOVX" is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids 25 and their encoded polypeptides.

TABLE 1. Sequences and Corresponding SEQ ID Numbers

NOVX No.	Internal Acc. No.	Homology	Nucleic Acid SEQ ID NO.	Polypeptide SEQ ID NO.
1a	COR87920446_A	Delta serrate ligand receptor	1	2

100-200-300-400-500-600-700-800-900

1b	CG57012-01	Delta serrate ligand receptor	3	4
1c	CG57012-02	Delta serrate ligand receptor	5	6
1d	CG57012-03	Delta serrate ligand receptor	7	8
1e	CG57012-04	Delta serrate ligand receptor	9	10
2	COR87940554	Protein kinase	11	12
3	COR100339661	GPCR	13	14
4a	COR87934767	Ankyrin repeat containing protein	15	16
4b	CG57238-01	Ankyrin repeat containing protein	17	18
5	COR100396092	Ankyrin repeat containing protein	19	20
6	COR87941483	TNF intracellular domain interacting protein	21	22
7	COR101716725	Secretory protein	23	24
8a	CG56663-01	GPCR	25	26
8b	CG56663-02	GPCR	27	28
9	CG56787_01	Dual specificity phosphatase	29	30

NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.

NOV1a to NOV1e are homologous to the Delta serrate ligand receptor family of proteins. Thus, the NOV1a to NOV1e nucleic acids, polypeptides, antibodies and related compounds according to the invention are useful in potential diagnostic and therapeutic applications implicated in, for example, cardiovascular disease, Alagille syndrome, neural development defects, other developmental defects and other diseases, disorders and conditions of the like.

NOV2 is homologous to Protein kinases. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in, for example, Hypercalceimia, Ulcers, Hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, autoimmune disease, allergies, immunodeficiencies, transplantation, Graft versus host

disease (GVHD), Lymphaedema, Systemic lupus erythematosus , Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Cardiovascular disease, Hypercalceimia, Lesch-Nyhan syndrome, Fertility, Cancer and other diseases, disorders and conditions of the like.

5 NOV3, NOV8a and NOV8b are homologous to GPCRs. Thus, the NOV3, NOV8a and NOV8b nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example, Von Hippel-Lindau (VHL) syndrome, Cirrhosis, Transplantation, Hemophilia, Hypercoagulation, Idiopathic thrombocytopenic purpura, Immunodeficiencies, Graft versus host disorders and other diseases, disorders and conditions of the like.

10 NOV4a, NOV4b and NOV5 are homologous to the Ankyrin repeat containing proteins. Thus, NOV4a, NOV4b and NOV5 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example, Endometriosis, Fertility, Von Hippel-Lindau (VHL) syndrome, Alzheimer's disease, Stroke, Tuberous sclerosis, hypercalceimia, Parkinson's disease, Huntington's disease, Cerebral palsy, Epilepsy, Lesch-Nyhan syndrome, Multiple sclerosis, Ataxia-telangiectasia, Leukodystrophies, Behavioral disorders, Addiction, Anxiety, Pain, Neuroprotection, Systemic lupus erythematosus, Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, and other diseases, disorders and conditions of the like.

15 NOV6 is homologous to the TNF intracellular domain interaction proteins. Thus NOV6 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example, cardio-vascular disorders, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus , Pulmonary stenosis , Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Obesity, Transplantation, Systemic lupus erythematosus , Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Hypercalceimia, Lesch-Nyhan syndrome and other diseases, disorders and conditions of the like.

NOV7 is homologous to Secretory proteins. Thus, the NOV7 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example, cardio-vascular diseases, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect 5 (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus, Pulmonary stenosis, Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Obesity, Transplantation, Systemic lupus erythematosus, Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Hypercalceimia, Lesch-Nyhan syndrome and other diseases, disorders and conditions of the like.

NOV9 is homologous to Dual specificity phosphatase. Thus, the NOV9 nucleic acids, polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications implicated in, for example, the treatment of patients suffering from: brain disorders including epilepsy, eating disorders, schizophrenia, ADD, and cancer; heart disease; blood disorders, kidney disorders, liver diseases, inflammation and autoimmune disorders including Crohn's disease, IBD, allergies, rheumatoid and osteoarthritis, inflammatory skin disorders, allergies, blood disorders; psoriasis; colon-, ovarian-, testicular-, lymphatic-, brain-, and pancreatic cancers; leukemia AIDS; thalamus disorders; metabolic disorders including diabetes and obesity; lung diseases such as asthma, emphysema, cystic fibrosis, and cancer; pancreatic disorders including pancreatic insufficiency; and prostate disorders including prostate cancer and other diseases, disorders and conditions of the like.

The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit, e.g., neurogenesis, cell differentiation, cell proliferation, 25 hematopoiesis, wound healing and angiogenesis.

Additional utilities for the NOVX nucleic acids and polypeptides according to the invention are disclosed herein.

NOV1

One NOVX protein of the invention, referred to herein as NOV1, includes five delta serrate ligand receptors. The disclosed proteins have been named NOV1a, NOV1b, NOV1c, NOV1d and NOV1e.

5

NOV1a

A disclosed NOV1a (designated CuraGen Acc. No. COR87920446_A), which encodes a novel delta serrate ligand receptor and includes the 3063 nucleotide sequence (SEQ ID NO:1) is shown in Table 1A. An open reading frame for the mature protein was identified beginning with an ATG initiation codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 3061-3063. Putative untranslated regions, if any, are found upstream from the initiation codon and downstream from the termination codon and are underlined in Table 1A, and the start and stop codons are in bold letters.

Table 1A. NOV1a Nucleotide Sequence (SEQ ID NO:1)

ATGTACCGGCCCTGTGTCCTCTGGCTGGGCTGGCTGGCTGGAACCTCTCAACC
CCAGTGATCCCAATACCTGCAGCTCTGGGAAAGCTTCACTACCACCAAGGAGTCCCCTCC
GCCCTTCAGCCTGCTCCCCCTCAGAGCCCTGCGAGCGGGGCTGGAGGGCCCCATACTTGCCCCC
AGCCCCACGGTTGTATACCGGACCGTGTACCGTCAGGTGGTGAAGACGGACCCGCCAGCGCTGC
AGTGCTGCCATGGCTTCTATGAGAGCAGGGGTTCTGTGTCCTGCTGTGCCAGGAGTGTGTC
ATGGCCGTTGTGGCACCAATCAGTGCAATGTGTCAGGCTGGGGCGACGACTGTCCA
GTGAGTGTGCCCCAGGAATGTGGGGCCACAGTGTGACAAGGCCCTGCAGCTGGCAACAAACAGC
TCGTGTGATCCCAAGAGTGGGTATGTTCTGCCCTCTGGTCTGCAGCCCCGAACTGCCCTCAGC
CCTGTACCCCTGGCTACTATGCCCTGCCAGTCCGCTGCCAGTGCATGGGGCACCTGCGA
TCCCCAGACTGGAGGCCGCTTCTGCCCGCAGAGAGAACTGGGCCAGCTGTGACGTGCTCTGTC
CCAGGGCACTTCTGGCTTCTGCCAGCACCCATTGCCAAATGGAGGTGTCTTCCAAACC
CCACAGGGCTCTGCAGCTGCCCTGGCTGGATGGTATGGAGGGTGGGCTGTGGCATGGG
TGTGGGCTGGGAGAATTCTGTGGGTGGTCTAACGAGGGCTCAAGGGCACCATGCTCCCTG
CCCTGCCAGAGGGCTTACGGACCAACTGCTCCAGGAATTCGCTGCCACACGGCGGCC
TGTGACCGATTACTGGCAGTGGCTGCCCTGGTTACACTGGGATCGGTGCCGGAGGAG
TGCCCGGTGGGCCCTTGGCAGGACTGTGTCAGACGTGCAGTGCCTGGGCCAGCGGGTTGC
TTCCCGCCAACGGCGCATGTCTGCGAACACGGCTTCACTGGGACCGCTGCACGGATGCC
TGCCCCGACGGCTTACGGTCTCAGTGCAGGCCCTGCACCTGCAGCAGGGAGCACGCC
AGCTGCCACCGATGAACGGGAGTGCTCTGCCCTGGGCCAGGGCTCCACTGCAACGA
GAGCTGCCCGAGGACACCGATGGCCAGGGTGCAGGAGCACGTCTGCTGCCAGGGT
TCTGCCAGGCTACCAGCGGCCTGTCACTGCGCGCCGGTTACACGGGCCCTCACTGTGCTAGTC
TTTGTCTCTGACACCTACGGTGTCAACTGTTCTGCACGCTGCTCATGTAAAATGCC
CTCACCCATGACGGCAGTGGCTGCAAGGAAGGTGGCAGCGTGGTAAGTGCCTG
CCCACCCGAACCTGGGCTTCAGTGCATGCCAGTGTGCCACTGAGGGCAGTCTGCAG
CCCCCAAACGGAGGCCGTACCTGCACCCCTGGTGGCATGGGGCCACTGCCAGCTGCC
GAAGGGCAGTTGGAGAAGGTGTGCCAGTCGCTGTGACTGTGACCAACTGTG
TGTTCATGGACGCTGTCAGTGCAGGCTGGCTGGATGGGTGCCACCTGCTGCC
GGGCTTATGGGAGTCAACTGTAGCAACACCTGCACCTGCAAGAAATGGGGC
ACCTGTCTCCCTGAATGGCAACTGCGTGTGCACCCGGATTCCGGGCCCC
CTGCCAGAGATCCTGTCAGCGCTGG

CCGCTATGGCAAACGCTGTGCCCTGCAAGTGCCTAACCACTCCCTCGCCACCCCTCGAACGG
GACCTGCTACTGCCTGGCTGGACTGGACAGGCCCCGACTGCTCCCAGCGCTGCCCTGGGGACATT
TGGTGCTAAGTGCCTCCAGCCATGCCAGTGTGGTCTGGAGAAAAGTGCCACCCAGAGACTGGGGC
CTGTGTATGTCCCCCAGGGCACAGTGGTGCACCTGCAGGATTGGAATCCAGGAGGCCCTTACTGT
GATGCCGACCACTCCAGTAGCGTATAACTCGCTGGGTGCAGTGATTGCATTGCAGTGCTGGGTC
CCTTGTGGTAGCCCTGGTGGCACTGTTATTGGCTATGCCACTGGCAAAAGGCAAGGAGCACCA
CCACCTGGCTGGCTTACAGCAGGGCGCCTGGACGGCTCGAGTATGTCATGCCAGATGTCCC
TCCCAGCTACAGTCACTACTACTCCAACCCCCAGCTACCAACCCCTGTCGAGTGCTCCCCAAACCCC
CCACCCCTAACAAAGGTTCCAGGCCGCTTTGCCAGCCTGCAGAAACCTGAGCGGCCAGGTGGG
GCCAAGGGCATGATAACCACACCACCCCTGCCGTGACTGGAAGCACCAGGGAGCCCCCTCCA
GGCCTCTGGACAGGGGAGCAGCCGCTGGACCGAAGCTACAGCTATAGCTACAGCAATGGCCC
AGGCCCATCTACAATAAGGGCTCATCTGAAGAGGAGCTCGGGCCAGTGCTGGCTCCCTGAG
CACTGAGAACCCATATGCCACCATCCGGACCTGCCAGCTTGCAGGGGGCCCCGGAGAGCA
GCTACATGGAGATGAAAGGCCCTCCCTCAGGATCTCCCCCAGGCAGCCTCCAGTTCTGGGACA
GCCAGAGGGCGCGCAACCCCCAGCCACAGAGAGACAGTGGCACCTACGAGCAGCCCAGCCCCCTG
ATCCATGACCGAGACTCTGTGGGCTCCAGCCCCCTGCTCCGGGCCTACCCCCCGGCCACTATG
ACTCACCCAGAACGCCACATCCCTGGACATTATGACTTGCTCCAGTACGGCATCCCCCATCAC
CTCCACTTCGACGCCAGGAGCGTTGA

The disclosed NOV1a nucleic acid sequence maps to chromosome 1 and has 1120 of 1951 bases (57%) identical to a gb:GENBANK-ID:AB011532|acc:AB011532.1 mRNA from *Rattus norvegicus* (*Rattus norvegicus* mRNA for MEGF6, complete cds).

The NOV1a polypeptide (SEQ ID NO:2) is 1020 amino acid residues in length and is presented using the one-letter amino acid code in Table 1B. The SignalP, Psort and/or Hydropathy results predict that NOV1a has a signal peptide and is likely to be localized on the plasma membrane with a certainty of 0.6760. In alternative embodiments, a NOV1a polypeptide is located outside the cell with a certainty of 0.1000, in the endoplasmic reticulum (membrane) with a certainty of 0.1000, or in the endoplasmic reticulum (lumen) with a certainty of 0.1000. The SignalP predicts a likely cleavage site for a NOV1a peptide between amino acid positions 20 and 21, i.e., at the dash in the sequence AGT-LN.

Table 1B. Encoded NOV1a Protein Sequence (SEQ ID NO:2)

MSPLCPLLLAVGLRLAGTLNPSDPNTCSFWESFTTTKESHSRPFSLLPSEPCERPWEGPHTCPQPTV
VYRTVYRQVVKTDHRQLQCCHGFYESRGFCVPLCAQECSVHRCVAPNCQCVPGWRGDDCSSECA
PGMWGPQCDKPCSCGNNSCDPKSGVCSCPSGLQPPNCLQPCTPGYYGPACQFRCQCHGAPCDPQTG
ACFCPAERTGPSCDVSCSQTSGFFCPSTHSCQNGVFTQPQGSCSCPGWMVWRVGPVGMGCGSGE
NSVGGAKQGSKGTCISLPCPEGFHGPNCSCQECCRCHNGLCDRFTGQCRCAPGYTGDRCREECPVGRFG
QDCAETCDCAPDARCFPANGACLCEHGFDRCTDRLCDPGFYGLSCSQAPCTCDREHSLSCPBMNGE
CSCLPGWAGLHCNESCPQDTHGPQCQEHCCLCLHGGVCQATSGLCQCAPGTYGPHCASLCPPDTYGVN
CSARCSCENAIACSPIDGEVCVCKEGWQRGNCSVCPGGTWGFSCNASCQCAHEAVCSPQTGACTCTPG
WHGAHCQLPCPKGQFGEGCASRCDCDHSDGCDPVHRCQCQAGWMGARCHLSCPEGLWGVNCSNT
CTCKNGGTCLPENGNCVAPGFRGPSCQRSCQPGRYGKRCVCKCANHSFCHPSNGTCYCLAGWTGP
DCSQRCPLGTFGANCSQPCQCQGPGEKCHPETGACVCPPGHSGAPCRIGIQEPTVMPPTPVAYNSLGAV
IGIAVLGSLVVALVALFIGYRHQKGKEHHHLAVAYSSGRLDGSEYVMPDVPPSYSHYYSNPSYHTLS
QCSPNPPPNKVPGPLFASLOKPERPGGAQGHDNHTLPADWKHRREPPPGLDRGSSRLDRSYSYS

NGPGPFYNKGLISEEELGASVASLSENPYATIRDLPSLPGGPRESSYMEMKGPPSGSPPRQPPQFWDSQ
 RRRQPQPQRDSTYEQPSPLIHDRDSVGSQPPLPPGLPPGHYDSPKNSHIPGHYDLPPVRHPPSPPLRRQ
 DR

The NOV1a amino acid sequence has 834 of 1064 amino acid residues (78%) identical to, and 881 of 1064 amino acid residues (82%) similar to, the 1034 amino acid residue [gi|17386053|gb|AAL38571.1,AF444274_1](#) (AF444274) Jedi protein [Mus musculus] (E = 0.0).

5 Possible small nucleotide polymorphisms (SNPs) found for NOV1a are listed in Table 1C.

Table 1C: SNPs for NOV1a				
Variant	Nucleotide Position	Base Change	Amino Acid Position	Base Change
13374399	447	C>T	NA	NA
13374400	934	C>A	NA	NA
13374401	975	G>A	NA	NA
13374402	984	C>T	NA	NA
13374403	1011	T>C	NA	NA
13374404	1269	G>A	NA	NA
13374405	1278	T>C	NA	NA
13374406	1297	C>T	433	His > Tyr
13374407	1298	A>G	433	His > Arg
13374408	1398	T>A	NA	NA
13374409	1585	A>G	529	Ser > Gly
13374410	1595	C>T	532	Thr > Ile
13374411	1701	C>T	NA	NA
13374413	2300	G>A	767	Gly > Asp
13374414	2361	T>C	NA	NA

NOV1a is expressed in at least the following tissues: testis. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.

10

NOV1b

A disclosed NOV1b (designated CuraGen Acc. No. CG57012-01), which includes the 2919 nucleotide sequence (SEQ ID NO:3) shown in Table 1D. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 83-85 and ending with a TGA codon at nucleotides 2867-2869. The start and stop codons of the open reading frame are highlighted in bold type. Putative untranslated regions are underlined.

15

Table 1D. NOV1b Nucleotide Sequence (SEQ ID NO:3)

The disclosed NOV1b nucleic acid sequence maps to chromosome 1 and has 853 of 1409 bases (60%) identical to a gb:GENBANK-ID:AB011532|acc:AB011532.1 mRNA from *Rattus norvegicus* (*Rattus norvegicus* mRNA for MEGF6, complete cds).

The NOV1b polypeptide (SEQ ID NO:4) is 928 amino acid residues in length and is presented using the one-letter amino acid code in Table 1E. The SignalP, Psort and/or Hydropathy results predict that NOV1b has a signal peptide and is likely to be localized to the

plasma membrane with a certainty of 0.6760. In alternative embodiments, a NOV1b polypeptide is located to the outside of the cell with a certainty of 0.1000, the endoplasmic reticulum (membrane) with a certainty of 0.1000, or the endoplasmic reticulum (lumen) with a certainty of 0.1000. The SignalP predicts a likely cleavage site for a NOV1b peptide between amino acid 5 positions 20 and 21, i.e., at the dash in the sequence AGT-LN.

Table 1E. Encoded NOV1b Protein Sequence (SEQ ID NO:4)

MSPPLCPLLLLAVGLRLAGTLNPSDPNTCSFWESFTTTKESHSRPFSLLPSEPCERPWEWPHTCPQPTVVYRT
VYRQVVKTDHRQRQLQCCCHGFYESRGFCVPLCAQECVHGRCVAPNQCQCVCVGWRGDDCSSECAPGMWGPQCDKPC
SCGNNSSCDPKSGVCSCPSGLQPPNCLQPCPTPGYYGPACQFRCQCHGAPCDPQTGACFCPAERTGPSCDVSCSQ
GTSGFFCPSTHSCQNGGVFQTPQGSCSCPPGWMVWRVGPVGMGCGSGENSGGAKQGSKGTTICSLPCPEGFHGP
NCSQECRCHNGGLCDRFTGQCRCAPGYTGDRCREECPVGRFGQDCAETCDCAPDARCFPANGACLCEHGTGDR
CTDRLCPDGFYGLSCQAPRTCDREHSLSCHPMNGECSCLPGWAGLHCNESCPQDTHGPGCQEHLCLHGGVCQA
TSGLCQCAPGYTGPCHASLCPPDTYGVNCSCENAIACSPIDGEVCCKEGWQRGNCSVPCPPGTWGFSCNA
SCQCAHEAVCSPQTGACTCTPGWHGAHCQLPCPKGQFGEFCASRCDCDHSDGCDPVHGRQCQAGWMGARCHLS
CPEGLWGVMCSNTCTCKNGGTCLPENGNCVCAPGFRGPSCQRSCQPGRYGKRCVCKCANHSFCHPSNGACYCL
AGWTGPDCSQPCPPGHGENCAQTCQCHHGGTCHPQDGSCICPLGWTGHHCLEGCPPLGTFGANCSQPCQCGPGE
KCHPETGACVCPPGHGENCAQTCQCHHGGTCHPQDGSCICPLGWTGHHCLEGCPPLGTFGANCSQPCQCGPGE
HLAVAYSSGRLDGSEYVMPDVPPSYSHYNSPSYHTLSQCPNPPPNKVPGLFASLQNPERPGGAQGHDNHT
TLPADWKHRREPPPGLDRGRCLEARVSGAGGCVQPRCRV

The NOV1b amino acid sequence 834 of 1064 amino acid residues (78%) identical to, and 881 of 1064 amino acid residues (82%) similar to, the 1034 amino acid residue [gi|17386053|gb|AAL38571.1|AF444274_1](#) (AF444274) Jedi protein [Mus musculus] (E = 0.0).

Possible small nucleotide polymorphisms (SNPs) found for NOV1a are listed in Table 1F.

Table 1F: SNPs for NOV1b

Variant	Nucleotide Position	Base Change	Amino Acid Position	Base Change
13374399	529	C>T	NA	NA
13374400	1016	C>A	NA	NA
13374401	1057	G>A	NA	NA
13374402	1066	C>T	NA	NA
13374403	1003	T>C	NA	NA
13374408	1480	T>A	NA	NA
13374409	1667	A>G	529	Ser > Gly
13374410	1677	C>T	532	Thr > Ile
13374411	1783	C>T	NA	NA
13374413	2511	A>G	810	Asp > Gly
13374414	2572	T>C	NA	NA

NOV1c

A disclosed NOV1c (designated CuraGen Acc. No. CG57012-02), which includes the 2919 nucleotide sequence (SEQ ID NO:5) shown in Table 1G. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 83-85 and ending with 5 a TGA codon at nucleotides 2867-2869. The start and stop codons of the open reading frame are highlighted in bold type. Putative untranslated regions are underlined.

Table 1G. NOV1c Nucleotide Sequence (SEQ ID NO:5)

AGATCTCTGCAGACAGGTCCCTCAGGCTGCTGGCTGCAGGCCACTGCCACTCTGCCCGGTCTGCTGCAG
GCCTCTGCA**ATGT**CACCGCCTCTGTGT**CCCT**CTCTGGCTGTGGCCTGCCGCTGGCTGGAA**CT**CTCA
ACCCCA**G**AGT**G**AT**CC**AA**AT**AC**CT**GCAG**CT**CTGGAA**AG**CT**T**CA**T**ACC**AC**CC**AC**CA**AG**GA**GT**CC**AC**CC**GG**TT
CTTCAGCCTGCTCCCTCAGAGCCCTGCGAGCGGCCCTGGGAGGCCCCATACTTGCCCCCAGCCCACGGTT
GTATACC**GG**ACCGTGT**AC**CGT**AG**GT**GT**GA**AG**AC**GG**AC**CC**GC**AG**CGCCTGCA**GT**GT**CC**ATGG**CT**TCT
ATGAGAGCAGGGGGTCTGTGT**CC**CG**CT**GT**CC**AG**GG**AG**GT**GT**CC**ATGG**CC**GT**GT**GT**GG**AC**CC**AA**AT**CA
GTGCCA**AT**GT**GT**GC**CC**AG**GG**CTGG**GG**GC**AC**G**AC**T**GT**CC**AG**GT**GT**GC**CC**CA**GG**AA**AT**GTGGGGGCACAG
TGTGACA**AG**CC**CT**GC**AG**CT**GC**GG**CA**AC**AC**AG**CT**CG**GT**AT**CC**AA**AG**GTGGGTAT**GT**TTCTGGCC**CT**TG
GTCTGCAG**CC**CC**GA**CT**GC**CT**TC**AG**CC**CT**GG**CT**AC**AT**GG**CC**CT**GC**CC**AG**TT**CC**CG**CT**GC**CA
GTGCC**AT**GGGG**CC**AC**CC**CT**GC**AT**CC**CA**AG**CT**GG**CT**CT**GT**CC**CC**CG**AG**CT**GT
GACGTGT**CT**GT**CC**CC**AG**GC**AC**TT**CT**GT**CC**TT**CT**GT**CC**CC**CG**CA**AG**CA**CC**AT**CT**GT**CC**AA**AT**GG**AG**GT**GT**CT
TCCAA**AC**CC**CC**AC**AG**GG**GT**CT**CT**GC**AG**CT**GC**CC**CC**CT**GG**CT**GG**AT**GG**AT**GG**GG**GT**GGGG**CC**GT**GG**
GTGTGGGTCTGGGGAGA**AT**CTGTGG**GT**GT**CT**TA**AG**CA**GG**GT**CC**AA**GG**CA**CC**AT**CT**GT**CC**CT**GC**CT**GC**
CCAGAGGGCT**TT**CA**GG**AC**CC**AA**CT**GT**CC**CA**GG**AT**GT**GT**CC**AC**AC**GG**CC**CT**GT**GT**AC**GG**AT**CA
CTGGGCAGTGC**CG**CT**GC**CT**CC**GG**TT**AC**AT**GGGG**AT**CG**GT**GC**CC**GG**AG**GT**CC**GG**GT**GGGG**CC**GT**TT**GG
GCAGGACTGT**GT**GT**GA**GT**GC**ACT**GC**GC**CC**GG**AC**CC**GG**GT**GT**CT**CC**GG**CC**AC**GG**CG**GT**GT**TC**
GAACACGG**CT**CA**CT**GGGG**AC**CC**GT**GC**AC**GG**GG**AC**AC**G**CC**CT**AC**GG**GT**GT**CC**AG**GG**GG**GT**GGGG**CC**GT**CC**
CCCCCG**GC**AC**CT**GC**G**AC**GG**GG**AC**AC**GG**CT**AC**GT**CC**AC**CC**GT**GA**AC**GG**GG**AG**GT**GT**CT**CC**GT**CC**GG**GG**
CTGGGC**GG**CC**CT**CC**AC**GT**GC**AA**CC**AG**AG**GT**GC**CC**GG**CA**GG**AC**AC**GC**AT**GGGG**CA**GG**GT**GC**CC**AG**GG**GC**GT**GT**TC**
TG**CC**GT**CC**AC**GG**GT**GG**GT**CT**GC**CC**AG**GG**CT**AC**GG**CC**CT**GT**GC**CC**GG**GG**TT**AC**GGGG**CC**CT**TC**ACT
GT**G**CT**AG**GT**CT**GT**CC**CT**GT**GC**AC**CC**CT**AC**GG**GT**GT**CA**CT**GT**CC**AT**GG**AA**AT**GC**CC**AT**CG**
CT**G**CT**GC**AC**CC**AT**CG**AC**GG**GT**GC**GT**CC**CT**GT**GC**AC**GG**GT**GT**CC**AT**GG**CC**CT**GT**CC**AA**AC**GT
CCCCGG**AC**CT**GG**GG**CC**CT**AC**GT**GC**GT**CC**CT**GT**GC**AC**GG**GT**GT**CC**AT**GG**CC**CT**GT**CC**GG**GG**
CTCCTGC**CA**GG**AT**CT**GT**GC**AC**CC**CT**GG**CC**GT**AT**GG**CA**AC**GG**CT**GT**GT**CC**GT**CC**GA**AG**GGGG**CC**ACT**TT**GG**AG**
TT**CT**GT**CC**AC**CC**CT**GC**AA**CG**GG**CC**GT**CT**ACT**GC**CT**GG**GT**CC**GA**AG**GGGG**CC**ACT**CC**AG**GT**
CTCC**AG**GA**AC**CT**GG**GG**AA**ACT**GT**GT**CC**AG**AC**CT**GC**CA**AT**GT**CC**AC**CT**GG**GG**AC**CT**GC**CC**AT**CC**AG**GA**
TGGGAG**GT**AT**CT**GG**CC**CT**AG**GT**GG**AC**AC**ACT**GT**GT**CC**CT**GT**GG**GG**AC**AT**TT**GG**
GCT**AA**CT**GT**CC**CC**AG**CC**AT**GC**CA**GT**GT**CC**CT**GG**AG**AA**AG**GT**GC**CC**AC**CC**AG**AG**AC**GT**GGGG**CC**GT**GT**AT**GT**
CCCC**AG**GG**CC**AC**AG**GT**GG**GC**AC**CT**TC**GC**AG**GT**GT**CA**CT**GG**AC**CC**CC**TT**AC**GT**GT**GA**CC**ACT**CC**AG**GT**
AG**CG**TA**TA**ACT**CG**CT**GG**GT**GC**AG**U**TT**GG**CA**TT**GC**AG**GT**GT**CT**GG**GT**CC**TT**GT**GG**GT**AC**CC**CT**GG**ACT**U**
TTC**AT**GG**GT**AT**CT**GG**CC**ACT**GG**CA**AA**AG**AC**AA**AG**AG**AC**CC**AC**AC**CC**GT**GT**GG**GT**TT**AC**GC**AG**GG**CC**GC
TGGACGG**GT**CC**GA**GT**AT**GT**CA**GT**CC**AG**AT**GT**CC**CT**CC**AG**GT**AC**AG**TC**AC**ACT**AC**TC**CA**AC**CC**CC**AC**GT**AC**CA**CC**
CAC**CC**CT**GT**GC**AG**GT**GT**CT**CC**AA**AC**CC**CC**AC**CC**CT**AC**AA**AG**GT**CC**AG**GC**CC**GT**CT**TT**GC**AG**CC**CT**GC**AG**
AAC**CC**CT**GA**GC**GG**CC**AG**GT**GG**GG**CC**AA**GG**CA**GT**ATA**AC**AC**CC**AC**CC**GT**GT**GT**AC**GG**GA**GC**AC**CC**GG**
GG**GG**AG**CC**CC**CT**CC**AG**GG**CC**CT**GT**GG**AC**GG**GG**GT**AG**GT**GT**GT**CT**GG**AG**AC**GG**GG**CC**CT**GT**GT**AC**GG**GA**GC**AC**CC**GG**
GCAG**CC**CA**GT**GC**CG**GT**CT**GA**GT**GT**GT**GT**CT**GG**AG**AC**GG**GG**CC**CT**GT**GT**AC**GG**GA**AG**GT**

The nucleic acid sequence of NOV1c maps to chromosome 1 and has 852 of 1409 bases (60%) identical to a gb:GENBANK-ID:AB011532|acc:AB011532.1 mRNA from *Rattus norvegicus* (*Rattus norvegicus* mRNA for MEGF6, complete cds).

The NOV1c polypeptide (SEQ ID NO:6) is 928 amino acid residues in length and is presented using the one-letter amino acid code in Table 1H. The SignalP, Psort and/or Hydropathy results predict that NOV1c has a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.6760. In alternative embodiments, a NOV1c polypeptide is located to the outside of the cell with a certainty of 0.1000, the endoplasmic reticulum (membrane) with a certainty of 0.1000, or the endoplasmic reticulum (lumen) with a certainty of 0.1000. The SignalP predicts a likely cleavage site for a NOV1c peptide between amino acid positions 20 and 21, i.e. at the dash in the sequence AGT-LN.

Table 1H. Encoded NOV1c Protein Sequence (SEQ ID NO:6)

```
MSPPLCPLLLLAVGLRLAGTLNPSDPNTCSFWESFTTTKESHSRPFSSLPEPCERPWECPHTCPQPTVVYRT  
VYRQVVKTDRQRLQCCCHGFYESRGFCVPLCAQECSVHGRCVAPNQCQCVPGWRGDDCSSECAPGMWGPQCDKPC  
SCGNNSCDPKSGVCSCPSGLQPPNCLQPCTPGYYGPACQFRCQCHGAPCDPQTGACFCPAERTGPSCDVSCSQ  
GTSGFFCPSTHSCQNGGVQTPQGSCSCPPGWMVWRVGPVGMCGSGENSVGAQKGSKGTCISLPCPEGFHGP  
NCSQECRCHNGLCDRTGQCRCAPGYTGDRCREECPVGRFGQDCAETCDCAPDARCFPANGACLCEHGFITGDR  
CTDRLCPDGFYGLSCQAPRTCDREHSLSCPMNGECSCLPGWAGLHCNESCQDTHGPGCQERCLCLHGGVCQA  
TSGLCQCAPGYTGPHCASCSCPDTYGVNCSCRNCSCEAIACTSPIDGEVCCKEGWQRGNCSVCPPPGTWGFSCNA  
SCQCAHEAVCSPQTGACTCTPGWHGAHCQLPCPKQFGEGLCASRCDCDHSDGCDPVHGRCQCQAGWMGARCHLS  
CPEGLWGVNCNSNTCTCKNGGTCLPENGNCVAPGFRGPSCQRSCQPGRYGKRCVPCCKCANHSFCHPSNGACYCL  
AGWTGPDCSQPCPPGHGENCAQTCQCHGGTCHPQDGSCICPLGWTGHHLEGCPPLGTFGANCSQPCQCGPGE  
KCHPETGACVCPGHSAPCRIGIQEPFTVMPPTPVAYNSLGAIVIGIAVLGLSIVVALVALFIGYRHWQKDKEHH  
HLAVAYSSGRLDGSEYVMPDVPPSYSHYNSPSYHTLSQCSNPNNKVPGPLFASLQNPERPGGAQGHNDNHT  
TLPADWKHRREPPPGLDRGRCREARVSGAGGCVQPRCRV
```

The NOV1c amino acid sequence has 834 of 1064 amino acid residues (78%) identical to, and 881 of 1064 amino acid residues (82%) similar to, the 1034 amino acid residue

15 [gi|17386053|gb|AAL38571.1|AF444274_1](#) (AF444274) Jedi protein [*Mus musculus*] (E = 0.0).

NOV1d

A disclosed NOV1d (designated CuraGen Acc. No. CG57012-03), which includes the 5000 nucleotide sequence (SEQ ID NO:7) shown in Table 1I. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 83-85 and ending with a TGA codon at nucleotides 3194-3196. The start and stop codons of the open reading frame are highlighted in bold type.

Table 11. NOV1d Nucleotide Sequence (SEQ ID NO:7)

GATTTCAGACATCGTGTGGGTACCTTCTGTGATGCTCAGCCTGGCTCTGCGTGTGTG
TGTTCTGTGATTAGAAGGGTACCAAGGCACAGGTTCTGCTCTAGGGCACTTACATTAGTAG
GGAGATGGAACCAACCCAACTTAACCTAGCAATAGCCTCTAACACTGGCCTCCTCCATTGATTCA
TGAACCTCCAATGCATGGCTCATATTCAAACACAGGCTGGTTAGTTACTCCCTACCTGAAA
GCCTCATAGGTGCCCTTGTCTCTGCCAGTACAAACACTTTGAAGGCCTAAAGGCCCTG
CTTGCCCTGGCCCATCTGTCTCCAGCCTCACCTGAACCTGTTCTGCACGCCAGTC
ACACCGGCCTCTAGGTCCCTGTAGGCCACTCTCTTCTGGCACAGGGACCTGCACACCTGGA
GTGCCCTCCTCCCCACTCGCCTGTTCACCCCTGCTTACACCTCCTCAGGGAAGT
GCCCACCCCTCCGTACATCTTACAGCCCTGATTGCACTGTTACTCACCAAGGTACCTGCA
AAGGCCTACAGGGTGCCAGGCACCTCTTAATGGGTTCTTCTTATGTGATTATTGATTAATCT
CTGCCTCCCCACTAGACTGTAAGCTCCCTGAAGGCAAGAAATCCTGTGCTTATGCTCAATATTAG
CTCTCCCTGGCACAGAGTAGGCACCAACAAATGCTCCCCAAAGGCTGAGTGGCTGACTGAA
TTAAGTACCAAGTGACATGCACTGTAAGATAGATGAGCCATCTGTATGCTCTGACAGTTAC
AGACTGAATAAGTGGAGACTTCCCTAAAGGGTGGCATTCCCCAGGGTAACAACGCAGAGCTC
AGGTGTGGAAAGGTGCCAGGGGAGGGGTGCAAGAGGGCTGAGGCTGAGGGGGTGCAGAGG
CTGGAGAAAGGATAACAGGAGAGATATACAGGCATGCCCTGATTATTGCACTCACAGGTAG
CAGAATTAAAGAAATTGAAGGTTGGACATATATGTGACAGCAATAGGTTAAGAAAAGC
AAAGCAGAGAAATTGAAGATTGTGCAACACTGCTTAAAGCAAATCTGTGGCACCATTTCC
AATAGCATGTGCCCATTTGGGCTCTACATTGCATTTGTAATTGCTGCAATATTCAAGCAT
TTTCATTGTTATTATATGTGTTAGTGATCTGTGATCAGTGTCTTGATATATTATTGTAATTG
TTTCGGGGCGCCATGAACCGCACCCATATAACACGGTAAACTTAATCAGCAAAAAAA
AAAAAAAAACCCGAAAAATTAGAATTGAAAAATATGAAAAACCCCCGGGGGGTCTTCA
GGGGGGGGCGGGGCCCAATTAAATTTTTTAACAAAGGTAAGTCCCTTTGAGA
AAAAAAATCCTCCTGAAAGATTAAATTGGGGGCC

The nucleic acid sequence of NOV1d has 414 of 421 bases (98%) identical to a
 gb:GENBANK-ID:AX071876|acc:AX071876.1 mRNA from Homo sapiens (Sequence 2348 from
 Patent WO0102568).

The NOV1d polypeptide (SEQ ID NO:8) is 1037 amino acid residues in length and is
 presented using the one-letter amino acid code in Table 1J. The SignalP, Psort and/or Hydropathy
 results predict that NOV1d has a signal peptide and is likely to be localized to the plasma
 membrane with a certainty of 0.6760. In alternative embodiments, a NOV1d polypeptide is
 located to the outside of the cell with a certainty of 0.1000, the endoplasmic reticulum
 10 (membrane) with a certainty of 0.1000, or the endoplasmic reticulum (lumen) with a certainty of
 0.1000. The SignalP predicts a likely cleavage site for a NOV1d peptide between amino acid
 positions 20 and 21, i.e., at the dash in the sequence AGT-LN.

Table 1J. Encoded NOV1d Protein Sequence (SEQ ID NO:8)

<u>MSPPLCPLLLLAVGLRLAGTLPNSDPNTCSFWESFTTCKESHSRPFSLLPSEPCERPWE</u> <u>GHTCPQPTV</u> <u>VYRTVYRQVVKTDHRQRLQCCHGFYESRGFCVPLCAQECVHGRCVAPNQCQCVP</u> <u>WRGDDCSSEC</u> <u>APGMWGPQCDKPCSCGNNSCDPKSGVCSCPSGLQPPNCLQPC</u> <u>CTPGYYGPACQFRCQCHGAPCDPQT</u> <u>GACFCPAERTGPSCDVSCSQGTSGFFCPSTHPCQNGGVFQTPQGSCSCPPGWMGTICSL</u> <u>PCPEGFHGPNC</u> <u>CSQECRCHNGLCDRTGQCRCAPGYTGDRCREECPVGRFGQDCAETCDCAPDARCFP</u> <u>ANGACLCEH</u> <u>GFTGDRCTDRLCPDGFYGLSCQAPRTCDREHSLSCPMNGECSCLPGWAGLHCN</u> <u>ESCPQDTHGPGCQ</u> <u>EHCLCLHGGVCQATSGLCQCAGPYTGPHCASLCPPDTYGVNCSARCS</u> <u>CENAIACSPIDGECVCKEGW</u> <u>QRGNCSVPCPPGTWGFSCNASCQCAHEAVCSPQTGACTCTPGWHGAHCQLPCPKQFGE</u> <u>GCASRCD</u>
--

CDHSDGCDPVHGRQCQCQAGWMGARCHLSCPEGLWGVNCSNTCTCKNGGTLPEENGNCVCAPGFRG
 PSCQRSCQPGRYGKRCVCKCANHSFCHPSNGTCYCLAGWTGPDCSQPCPPGHWGENCAQTCQCHH
 GGTCHPQDGSCICPLGWTGHHCLEGCPGLTFGANCSQPCQCGPGEKCHPETGACVCPPGHSGAPCRIG
 IQEPFTVMPTTPVAYNSLGAIVIGIAVLGSLVVALVALFIGYRHQKDKEHHHLAVAYSSGRLDGSEYV
 MPDVPPSYSHYSNPSYHTLSQSCPNNPPPNKVPGLFASLQNPERPGGAQGHDNHTLPADWKHRRE
 PPPGPLDRGSSRLDRSYSYSNSGPFPYNKGLISEEEELWASVASLSENPYATIRDLPSLPGGPRESSY
 MEMKGPPSGSPRQPPQFWDSQRRRQPQQRDSTYEQPSPLIHDRDSVGSQPPLPPGHYDSPKN
 SHIPGHYDLPPVRHPPSPLRRQDR

NOV1e

A disclosed NOV1e (designated CuraGen Acc. No. CG57012-04), which includes the 3114 nucleotide sequence (SEQ ID NO:9) shown in Table 1K. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 1-3 and ending with a TGA codon at nucleotides 3112-3114. The start and stop codons of the open reading frame are highlighted in bold type.

Table 1K. NOV1e Nucleotide Sequence (SEQ ID NO:9)

ATGTCACCGCCTCTGTGTCCCCTCTTCTCTGGCTGGGCTGCGCTGGCTGGAACTCTCAACCCCAGTG
 ATCCAATACCTGCAGCTCTGGAAAGCTTCACTACCACCAAGGAGTCCACTCCGCCCTTCAGCCT
 GCTCCCTCAGAGCCCTCGCAGGGCCCTGGGAGGGCCCCATACTTGCCCCAGCCCACGGTTGTATACCGG
 ACCGTGTACCGTCAGGTGGTGAAGACGGACCCGCCAGCGCTGCAGTGCTGCCATGGCTCTATGAGAGCA
 GGGAGTTCTGTGTCCCCTCTGTGCCAGGAGTGTGTCATGGCCGGTGTGGCACCCAATCAGTGCCAATG
 TGTGCCAGGCTGGCGGGCGACGACTGTTCCAGTGAGTGCCCCAGGAATGTGGGGCACAGTGTGACAAG
 CCTGCAGTTGCCAACACAGCTGTGTGATCCAAGAGTGGGGTATGTTCTGCCCTCTGGCTGCAGC
 CCCGAACTGCCCTCAGCCCTGGCTACTATGCCCTGCCAGTCCGCCAGTGCCATGG
 GCCACCCCTGCGATCCCAGACTGGAGCCTGCTCTGCCCGCAGAGAGAACTGGGCCAGCTGTGACGTGTCC
 TGTCCAGGGACTTCTGGCTTCTGCCAGCACCCATCCTGCCAAATGGAGGTGTCTTCAAACCC
 CACAGGGCTCTGCAGTGCACCCCTGGCTGGATGGCACCATCTGCTCCCTGCCAGAGGGCTTCA
 CGGACCCAACTGCTCCAGGAATGTCGCTGCCACAACGGCGCCTGTGACCGATTACTGGCAGTGCC
 TCGCCTCCGGTTACACTGGGATCGGTGCCGGAGGAGTGCCCGGTGGGCCGTTGGCAGGACTGTGCTG
 AGACGTGCGACTGCGCCCCGGACGCCGTTGCTTCCCCGCCAACGGCGATGCTGTGCGAACACGGCTTCAC
 TGGGGACCGCTGCACGGATGCCCTTGCCCCGACGGCTTACCGGCTCAGCTGCCAGGCCCTGCACCTGC
 GACCGGGAGCACGCCCTAGCTGCCACCCGATGAACGGGAGTGTCTCTGCCGGCTGGCGGGCTCC
 ACTGCAACGAGAGCTGCCCGCAGACGATGGCCAGGGTCCAGGAGTACTGTCTGCCCTGACGGTGG
 CGTCTGCCAGGCTACCAAGCGGCCCTGTCACTGCGCCGGTTACACGGCCCTACTGTGCTAGTCTTGT
 CCTCCTGACACCTACGGTGTCAACTGTTCTGCACGCTGCTCATGTGAAAATGCCATGCCCTGCTCACCCATCG
 ACGGCGAGTGCCTGCAAGGAAGGTTGGCAGCGTGGTAAGTGTCTGTGCCCTGCCACCCGAACCTGGGG
 CTTCACTGCAATGCCAGCTGCCAGTGTGCCCATGAGGCAGTCTGCAAGCCCCAAACTGGAGCCTGTACCTGC
 ACCCCCTGGGTTGCATGGGCCACTGCCAGCTGCCCTGTCCGAAGGGGAGTTGGAGAAGGTTGCCAGTC
 GCTGTGACTGTGACCACTCTGATGGCTGTGACCCCTGTTACGGACGCTGCTAGGCCAGGCTGGCTGGATGGG
 TGCCCGCTGCCACCTGCTCTGCCCTGAGGGCTTATGGGAGTCACTGTAGCAACACCTGCACCTGCAAGAAT
 GGGGGCACCTGTCTCCCTGAGAATGCACTGCGTGTGCAACCCGGATTCCGGGGCCCTCTGCCAGAGAT
 CCTGTCAGCCTGGCCGCTATGGCAAACGCTGTGTGCCCTGCAAGTGCCTAACCACTCCCTCTGCCACCCCTC
 GAACGGGACCTGCTACTGCCCTGGCTGGACAGGCCGACTGCTCCAGCCATGCCCTCAGGACACTGG
 GGAGAAAATGTGCCAGACCTGCCATGTCACCATGGTGGACCTGCCATCCCCAGGATGGGAGCTGTATCT
 GCCCCCTAGGCTGGACTGGACACCACGTGCTAGAAGGCTGCCCTGGGGACATTGGCTAACGTGCTCCCA
 GCCATGCCAGTGTGGCTCTGGAGAAAAGTGCCACCCAGAGACTGGGGCTGTGTATGCCCCCAGGGCACAGT
 GGTGCACCTGCACTGGAGATTGGAATCCAGGAGCCCTTACTGTGATGCCGACCACTCCAGTAGCGTATAACTCGC
 TGGGTGCAGTGATTGGCATTGCACTGCTGGGCTCCCTGTGGTAGCCCTGGACTGTTCATTGGCTATCG
 GCACTGGCAAAAGGCAAGGAGCACCACCACTGGCTGTGGCTTACAGCAGGGCGCTGGACGGCTCCGAG
 TATGTCATGCCAGATGTCCTCCGAGCTACAGTCACTACTCTCAACCCAGCTACCAACCCCTGCGCAGT

GCTCCCCAAACCCCCCACCCTAACAGGTTCCAGGCCGCTTTGCCAGCCTGCAGAACCTGAGCGGCC
 AGGTGGGGCCAAGGGCATGATAACCACACCACCTGCCTGCTGACTGGAAGCAGGCCGGAGCCCCCTCA
 GGGCCTCTGGACAGGGGAGCAGCCACCTGGACCGAAGCTACAGCTATAGCTACAGCAATGGCCAGGCCAT
 TCTACGATAAAGGGCTCATCTGAAGAGGAGCTGGGGCCAGTGTGACTTCCCTGAGCAGTGAGAACCCATA
 TGCCACCACCCGGGACCTGCCAGCTGCCAGGGGCCGGAGAGCAGCTACATGGAGATGAAAGGCC
 CCCTCAGGATCTCCCCCAGGCAGCCTCAGTCTGGACAGCCAGAGGGCGGCAACCCAGCCACAGA
 GAGACAGTGGCACCTACGAGCAGCCAGCCCCCTGATCCATGACCGAGACTCTGTGGCTCCAGCCCCCT
 GCTCCGGGCTACCCCCGGCCACTATGACTCACCAAGAACAGCCACATCCCTGGACATTATGACTTGCT
 CCAGTACGGCATCCCCATCACCTCCACTCGACGCCAGGACCGTTGA

The NOV1e polypeptide (SEQ ID NO:10) is 1037 amino acid residues in length and is presented using the one-letter amino acid code in Table 1L. The SignalP, Psort and/or Hydropathy results predict that NOV1e has a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.6760. In alternative embodiments, a NOV1e polypeptide is located to the outside of the cell with a certainty of 0.1000, the endoplasmic reticulum (membrane) with a certainty of 0.1000, or the endoplasmic reticulum (lumen) with a certainty of 0.1000. The SignalP predicts a likely cleavage site for a NOV1e peptide between amino acid positions 20 and 21, i.e., at the dash in the sequence AGT-LN.

Table 1L. Encoded NOV1e Protein Sequence (SEQ ID NO:10)

MSPLCPLLLAVGLRLAGTLPNSDPNTCSFWESFTTTKESHSRPFSLPSEPCERPWEGLPHTCPQPTV
 VYRTVYRQVVKTDHRQRLQCCCHGFYESREFCVPLCAQECVHGRVAPNQCQCVPGWRGDDCSSECA
 PGMWGPQCDKPCSCGNSSCDPKSGVSCPSGLQPPNCLQPCPTPGYYGPACQFRQCQCHGAPCDPQTG
 ACFCPAERTGPSCDVSCSQGTSFFCPSTHPCQNGGVFQTPQGSCSCPPGWMGTICSLCPPEGFHGPNC
 SQECRCHNGLCDRFTGQCRCAPGYTGDRCREECPVGRFGQDCAETCDCAPDARCFPANGACLCEH
 GFTGDRCTDRLCPDGFYGLSCQAPCTCDREHSLSCHPMNGECSCLPGWAGLHCNESCQDTHGPGCQ
 EYCLCLHGGVCQATSGLCQCAPGYTGPHCASLCPPDTYGVNCSARCSCEAICSPIDGEVCKEGW
 QRGNCSVPCCPGTWGFSCNASCQCAHEAVCSPQTGACTCTPGWHGAHCQLPCPKQFGEGCASRCD
 CDHSDGCDPVHGRQCQAGWMGARCHLSCPEGLWGVNCNTCTCKNGGTCLPENGNCVCPGFRG
 PSCQRSCQPGRYGKRCVPCCKCANHSFCHPSNGTCYCLAGWTGPDCSQPCPPGHWGENCAQTCQCHH
 GGTCHPQDGSCICPLGWTGHHCLEGCPLGTFGANCSQPCQCGPGEKCHPETGACVCPGHSGAPCRIG
 IQEPTVMPPTPVAYNSLGAIGIAVLGSLVVALVALFIGYRHWQKGKEHHHLAVAYSSGRLDGSEYY
 MPDVPPSYSHYSNPSYHTLSQCSPNPPPKVPGPLFASLQNPERPGGAQGHDNHTLPADWKRRE
 PPPGPLDRGSSHLDRSYSYSNPGPFYDKGLISEELGASVTSLSSENPYATIRDLPSLPGGPRESSYM
 EMKGPPSGSPPRQPPQFWDSQRRQPQQRDSGTYEQPSPLIHDRDSVGSQPLPGLPPGHYDSPKNS
 HIPGHYDLPPVRHPPSPPLRRQDR

10

One or more consensus positions (Cons. Pos.) of the nucleotide sequence have been identified as SNPs as shown in Table 1M. "Depth" represents the number of clones covering the region of the SNP. The Putative Allele Frequency (Putative Allele Freq.) is the fraction of all the clones containing the SNP. A dash ("-"), when shown, means that a base is not present. The sign ">" means "is changed to".

Table 1M. SNPs of NOV1e

Cons.Pos.	Depth	Change	Putative	Fragment Listing
-----------	-------	--------	----------	------------------

			Allele Freq.	
2716	10	G > A	0.200	163608053(-,i,119650936) Fpos: 482 163610839(-,i,119650936) Fpos: 485
2758	9	G > A	0.333	172614573(+,i,-1) Fpos: 132 172614575(+,i,-1) Fpos: 148 172614579(+,i,-1) Fpos: 146

The NOV1 amino acid sequence has 834 of 1064 amino acid residues (78%) identical to, and 881 of 1064 amino acid residues (82%) similar to, the 1034 amino acid residue gi|17386053|gb|AAL38571.1 AF444274_1 (AF444274) Jedi protein [Mus musculus] (E = 0.0).

NOV1b, NOV1c and NOV1d are expressed in at least the following tissues: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea and uterus. NOV1e is expressed in at least the following tissues: adipose, heart, aorta, umbilical vein, pancreas, parathyroid gland, thyroid, stomach, liver, colon, bone marrow, peripheral blood, bone, cartilage, synovium/synovial membrane, brain, thalamus, cervix, placenta, amnion, vulva, testis, lung, kidney, skin, epidermis and dermis. Expression information was derived from the tissue sources of the sequences that were included in the derivation of each of the sequences of NOV1.

NOV1a, NOV1b, NOV1c, NOV1d and NOV1e are very closely homologous as is shown in the amino acid alignment in Table 1N.

Table 1N. Amino Acid Alignment of NOV1a, NOV1b, NOV1c, NOV1d and NOV1e

COR87920446
CG57012-01
CG57012-02
CG57012-03
CG57012-04

COR87920446_A
CG57012-01
CG57012-02
CG57012-03
CG57012-04

四

110 120 130 140 150

COR87920446_A
CG57012-01

CG57012-02
CG57012-03
CG57012-04

160 170 180 190 200
.....|.....|.....|.....|.....|.....|.....|.....|

COR87920446_A

CG57012-01
CG57012-02
CG57012-03
CG57012-04

210 220 230 240 250
.....|.....|.....|.....|.....|.....|.....|.....|

COR87920446_A

CG57012-01
CG57012-02
CG57012-03
CG57012-04

P
P

260 270 280 290 300
.....|.....|.....|.....|.....|.....|.....|.....|

COR87920446_A

CG57012-01
CG57012-02
CG57012-03
CG57012-04

310 320 330 340 350
.....|.....|.....|.....|.....|.....|.....|.....|

COR87920446_A

CG57012-01
CG57012-02
CG57012-03
CG57012-04

360 370 380 390 400
.....|.....|.....|.....|.....|.....|.....|.....|

C

COR87920446_A

CG57012-01
CG57012-02
CG57012-03
CG57012-04

410 420 430 440 450
.....|.....|.....|.....|.....|.....|.....|.....|

R

COR87920446_A

CG57012-01
CG57012-02
CG57012-03
CG57012-04

Y

460 470 480 490 500
.....|.....|.....|.....|.....|.....|.....|.....|

COR87920446_A

CG57012-01
CG57012-02
CG57012-03
CG57012-04

510 520 530 540 550
.....|.....|.....|.....|.....|.....|.....|.....|

COR87920446_A

CG57012-01
CG57012-02
CG57012-03
CG57012-04

560 570 580 590 600
.....|.....|.....|.....|.....|.....|.....|.....|

COR87920446_A

CG57012-01

CG57012-02	-----
CG57012-03	-----
CG57012-04	-----
COR87920446_A	1060
CG57012-01	-----
CG57012-02	-----
CG57012-03	-----
CG57012-04	-----

Homologies to any of the above NOV1 proteins will be shared by the other NOV1 proteins insofar as they are homologous to each other as shown above. Any reference to NOV1 is assumed to refer to both of the NOV1 proteins in general, unless otherwise noted.

NOV1 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 1O.

Table 1O. BLAST results for NOV1					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<u>gi 17386053 gb AAI38571.1 AF444274_1</u> (AF444274)	Jedi protein [Mus musculus]	1034	834/1064 (78%)	881/1064 (82%)	0.0
<u>gi 17017251 gb AAL3_3583.1 AF440279_1</u> (AF440279)	MEGF12 [Mus musculus]	1034	836/1064 (78%)	882/1064 (82%)	0.0
<u>gi 14192943 ref NP_115822.1 </u> (NM_032446)	MEGF10 protein [Homo sapiens]	1140	349/713 (48%)	422/713 (58%)	e-163
<u>gi 14724016 ref XP_030163.1 </u> (XM_030163)	MEGF10 protein [Homo sapiens]	1140	349/713 (48%)	422/713 (58%)	e-163
<u>gi 14017777 db BAB_47409.1 </u> (AB058676)	MEGF10 protein [Homo sapiens]	1140	349/713 (48%)	422/713 (58%)	e-163

The homology of these sequences is shown graphically in the ClustalW analysis shown in 10 Table 1P.

Table 1P. ClustalW Analysis of NOV1

- 1) NOV1a (SEQ ID NO:2)
- 2) NOV1b (SEQ ID NO:4)
- 3) NOV1c (SEQ ID NO:6)
- 4) NOV1e (SEQ ID NO:10)
- 5) NOV1d (SEQ ID NO:8)
- 6) gi|17386053|gb|AAI38571.1|AF444274_1 (AF444274) Jedi protein [Mus musculus]
(SEQ ID NO:31)

7) gi|7017251|gb|AAL33585.1|AF440279| (AF440279) MEGF12 [Mus musculus] (SEQ ID NO:32)
 8) gi|14192943|ref|NP_115822.1| (NM_032446) MEGF10 protein [Homo sapiens] (SEQ ID NO:33)
 9) gi|14192941|ref|NP_115821.1| (NM_032445) MEGF11 protein [Homo sapiens] (SEQ ID NO:34)
 10) gi|16161114|ref|XP_050906.2| (XM_050906) MEGF11 protein [Homo sapiens] (SEQ ID NO:35)

	10	20	30	40	50
NOV1a COR87920446_A	-----M P	V	PS	T	S
NOV1b CG57012-01	-----M P	V	PS	T	S
NOV1c CG57012-02	-----M P	V	PS	T	S
NOV1e CG57012-04	-----M P	V	PS	T	S
NOV1d CG57012-03	-----M P	V	PS	T	S
gi 17386053	-----M	L T	SN	V T	L
gi 17017251	-----M	L T	SN	V T	L
gi 14192943	MVISLN	CLSFIC	CHWIGT	SP	LE V H YSV VQ YPH
gi 14192941	-----	-----	-----	-----	-----
gi 16161114	-----	-----	-----	-----	-----
	60	70	80	90	100
NOV1a COR87920446_A	S P E	G P		H Q	H
NOV1b CG57012-01	S P E	G P		H Q	H
NOV1c CG57012-02	S P E	G P		H Q	H
NOV1e CG57012-04	S P E	G P		H Q	H
NOV1d CG57012-03	S P E	G P		H Q	H
gi 17386053	A S H	D A		M S P	R Y
gi 17017251	A S H	D A		M S P	R Y
gi 14192943	DQIYYTS	TDILN-WFK	TRHR S	A HGE	MY RKS P
gi 14192941	-----	MH PSI	-SITHDAQ	SSTGSS--AP	--
gi 16161114	-----	MH PSI	-SITHDAQ	SSTGSS--AP	--
	110	120	130	140	150
NOV1a COR87920446_A	F		V D		
NOV1b CG57012-01	F		V D		
NOV1c CG57012-02	F		V D		
NOV1e CG57012-04	EF		V D		
NOV1d CG57012-03	F		V D		
gi 17386053	A		A G		
gi 17017251	A		A G		
gi 14192943	GEM H DK	I T E	G TN	A DGDH	H T
gi 14192941	-----TA TE	S DT H E	G P	G DSDH	H S
gi 16161114	-----TA TE	S DT H E	G P	G DSDH	H S
	160	170	180	190	200
NOV1a COR87920446_A	P S	V S	T Y	-	
NOV1b CG57012-01	P S	V S	T Y	-	
NOV1c CG57012-02	P S	V S	T Y	-	
NOV1e CG57012-04	P S	V S	T Y	-	
NOV1d CG57012-03	P S	V S	T Y	-	
gi 17386053	F H	A F	PA H	D	-Y
gi 17017251	F H	T F	PA H	D	-Y
gi 14192943	SR Q K	GAL N IT A H AA	FRGWR EDR EQ T	ND HQ	QN
gi 14192941	NR Q Q	GAL N IT A V AA	FRGWR EEL A TH KG	LP	R
gi 16161114	NR Q Q	GAL N IT A V AA	FRGWR EEL A TH KG	LP	R
	210	220	230	240	250
NOV1a COR87920446_A	P	AE	D S	S	S HS F TP
NOV1b CG57012-01	P	AE	D S	S	S HS F TP
NOV1c CG57012-02	P	AE	D S	S	S HS F TP
NOV1e CG57012-04	P	AE	D S	S	S HS F TP
NOV1d CG57012-03	P	AE	D S	S	S HS F TP
gi 17386053	S D	PG A	N P	D R Y	P GS
gi 17017251	S D	PG A	N P	D R Y	P GS
gi 14192943	T HV E R	PGY AF	EDL PP KH PQ	EQRC	CHHV

gi 14192941	S RA E L APGY VY EEL PP SH AH ELRC	TCHHI
gi 16161114	S RA E L APGY VY EEL PP SH AH ELRC	TCHHI
	260 270 280 290 300	
NOV1a COR87920446_A	VWRVGPVGMCGCGSENVGGAKQGSK	
NOV1b CG57012-01	VWRVGPVGMCGCGSENVGGAKQGSK	
NOV1c CG57012-02	VWRVGPVGMCGCGSENVGGAKQGSK	
NOV1e CG57012-04	-----	
NOV1d CG57012-03	-----	
gi 17386053	----- V	
gi 17017251	----- V	
gi 14192943	T E S ----- V GQ RF	
gi 14192941	T E A T ----- AV AQ P TF	
gi 16161114	T E A T ----- AV AQ P TF	
	310 320 330 340 350	
NOV1a COR87920446_A	R R	
NOV1b CG57012-01	R R	
NOV1c CG57012-02	R R	
NOV1e CG57012-04	R R	
NOV1d CG57012-03	R R	
gi 17386053	T H I Q	
gi 17017251	T H I Q	
gi 14192943	K Q T AA H S E QD TY VL	
gi 14192941	Q D P H Q HV H TA M Q F S FQ SQR	
gi 16161114	Q D P H Q HV H TA M Q F S FQ SQH	
	360 370 380 390 400	
NOV1a COR87920446_A	D D F A R	
NOV1b CG57012-01	D D F A R R	
NOV1c CG57012-02	D D F A R R	
NOV1e CG57012-04	D D F A R	
NOV1d CG57012-03	D D F A R R	
gi 17386053	G E R E P	
gi 17017251	G E R E P	
gi 14192943	Q VNGGK YHVS A A E EA E L IK DKR P HL	
gi 14192941	HNGGQ S TT E P YK P QE E LH PG TL P AD	
gi 16161114	HNGGQ S TT E P YK P QE E LH PG TL P AD	
	410 420 430 440 450	
NOV1a COR87920446_A	N L H V Q	
NOV1b CG57012-01	N L H V Q	
NOV1c CG57012-02	N L R V Q	
NOV1e CG57012-04	N L Y V Q	
NOV1d CG57012-03	N L H V Q	
gi 17386053	H Q H L L	
gi 17017251	H Q H L L	
gi 14192943	NTH S A K S Y T SPGFY EA QI S QN AD DS	
gi 14192941	NTI VT A T Q S H VGYY D LP T QN AD HS	
gi 16161114	NTI VT A T Q S H VGYY D LP T QN AD HS	
	460 470 480 490 500	
NOV1a COR87920446_A	T Q S V A E V	
NOV1b CG57012-01	T Q S V A E V	
NOV1c CG57012-02	T Q S V A E V	
NOV1e CG57012-04	T Q S V A E V	
NOV1d CG57012-03	T Q S V A E V	
gi 17386053	D R N I S T I	
gi 17017251	D R N I S T I	
gi 14192943	VT K T FK ID STP LG I S G K DAV V S T	
gi 14192941	IT G T FM EV VS AAG P SI N GGT V S T	
gi 16161114	IT G T FM EV VS AAG P SI N GGT V S T	
	510 520 530 540 550	
NOV1a COR87920446_A	P S E	
NOV1b CG57012-01	P S E	

NOV1c CG57012-02	P	S	E																	
NOV1e CG57012-04	P	S	E																	
NOV1d CG57012 03	P	S	E																	
gi 17386053	L	N	DG																	
gi 17017251	L	N	DG																	
gi 14192943	A	HGVD	IR	S	G	LT	LNGGA	NTLD	T	A	R	E								
gi 14192941		GLD	TL	S	LN	E	T	NG	A	ID	S	S								
gi 16161114		GLD	TL	S	LN	E	T	NG	A	ID	S	S								
					560	570	580	590	600											
															
NOV1a COR87920446_A							R	Q		A	S									
NOV1b CG57012-01							R	Q		A	S									
NOV1c CG57012-02							R	Q		A	S									
NOV1e CG57012-04							R	Q		A	S									
NOV1d CG57012-03							R	Q		A	S									
gi 17386053					V		Q	R		T	P									
gi 17017251					V		Q	R		T	P									
gi 14192943	K	E	QD	TY	LN	E	S	A	H	TT	H	R	LP	S	VH	DSV	A			
gi 14192941	T	E	D	T	LN	SEH	S	A		T	H	C	L	T	I	DST				
gi 16161114	T	E	D	T	LN	SEH	S	A		T	H	C	L	T	I	DST				
					610	620	630	640	650											
															
NOV1a COR87920446_A	L	V				L					S	Q								
NOV1b CG57012-01	L	V				L					S	Q								
NOV1c CG57012-02	L	V				L					S	Q								
NOV1e CG57012-04	L	V				L					S	Q								
NOV1d CG57012-03	L	V				L					S	Q								
gi 17386053	F	A				VS					P	P								
gi 17017251	F	A				VS					P	P								
gi 14192943	R	P	LP	Y	AS	S	DD	I	E		TT	I	S	F	H					
gi 14192941	P	R	P	VS	S	E	S	S	D	E		L	I	P	F	HG				
gi 16161114	P	R	P	VS	S	E	S	S	D	E		L	I	P	F	HG				
					660	670	680	690	700											
															
NOV1a COR87920446_A	P--	A	-	F	N	T	Y			R	-----									
NOV1b CG57012-01	P--	A	-	F	N	A	Y			P	EN	T								
NOV1c CG57012-02	P--	A	-	F	N	A	Y			P	EN	T								
NOV1e CG57012-04	P--	A	-	F	N	T	Y			P	EN	T								
NOV1d CG57012-03	P--	A	-	F	N	T	Y			P	EN	T								
gi 17386053	Q--	N	N	S	D	T	S			EA	LK	S	L							
gi 17017251	Q--	N	N	S	D	T	S			EA	LK	S	L							
gi 14192943	SQTCPQ	VHSSGP	HIT	L	D	P	F	AL	NEV	S	RF	KN	GI							
gi 14192941	AQPCPL	VHSSRP	HIS	I	E	P	FS	AL	N	V	AG	YF	QD	L						
gi 16161114	AQPCPL	VHSSRP	HIS	I	E	P	FS	AL	N	V	AG	YF	QD	L						
					710	720	730	740	750											
															
NOV1a COR87920446_A	-----						L	T	A	P	GP	K								
NOV1b CG57012-01							PL	HH	L	T	A	P	GP	K						
NOV1c CG57012-02							PL	HH	L	T	A	P	GP	K						
NOV1e CG57012-04							PL	HH	L	T	A	P	GP	K						
NOV1d CG57012-03							PL	HH	L	T	A	P	GP	K						
gi 17386053							TP	PN	PRM	V	L	DL	M							
gi 17017251							TP	PN	PRM	V	L	DL	M							
gi 14192943	T	TNN	N	I	R	Q	Y	P	I	SD	SQ	PAHW	P	IHT	N	HN	AF			
gi 14192941	S	ANN	S	I		Q	FP		I	KD	SQA	P	FW	PA	FHA	S	HN	AS		
gi 16161114	S	ANN	S	I		Q	FP		I	KD	SQA	P	FW	PA	FHA	S	HN	AS		
					760	770	780	790	800											
															
NOV1a COR87920446_A							P	RI	I	P	V	T	AY	-						
NOV1b CG57012-01							P	RI	I	P	V	T	AY	-						
NOV1c CG57012-02							P	RI	I	P	V	T	AY	-						
NOV1e CG57012-04							P	RI	I	P	V	T	AY	-						
NOV1d CG57012-03							P	RI	I	P	V	T	AY	-						
gi 17386053							Q		D	KM	S	S	I	S	TH	-				
gi 17017251								D	KM	S	S	I	S	TH	-					
gi 14192943	SAYD	E	K	T	WT	LY	TQRCPLG	YGKDCALICQCQN	DCDH	SGQ										
gi 14192941	SA	D	H	T	WT	LF	TQRCPAA	FGKDCGR	CQCQN	SCDH	SGK									

gi 16161114	SA	D	H	T	WT	LF	TQRCPAA	FGKDCGR	CQCQN	SCDH	SGK			
					810		820		830		840		850	
.	
NOV1a	COR87920446_A	S	V	H	--	H		S	--	E				
NOV1b	CG57012-01	S	V	H	--	D	H	S	--	E				
NOV1c	CG57012-02	S	V	H	--	D	H	S	--	E				
NOV1e	CG57012-04	S	V	H	--	H		S	--	E				
NOV1d	CG57012-03	S	V	H	--	D	H	S	--	E				
gi 17386053		T	I	Q	--	E		T	--	D				
gi 17017251		T	I	Q	--	E		T	--	D				
gi 14192943		CTCRTGFMGRHCEQKCPGTY YGCRQICDCLNNSTC HIT TC CS GW												
gi 14192941		CTCRTGFTGQHCEQ CAPGTF YGCQQ CECMNNSTC HVT TC CS GF												
gi 16161114		CTCRTGFTGQHCEQ CAPGTF YGCQQ CECMNNSTC HVT TC CS GF												
					860		870		880		890		900	
.	
NOV1a	COR87920446_A	P												
NOV1b	CG57012-01	P												
NOV1c	CG57012-02	P												
NOV1e	CG57012-04	P												
NOV1d	CG57012-03	P												
gi 17386053		S						S						
gi 17017251		S						S						
gi 14192943		KGARCDQAGVIIVGVLNS RT TAL ADSYQI AIAIGIIILVVLVLFLL												
gi 14192941		KGIRCDQA-ALMMEELNPYTKI ALGAERHSV AVTGIMLLLFFIVVLL												
gi 16161114		KGIRCDQA-ALMMEELNPYTKI ALGAERHSV AVTGIMLLLFLIVVLL												
					910		920		930		940		950	
.	
NOV1a	COR87920446_A	P	L	K	G	Q	HD		PPG					
NOV1b	CG57012-01	P	L	N	G	Q	HD		PPG					
NOV1c	CG57012-02	P	L	N	G	Q	HD		PPG					
NOV1e	CG57012-04	P	L	N	G	Q	HD		PPG					
NOV1d	CG57012-03	P	L	N	G	Q	HD		PPG					
gi 17386053		Q	V	S	A	SR	H	RE	V					
gi 17017251		Q	V	S	A	SR	H	RE	V					
gi 14192943		A	IIYRHKQKGK-ESSMPAV	YT	MRVVNADYTISGTLPHSNGGNANS									
gi 14192941		G	WHRRRQKEK	RDLAPRVSYT	MRMTSTDYSLSL									
gi 16161114		G	WHRRRQKEK	RDLAPRVSYT	MRMTSTDYSLSL									
					960		970		980		990		1000	
.	
NOV1a	COR87920446_A												PLD	
NOV1b	CG57012-01												PLD	
NOV1c	CG57012-02												PLD	
NOV1e	CG57012-04												PLD	
NOV1d	CG57012-03												PLD	
gi 17386053													HE	
gi 17017251													HE	
gi 14192943													HYFTNPSYHTLTQCATSPHVNDRMTVTKSKNNQLFVNLLKNVNPGRGP	
gi 14192941														
gi 16161114														
					1010		1020		1030		1040		1050	
.	
NOV1a	COR87920446_A	SSR	---	L	SY	--	S	SY	-----	SN	P	PFYN	GLIS	EELGA
NOV1b	CG57012-01	RCR	---	EA	-----	-----	-----	-----	-----	VS	A	-----	-----	-----
NOV1c	CG57012-02	RCR	---	EA	-----	-----	-----	-----	-----	VS	A	-----	-----	-----
NOV1e	CG57012-04	SSH	---	L	SY	--	S	SY	-----	SN	P	PFYD	GLIS	EELGA
NOV1d	CG57012-03	SSR	---	L	SY	--	S	SY	-----	SN	P	PFYN	GLIS	EELWA
gi 17386053		ASH	---	L	SYSCS	SH	-----	-----	-----	RN	P	PFCH	GPIS	EGLGA
gi 17017251		ASH	---	L	SYSCS	SH	-----	-----	-----	RN	P	PFCH	GPIS	EGLGA
gi 14192943		V	DCTGTLPA	WKHG-G	LNELGAFGLDRSYM	KS	--	L	DLGKNSEYNS					
gi 14192941		-	ACG	--	M	RQN-T	I	-----	-----	MDK	--	F	DYMK	SVCSS
gi 16161114		-	ACG	--	M	RQN-T	I	-----	-----	MDK	--	F	XXXXXXXXXX	
					1060		1070		1080		1090		1100	
.	
NOV1a	COR87920446_A	VA	-	R	L	S	PGGPR	S	M	G	PSGSP	RQPPQFWD		
NOV1b	CG57012-01	-----	GCVQ	RCRV	-----	-----	-----	-----	-----	-----	-----	-----		
NOV1c	CG57012-02	-----	GCVQ	RCRV	-----	-----	-----	-----	-----	-----	-----	-----		

NOV1e CG57012-04	VT	-	R L S PGGPR S M G PSGSP RQPPQFWD
NOV1d CG57012-03	VA	-	R L S PGGPR S M G PSGSP RQPPQFWD
gi 17386053	VM	-	R L S PGEPR G V G PSVSP RQSLHLRD
gi 17017251	VM	-	R L S PGEPR G V G PSVSP RQSLHLRD
gi 14192943	NC	S	K P V IPKSS CG V S ARRDS YAEINNST
gi 14192941	TC	N	K P I TCKLP S V S VHMGS YTDVPSLS
gi 16161114			XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX S VHMGS YTDVPSLS

		1110	1120	1130	1140	1150
NOV1a COR87920446_A					
NOV1b CG57012-01		SQR RQPQPQRDSGT	QPSPLIHDRDSV SQPP PPGLPPGH	S		
NOV1c CG57012-02		-----	-----	-----	-----	-----
NOV1e CG57012-04		SQR RQPQPQRDSGT	QPSPLIHDRDSV SQPP PPGLPPGH	S		
NOV1d CG57012-03		SQR RQPQPQRDSGT	QPSPLIHDRDSV SQPP PPGLPPGH	S		
gi 17386053		RQQ -QLQPQRDSGT	QPSPLSHNEESL STPP PPGLPPQ	S		
gi 17017251		RQQ -QLQPQRDSGT	QPSPLSHNEESL STPP PPGLPPGH	S		
gi 14192943		SAN -----NV	VEPTVSVVQGVFSNNGR SQ----DP	L		
gi 14192941		TSNK-----NI	VEPTVSVVQEGC HNSSYIQ----NA	L R		
gi 16161114		TSNK-----NI	VEPTVSVVQEGC HNSSYIQ----NA	L R		

		1160	1170	1180
NOV1a COR87920446_A			
NOV1b CG57012-01		P HP P-----	LRRQDR---	
NOV1c CG57012-02		-----	-----	-----
NOV1e CG57012-04		P HP P-----	LRRQDR---	
NOV1d CG57012-03		P HP P-----	SRRQDR---	
gi 17386053		P HP P-----	SRRQDR---	
gi 17017251		C L DSS SPKQEDSGGSSSNSSSSE		
gi 14192943		L QS AN-----G SQDKQS--		
gi 14192941		L QS AN-----G SQDKQS--		
gi 16161114				

A sequence of about thirty to forty amino-acid residues long found in the sequence of epidermal growth factor (EGF) has been shown to be present, in a more or less conserved form, in a large number of other, mostly animal proteins. The list of proteins currently known to contain one or more copies of an EGF-like pattern is large and varied. The functional significance of EGF domains in what appear to be unrelated proteins is not yet clear. However, a common feature is that these repeats are found in the extracellular domain of membrane-bound proteins or in proteins known to be secreted (exception: prostaglandin G/H synthase). The EGF domain includes six 5 cysteine residues which have been shown (in EGF) to be involved in disulfide bonds. The main structure is a two-stranded beta-sheet followed by a loop to a C-terminal short two-stranded sheet. Subdomains between the conserved cysteines vary in length.

Ligands of the Delta/Serrate/lag-2 (DSL) family and their receptors, members of the lin-12/Notch family, mediate cell-cell interactions that specify cell fate in invertebrates and 10 vertebrates. In *C. elegans*, two DSL genes, lag-2 and apx-1, influence different cell fate decisions during development. Molecular interaction between Notch and Serrate, another EGF-homologous transmembrane protein containing a region of striking similarity to Delta, has been shown and the same two EGF repeats of Notch may also constitute a Serrate binding domain.

The Notch signaling pathway is a conserved intercellular signaling mechanism that is essential for proper embryonic development in numerous metazoan organisms. Members of the Notch gene family encode transmembrane receptors that are critical for various cell fate decisions. Multiple ligands that activate Notch and related receptors have been identified, 5 including Serrate and Delta in *Drosophila* and JAG1 in vertebrates. By searching for human brain expressed sequence tags (ESTs) homologous to Serrate and Delta, (Luo et al. (1997) *Molec. Cell. Biol.* 17: 6057-6067) identified a cDNA which they called Jagged-2 (JAG2). The predicted 1,238-amino acid JAG2 protein has several recognizable motifs, including a signal peptide, 16 EGF-like repeats, a transmembrane domain, and a short cytoplasmic domain. The amino acid sequence of human JAG2 is 89% identical to that of rat Jag2. Northern blot analysis and in situ hybridization showed expression of Jag2 in various murine tissues. Immunohistochemistry revealed coexpression of Jag2 and Notch1 within murine fetal thymus and other murine fetal tissues. Coculture of fibroblasts expressing human JAG2 with murine C2C12 myoblasts inhibited myogenic differentiation. This effect was simulated by expression of constitutively active Notch1, suggesting that JAG2 engages the Notch1 pathway of signal transduction.

Jiang et al. (1998) (*Genes Dev.* 12: 1046-1057) examined the in vivo role of the Jag2 gene by making a targeted mutation that removed a domain of the Jagged-2 protein required for receptor interaction. Mice homozygous for this deletion died perinatally because of defects in craniofacial morphogenesis. The mutant homozygotes exhibited cleft palate and fusion of the tongue with the palatal shelves. They also exhibited syndactyly of the fore- and hindlimbs. The apical ectodermal ridge (AER) of the limb buds of the mutant homozygotes was hyperplastic, and Jiang et al. (1998) (*Genes Dev.* 12: 1046-1057) observed an expanded domain of Fgf8 expression in the AER. In the foot plates of the mutant homozygotes, both Bmp2 and Bmp7 expression and apoptotic interdigital cell death were reduced. Mutant homozygotes also displayed defects in thymic development, exhibiting altered thymic morphology and impaired differentiation of T cells of the gamma/delta lineage. These results demonstrated that Notch signaling mediated by Jag2 plays an essential role during limb, craniofacial, and thymic development in mice.

Lanford et al. (1999) (*Nature Genet.* 21: 289-292) showed that the genes encoding the receptor protein Notch1 and its ligand, Jag2, are expressed in alternating cell types in the 30 developing sensory epithelium of the mammalian cochlea (the organ of Corti). The sensory epithelium contains 4 rows of mechanosensory hair cells: a single row of inner hair cells and 3

rows of outer hair cells. Each hair cell is separated from the next by an interceding supporting cell, forming an invariant and alternating mosaic that extends the length of the cochlear duct. Previous results had suggested that determination of cell fates in the cochlear mosaic occurs via inhibitory interactions between adjacent progenitor cells. Cells populating the cochlear epithelium appear to constitute a developmental equivalence group in which developing hair cells suppress differentiation in their immediate neighbors through lateral inhibition. Lanford et al. (1999) (Nature Genet. 21: 289-292) also found that genetic deletion of Jag2 results in a significant increase in sensory hair cells, presumably as the result of a decrease in Notch activation. These results provided direct evidence for Notch-mediated lateral inhibition in a mammalian system and supported a role for Notch in the development of the cochlear mosaic.

The protein similarity information, expression pattern, and map location for the NOV1 proteins and nucleic acids disclosed herein suggest that it may have important structural and/or physiological functions characteristic of the family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

The nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: cardiovascular disease, Alagille syndrome, neural development defects, other developmental defects and other diseases, disorders and conditions of the like.

NOV2

A disclosed NOV2 nucleic acid (designated as CuraGen Acc. No. COR87940554), which encodes a novel secretin receptor precursor-like protein includes the 1833 nucleotide sequence (SEQ ID NO:11) shown in Table 2A. An open reading frame for the mature protein was

identified beginning with an ATG codon at nucleotides 74-76 and ending with a TGA codon at nucleotides 1745-1747. Putative untranslated regions are underlined in Table 2A, and the start and stop codons are in bold letters.

Table 2A. NOV2 Nucleotide Sequence (SEQ ID NO:11)

AGCGAGTCGCTGTCAGGCCGCTCCTCTCCGGCGTCTGATTTCTACCCCTCGCGCCCTGCTCTCCTCAT
GTTGGCATCCCCGGCACGGAGACCACCGCTCTCATGTCCTCAGACTGAGGCCACCTGGCCCTGCGGGCCCCGCC
TCCTCTTGGCACCGCGGGCAGCCCCGCTCGGCCCCCTCTCGCGAGCGCCGCTCTCCGGGAAGGCTGA
GCCCGGCGCGCTCTCGAGACCTAGCCGCCAGCTCAGTCATCTGGGACTGCTGAGCTCTGGTCTCAACC
AGCCTCACTCCTCCGGAACCCCCGGATCCTCCAGACTCCGCTGGCCCACGAGGAGCCCACCTCAAGCTCTAA
AGAACCCCCCAGGGCACATGGATGGGGCAGCTCCGTGAAGGCTGTGGACTCTGCATGCTCTGAGCTACGGG
ATCTTCAGGGGCCGGGCTCCAGGGAGCCCTAAGGGCTCTGAAGCTGTGGCCCTAGAGCGGCGGGAGCA
GGAAGAAAAGGAGGACATGGAGACCCAGGCTGTGGCAACGTCCCCGATGGCCGATACCTCAAGTTGACATCGA
GATTGGACGTGGCTCTCAAGACGGTGTATCGAGGGCTAGACACCGACACCAAGTGGAGGTGGCTGGTGTGA
GCTCAGACTCGAAACTGTCTAGAGCTGAGCGGCAGCGCTCTCAGAGGAGGTGGAGATGCTCAAGGGCTGCA
GCACCCCAACATCGCCCTCTATGATTGGAAAGTCGGTGTAGGGGCCAGGTTGATCGTGTGGCTAC
CGAACTCATGACCTCGGCACGCTCAAGACGTACCTGAGGGCTCCGGGAGATGAAGCCGGGTCTTCAGCG
CTGGAGCGCCAATCTGCGGGACTTCATTCCTACACTCCGGTCTCCCATCTGCACCGGGATCTCAA
GTGGCACAATGTCTTATCACGGGACCTACTGGCTCTGCTAAAATCGGGACCTGGGCTGGCACGCTCAAGCG
CGCCTCTTGCAGGTGTACGGACGGTGTGCACTGGGAGATGGCCACCTCTGAGTACCGTACTCCGAGTGCCA
GGCCGTGGACGTGTACGGCGATGTGCACTGGGAGATGGCCACCTCTGAGTACCGTACTCCGAGTGCCA
GAATGCCCGCAAATCTACCGCAAGGTCACTCGGGCAGAAAGCCGAACAGCTCCACAAGGTGAAGATAACCGA
GGTGAAGGAGATCATTGAAGGCTGACCGACGGATAAGAACGAGAGGTTACCATCCAGGACCTCTGGCCA
CGCCTCTTCCCGAGGGAGCGCGGTGTGCACTGGGAGATGGCCACCTCTGAGTACCGTACTCCGAGTGCCA
GCTCTGGCTGCGCATGGAGGACGCGCGGGCGGGGGCGCCACGGGACAACCAGGCCATGAGTTCTGTTCCA
GCTGGCCGGGACGCGGGCAGGGAGGTGGCACAGGAGATGGTGGCTCTGGGCTTGGTCTGTGAAGCCGATTACCA
GCCAGTGGCCGTGCACTGAAACGGTTGCTGCCATCCAGCGAAAGCGTGAAGCTGCTAAAGCAAGGGA
ATTGGAGGCACTCCACCAAGAGCCAGGACCTCCACCAGCAACTGTGCCATGGACCCCGGTCCACCAACAGATGT
CTATCCACCCATGAGACCTGAGGAGCAAGAGGCAAGACAGCACCTCCTTATTACAGACACGCCAA
GCTACTCATCTACCACTTCGGATTGCGAGACTG

5

The nucleic acid sequence of NOV2 maps to chromosome 17 and has 1025 of 1464 bases (70%) identical to a gb:GENBANK-ID:AB044546|acc:AB044546.1 mRNA from Homo sapiens (Homo sapiens P/OKcl.13 mRNA for mitogen-activated protein kinase kinase kinase, partial cds).

The NOV2 polypeptide (SEQ ID NO:12) is 557 amino acid residues in length and is presented using the one-letter amino acid code in Table 2B. The SignalP, Psort and/or Hydropathy results predict that NOV2 is likely to be localized in the nucleus with a certainty of 0.6000. In alternative embodiments, a NOV2 polypeptide is located in the mitochondrial matrix space with a certainty of 0.3600 or the lysosome (lumen) with a certainty of 0.1000.

Table 2B. Encoded NOV2 Protein Sequence (SEQ ID NO:12)

MLASPATETTVLMQSQTeadLALRPPPLGTAGQPRLGPPPRARRFSGKAEPRPRSSRPSRSSVLDGLLSSWS

QPASLLPEPPDPPDSAGPTRSPPSSSKEPPEGTWMGAAPVKAVDSACPELTGSSGGPGSREPLRVPEAVALERR
 REQEEKEDMETQAVATSPDGRYLKFDIEIGRGSFKTVYRGLDTDTTVEAWCELQTRKLSRAERQRFSEEVEML
 KGLQHPNIVRFYDSWKSVLRGQCVICLVTELMTSGLTKYLRRFREMKPRLQRWSRQILRGLHFLHSRVPPIL
 HRDLKCDNVFITGPTGSVKIGDLGLATLKRASFAKSVIGTPEFMAPEMYEEKYDEAVDVAFGMCMLEMATSEY
 PYSECQNAAQIYRKVTSGRKPNFHKVKIPEVKEIEGCIRTDKNERFTIQDLLAHAFFREERGVHVELAEDD
 GEKPGKLWLRMEDARRGGRPRDNQAIEFLFQLGRDAEEVAQEMVALGLVCEADYQPVARAVRERVAIQRKR
 EKLKARELEALPPEPGPPPATVPMMDPGPPTDVYPPHET

The NOV2 amino acid sequence to 521 of 552 amino acid residues (94%) identical to, and 524 of 552 amino acid residues (94%) similar to, the 1243 amino acid residue
 5 gi|15212448|gb|AAK91995.1|AF390018_1 (AF390018) protein from Homo sapiens (PUTATIVE PROTEIN KINASE WNK4) (E = 0.0).

NOV2 is expressed in at least the following: blood, lymphocyte, breast, tonsil, colon, lymph, stomach, adrenal gland, kidney, testis, lung.

NOV2 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 2C.

Table 2C. BLAST results for NOV2					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<u>gi 15212448 gb AAK91995.1 AF390018_1</u> (AF390018)	putative protein kinase WNK4 [Homo sapiens]	1243	521/552 (94%)	524/552 (94%)	0.0
<u>gi 15277312 ref NP_115763.1 </u> (NM_032387)	putative protein kinase WNK4 [Homo sapiens]	1231	509/540 (94%)	512/540 (94%)	0.0
<u>gi 15131540 emb CAC48387.1 </u> (AJ316534)	serine/threonine protein kinase [Homo sapiens]	1231	509/540 (94%)	512/540 (94%)	0.0
<u>gi 6933864 gb AAF31483.1 </u> (AF061944)	kinase deficient protein KDP [Homo sapiens]	670	309/479 (64%)	372/479 (77%)	e-159
<u>gi 16758634 ref NP_446246.1 </u> (NM_053794)	protein kinase, lysine deficient 1 [Rattus norvegicus]	2126	304/476 (63%)	363/476 (75%)	e-153
<u>gi 8272557 gb AAF74258.1 AF227741_1 </u> (AF227741)	protein kinase WNK1 [Rattus norvegicus]	2126	304/476 (63%)	363/476 (75%)	e-153

gi 12711660 ref NP_061852.1 (NM_018979)	protein kinase, lysine deficient 1; kinase deficient	2382	309/479 (64%)	372/479 (77%)	e-153
gi 11125348 emb CAC_15059.1 (AJ296290)	putative protein kinase [Homo sapiens]	2382	309/479 (64%)	372/479 (77%)	e-153

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 2D.

Table 2D. ClustalW Analysis for NOV2

1) NOV2 (SEQ ID NO:12)
 2) gi|15212448|gb|AAK91995.1|AF390018.1 (AF390018) putative protein kinase WNK4 [Homo sapiens] (SEQ ID NO:36)
 3) gi|15277312|ref|NP_115763.1| (NM_032387) putative protein kinase WNK4 [Homo sapiens] (SEQ ID NO:37)
 4) gi|6933864|gb|AAF31483.1| (AF061944) kinase deficient protein KDP [Homo sapiens] (SEQ ID NO:38)
 5) gi|16758634|ref|NP_446246.1| (NM_053794) protein kinase, lysine deficient 1 [Rattus norvegicus] (SEQ ID NO:39)
 6) gi|12711660|ref|NP_061852.1| (NM_018979) protein kinase, lysine deficient 1; kinase deficient protein [Homo sapiens] (SEQ ID NO:40)

15	10 20 30 40 50	
	
	NOV2 COR87940554	MLASPATETTVL M Q EAD A R P LGTA QP-----R PPPR--
	gi 15212448	MLASPATETTVL M Q EAD A R P LGTA QP-----R PPPR--
	gi 15277312	-----M Q EAD A R P LGTA QP-----R PPPR--
	gi 6933864	---MSGGAAEKQ S PGS F S A APKN SSSDSSVGEK AAAADA
	gi 16758634	---MSDGTAEKQ G PG--F S A VPKN SSSDSSVGEK AAVADS
	gi 12711660	---MSGGAAEKQ S PGS F S A APKN SSSDSSVGEK AAAADA
20	60 70 80 90 100	
	
	NOV2 COR87940554	-----A FSGKAEP ----- RSS PS SVDLGLLSSWSQ
	gi 15212448	-----A FSGKAEP ----- RSS LS SVDLGLLSSWS
	gi 15277312	-----A FSGKAEP ----- RSS LS SVDLGLLSSWS
	gi 6933864	VTGRTEEY R HTMDKDS GAAATTTTEH FF VICDSNATALE
	gi 16758634	GIGRTEEY R HTMDKDS GAAATTTEH FF VICDSNATALE
	gi 12711660	VTGRTEEY R HTMDKDS GAAATTTTEH FF VICDSNATALE
25	110 120 130 140 150	
	
	NOV2 COR87940554	ASL -- E PD --- D G-- T SP----- SSSKE P G
	gi 15212448	AS A-- D PD --- D G G A SP----- SSKE P G
	gi 15277312	AS A-- D PD --- D G G A SP----- SSKE P G
	gi 6933864	GL SL Q SI AAV Q P E H EETVTATATSQVAQQ AAAA G Q
	gi 16758634	GL SI Q SV AVV Q P E H EETLTATVASQVSQQ SAAAS G Q
	gi 12711660	GL SL Q SI AAV Q P E H EETVTATATSQVAQQ AAAA G Q
35	160 170 180 190 200	
	
	NOV2 COR87940554	TWM A -- KAVD-SAC ELTG SG --- G- EPLR---VPEAVA
	gi 15212448	TWTEG -- KAAEDSA ELPD A ---- G- EPLR---VPEAVA
	gi 15277312	TWTEG -- KAAEDSA ELPD A ---- G- EPLR---VPEAVA

gi 6933864	AVA P ST PSSTSVD	VSQP L SKEE PPA SGSG--GGSAKEPQ	
gi 16758634	AVV S TAT PSSTSVD	VSQP L SKEE PP SGSGSGGASAKEPQ	
gi 12711660	AVA P ST PSSTSVD	VSQP L SKEE PPA SGSG--GGSAKEPQ	
5	210 220 230 240 250	
NOV2 COR87940554	L RRE EEK DM Q AT P Y	R D	
gi 15212448	L RRE EEK DM Q AT P Y	R D	
gi 15277312	L RRE EEK DM Q AT P Y	R D	
10	gi 6933864	E SQQ DDI EL K GM N F	K E
gi 16758634	E NQQ DDI EL K GM N F	K E	
gi 12711660	E SQQ DDI EL K GM N F	K E	
15	260 270 280 290 300	
NOV2 COR87940554	T SRA S V	K VLR Q	
gi 15212448	T SRA S V	K VLR Q	
gi 15277312	T SRA S V	K VLR Q	
20	gi 6933864	D TKS K A	E TVK K
gi 16758634	D TKS K A	E TVK K	
gi 12711660	D TKS K A	E TVK K	
25	310 320 330 340 350	
NOV2 COR87940554	V R RE PR QR S R H S V		
gi 15212448	V R RE PR QR S R H S V		
gi 15277312	V R RE PR QR S R H S V		
30	gi 6933864	K KV IK RS C K Q T T	
gi 16758634	K KV IK RS C K Q T T		
gi 12711660	K KV IK RS C K Q T T		
35	360 370 380 390 400	
NOV2 COR87940554	L V		
gi 15212448	L V		
gi 15277312	L V		
35	gi 6933864	I I	
gi 16758634	I I		
40	gi 12711660	I I	
40	410 420 430 440 450	
NOV2 COR87940554	A	K R N	
gi 15212448	A	K R N	
45	gi 15277312	A	K R N
gi 6933864	S	R V A	
gi 16758634	S	R V A	
gi 12711660	S	R V A	
50	460 470 480 490 500	
NOV2 COR87940554	H K TD N FT Q A R R H		
gi 15212448	H K TD N FT Q A R R H		
55	gi 15277312	H K TD N FT Q A R R H	
gi 6933864	D A QN D YS K N Q T R		
gi 16758634	D A QN D YS K N Q T R		
gi 12711660	D A QN D YS K N Q T R		
60	510 520 530 540 550	
NOV2 COR87940554	PGL M ARR-G RPR Q L Q G AA E AL		
gi 15212448	PGL M ARR-G RPR Q L Q G AA E AL		
gi 15277312	PGL M ARR-G RPR Q L Q G AA E AL		
gi 6933864	IAI I IKKLK KYK E S D E VP D ES		

gi 16758634	IAI	I	IKKLK	KYK	E	S	D	E	VP	D	ES		
gi 12711660	IAI	I	IKKLK	KYK	E	S	D	E	VP	D	ES		
		560	570	580	590	600							
5	NOV2 COR87940554	L	A	YQPV	R	VRE	AA	Q	KLRKA	-	L	ALPP	PG-----
gi 15212448	L	A	YQPV	R	VRE	AA	Q	KLRKA	-	L	ALPP	PG-----	
gi 15277312	L	A	YQPV	R	VRE	AA	Q	KLRKA	-	L	ALPP	PG-----	
10	gi 6933864	Y	G	HKT	M	IKD	SL	K	QRQLV	E	Q	KKKQ	ESSLKQQVE
gi 16758634	Y	G	HKT	M	IKD	SL	K	QRQLV	E	Q	KRKQ	ESSFKQQNE	
gi 12711660	Y	G	HKT	M	IKD	SL	K	QRQLV	E	Q	KKKQ	ESSLKQQVE	
		610	620	630	640	650							
15	NOV2 COR87940554	---PPPA	-----V	MD	GPPTD	YP	-----HET	-----					
gi 15212448	---PPPA	-----V	M	GPPSVFPP	--		PFLFR						
gi 15277312	---PPPA	-----V	M	GPPSVFPP	--		PFLFR						
gi 6933864	Q-SSASQ	GIKQLPSASTGI	T	STTSAS	STQV		QLQYQ						
gi 16758634	QQASV	SQAGIQPLSVASTGI	T	TTTSAS	STQV		QLQYQ						
gi 12711660	Q-SSASQ	GIKQLPSASTGI	T	STTSAS	STQV		QLQYQ						
		660	670	680	690	700							
20	NOV2 COR87940554	-----	-----	-----	-----	-----							
gi 15212448	HA	Y	STT	CET	GYLS	G	LDASDPAL	-----P					
gi 15277312	HA	Y	STT	CET	GYLS	G	LDASDPAL	-----P					
gi 6933864	QP	I	-VL	GTV	SGQG	V	TESRGG	-----					
gi 16758634	QP	I	-VL	GTV	SGQG	V	TESRVSSQ	TVSYGSQHEQAHSIGTA					
gi 12711660	QP	I	-VL	GTV	SGQG	V	TESRVSSQ	TVSYGSQHEQAHSIGTV					
		710	720	730	740	750							
25	NOV2 COR87940554	-----	-----	-----	-----	-----							
gi 15212448	GVP	SLAES	---HLCL	AF	LSIPRSG	G	D	-----					
gi 15277312	GVP	SLAES	---HLCL	AF	LSIPRSG	G	D	-----					
gi 6933864	-----	-----	-----	-----	-----	-----	-----	-----					
gi 16758634	HTV	SIQAQSQPHGVYP	SM	QGQNQGQ	S	S-LAGVLSSQPVQHPQQQ							
gi 12711660	HIP	TVQAQSQPHGVYP	SV	QGQSQGQ	S	SSLTGVSSSQPIQHPQQQ							
		760	770	780	790	800							
30	NOV2 COR87940554	-----	-----	-----	-----	-----							
gi 15212448	-----	-----	-----	-----	-----	-----	F P	---					
gi 15277312	-----	-----	-----	-----	-----	-----	F P	---					
gi 6933864	-----	-----	-----	-----	-----	-----							
gi 16758634	-GIQPTVPPQQAVQYSLPQAAASSSEG	-TVQPVSQPQ	-----	V	A	---							
gi 12711660	QGIQQTAPPQQTVQYSLSQTSSEATTAQPVSQPQAPQVLPQV	A	KQL										
		810	820	830	840	850							
35	NOV2 COR87940554	-----	-----	-----	-----	-----							
gi 15212448	-----	-----	-----	-----	-----	-----							
gi 15277312	-----	-----	-----	-----	-----	-----							
gi 6933864	-----	-----	-----	-----	-----	-----							
55	gi 16758634	--TQS	-----	PVSQPVPTIQGEQIPVATQPSVVPHSGAHFLPVGQPLPTPLLPQYPVS									
gi 12711660	PVSQPVPTIQGEQIPVATQPSVVPHSGAHFLPVGQPLPTPLLPQYPVS												
		860	870	880	890	900							
50	NOV2 COR87940554	-----	-----	-----	-----	-----							
gi 15212448	-----	-----	-----	-----	-----	-----							
gi 15277312	-----	-----	-----	-----	-----	-----							
gi 6933864	-----	-----	-----	-----	-----	-----							
60	gi 16758634	--TQS	-----	PVSQPVPTIQGEQIPVATQPSVVPHSGAHFLPVGQPLPTPLLPQYPVS									
gi 12711660	PVSQPVPTIQGEQIPVATQPSVVPHSGAHFLPVGQPLPTPLLPQYPVS												

	gi 12711660	QIPISTPHVSTAQTGFSSLPITMAAGITQPLLTLASSATTAAIPGVSTVV
		910 920 930 940 950
5	NOV2 COR87940554	-----
	gi 15212448	-----
	gi 15277312	-----
	gi 6933864	-----
10	gi 16758634	-----
	gi 12711660	PSQLPTLLQPVTQLPSQVHPQLQPAVQSMGIPANLGQAAEVPLSSGDV
		960 970 980 990 1000
15	NOV2 COR87940554	-----
	gi 15212448	-----
	gi 15277312	-----
	gi 6933864	-----
	gi 16758634	-----
	gi 12711660	YQGFPPRLPPQYPGDSNIAPSSNVASVCIHSTVLSPPMPTEVLATPGYFP
20		1010 1020 1030 1040 1050
25	NOV2 COR87940554	-----
	gi 15212448	-----
	gi 15277312	-----
	gi 6933864	-----
	gi 16758634	-----
	gi 12711660	STQGV TVVQPYVESNLLVPMGGVGGQVQVSQPGGSLAQAPTTSSQQAVLESTQGV
30		1060 1070 1080 1090 1100
35	NOV2 COR87940554	-----
	gi 15212448	----- YA A L VG GMG-----
	gi 15277312	----- YA A L VG GMG-----
	gi 6933864	-----
	gi 16758634	SQAAPPEQTPTIQSQPTQPVPLVSSV AH V M GN NAPSSSGR
	gi 12711660	SQVAPAEPVAVAQQPQATQPTTLASSV AH V M GN NVPSSSGR
40		1110 1120 1130 1140 1150
45	NOV2 COR87940554	-----
	gi 15212448	QMR PPG NL RRP ----- VTS DQN Q S
	gi 15277312	QMR PPG NL RRP ----- VTS DQN Q S
	gi 6933864	-----
	gi 16758634	HEG TTK HY KSV SRHEKTSRPK ILN NKG E R
	gi 12711660	HEG TTK HY KSV SRHEKTSRPK ILN NKG E R
50		1160 1170 1180 1190 1200
55	NOV2 COR87940554	-----
	gi 15212448	R S AA Y E PS DG LRRI QRVETL
	gi 15277312	R S AA Y E PS DG LRRI QRVETL
	gi 6933864	-----
	gi 16758634	K N TI N D AI ES VAQV EKADEM
	gi 12711660	K N TI N D AI ES VDQV EKADEM
60		1210 1220 1230 1240 1250
65	NOV2 COR87940554	-----
	gi 15212448	KR TGPMEAAEDT SPQE----- E APLPAL VPLPD
	gi 15277312	KR TGPMEAAEDT SPQE----- E APLPAL VPLPD
	gi 6933864	-----
	gi 16758634	SE VSVEPEGDQG ESLQGKDDYGFPGSQKLEGEFKQ IAVSSM QQIGV
	gi 12711660	SE VSVEPEGDQG ESLQGKDDYGFPGSQKLEGEFKQ IPASSM QQIGI

		1260	1270	1280	1290	1300	
						
5	NOV2 COR87940554	-----					
	gi 15212448	SNEEL SST LEH -----S-WTAFSTSSSS T					
	gi 15277312	SNEEL SST LEH -----S-WTAFSTSSSS T					
	gi 6933864	-----					
	gi 16758634	TSSLT VVH AGR FIVSPVPESRLRESKIFTSEIPDPVAASTSQG M					
	gi 12711660	TSSLT VVH AGR FIVSPVPESRLRESKVFPEITDTVAASTAQ S M					
10		1310	1320	1330	1340	1350	
						
15	NOV2 COR87940554	-----					
	gi 15212448	-----P P----- NPFS GTPISP I P-----					
	gi 15277312	-----P P----- NPFS GTPISP I P-----					
	gi 6933864	-----					
	gi 16758634	NLHSASS LQQAFSELKHGQMTE PNTA PNPNHP T S---PFLTS					
	gi 12711660	NLHSASS LQQAFSELRAQMTE PNTA PNFSHT T PVVPPFLSS					
20		1360	1370	1380	1390	1400	
						
25	NOV2 COR87940554	-----					
	gi 15212448	-----					
	gi 15277312	-----					
	gi 6933864	-----					
	gi 16758634	IAGVQTVAASTPSVSVPITSSPLNDISTSVMQSEGALPTDKIGGGVTTST					
	gi 12711660	IAGVPTTAAAT--APVPATSSPPNDISTSVIQSEVTVPTEEGIAGVATST					
30		1410	1420	1430	1440	1450	
						
35	NOV2 COR87940554	-----					
	gi 15212448	-----ITSPPCCHPS SPF PI -----QVS NPSPHP SP-----					
	gi 15277312	-----ITSPPCCHPS SPF PI -----QVS NPSPHP SP-----					
	gi 6933864	-----					
	gi 16758634	GVVASGGLTILSVSET TLS AV STAPAVVTVSTT QPVQAF GS--					
	gi 12711660	GVVTSGGLPIPPVSES VLS VV ITIPAVVSISTT PSLQVP TSEI					
40	NOV2 COR87940554		1460	1470	1480	1490	1500
						
	gi 15212448		-----LP				
	gi 15277312		-----LP				
	gi 6933864		-----				
45	gi 16758634	IASSTGSFPSGTFTTTGTTVSSVAVPNAKPPVLLQQVAGNTAGVAIVT					
	gi 12711660	VVSSTALYPSVTVSATASAGGSTATPGPKPPAVVSQQAAGSTTVGATLT					
		1510	1520	1530	1540	1550	
						
50	NOV2 COR87940554						
	gi 15212448	FS S PE VPL CPWSSLPT P FSP-----T-----C QVT					
	gi 15277312	FS S PE VPL CPWSSLPT P FSP-----T-----C QVT					
	gi 6933864	-----					
	gi 16758634	SV T TP AMA PSLPLGSS A LAETVVVSAHSLDKASHS TAG					
	gi 12711660	SV T TS STA LSIQLSSS T LAETVVVSAHSLDKTSHS TTG					
55		1560	1570	1580	1590	1600	
						
60	NOV2 COR87940554						
	gi 15212448	SSPFFP CP T S-----F ST-----A					
	gi 15277312	SSPFFP CP T S-----F ST-----A					
	gi 6933864	-----					
	gi 16758634	GLSFCA SS S SGTAVSSSVSQPGIVHPLVISSAIAST VLPQPAVP S					
	gi 12711660	AFSLSA SS S PGAGVSSYISQPGGLHPLVIPSIAST ILPQAAGP S					

		1610	1620	1630	1640	1650		
							
	NOV2 COR87940554							
5	gi 15212448	A	SLASAFSLA	MT	-----	S LS--	S G	SQS P-----
	gi 15277312	A	SLASAFSLA	MT	-----	S LS--	S G	SQS P-----
	gi 6933864							
	gi 16758634	T	PQVPNIPPL	QP	NVPAVQ	T IHSQ	Q A	PNQ HTHCPEMDA
	gi 12711660	T	PQVPSIPPL	QP	NVPAVQ	T IHSQ	Q A	PNQ HTHCPEVDS
10			1660	1670	1680	1690	1700	
							
	NOV2 COR87940554							
15	gi 15212448							
	gi 15277312							
	gi 6933864							
	gi 16758634	DTQSKAPGIDDIKTLEEKLRLSLFSEHSSSGTQHASVSLTPLVVET-VTP						
	gi 12711660	DTQPKAPGIDDIKTLEEKLRLSLFSEHSSSGAQHASVSLTSLVIESTVTP						
20			1710	1720	1730	1740	1750	
							
	NOV2 COR87940554							
	gi 15212448							
	gi 15277312							
	gi 6933864							
	gi 16758634	GIPTTAVAPS KLMTSTTSTCL	TN	LGTAGM	VM VGT	QVST	GTH	
	gi 12711660	GIPTTAVAPS KLLTSTTSTCL	TN	LGTVAL	VT VVT	QVST	---	
25			1760	1770	1780	1790	1800	
							
	NOV2 COR87940554							
30	gi 15212448	---SPHTAEVESEAS	PPAR					L -
	gi 15277312	---SPHTAEVESEAS	PPAR					L -
	gi 6933864							
	gi 16758634	ASAPASTATGAKPGTT	PKPSLT	KTVPPVGTEL	SAAGTVPCEQLP	F	P	
	gi 12711660	---VSTTSGVKGPGTA	SKPPLTKAPVLPVGTEL	PAGTL	PSEQLP	F	P	
35			1810	1820	1830	1840	1850	
							
	NOV2 COR87940554							
40	gi 15212448							
	gi 15277312							
	gi 6933864							
	gi 16758634	SLIQTQQPLEDLDQL	RTLSPETI	PVTPAVG	PLSTMSSTAVT	A	SQ	
	gi 12711660	SLTQSQQPLEDLDQL	RTLSPEI	ITVTS	AVGPVSMAAPTAIT	A	TQ	
45			1860	1870	1880	1890	1900	
							
	NOV2 COR87940554							
50	gi 15212448							
	gi 15277312							
	gi 6933864							
	gi 16758634	KDGTEVH	---	VTASSSGAGVVKM		SVTMDD	QKERKNRSEDTK	VH
	gi 12711660	KGVSQVKEGPVLATSSGAGVFKM				SVAADG	QKEGKNNKSEDAK	VH
55			1910	1920	1930	1940	1950	
							
	NOV2 COR87940554							
60	gi 15212448	PKP	PQLTSE	DTED	AGGG	-----	REALAESDRAAEGLGAGV	EE
	gi 15277312	PKP	PQLTSE	DTED	AGGG	-----	REALAESDRAAEGLGAGV	EE
	gi 6933864							
	gi 16758634	FES	SESSVL	SSPE	TLVK	PNGI	VSGISLDVPDSTHRTPTP	AK
	gi 12711660	FES	SESSVL	SSPE	TLVK	PNGI	IPGISSDVPESAHKTTAS	AK
		1960	1970	1980	1990	2000		

5	NOV2 COR87940554	-----				
	gi 15212448	-----				
	gi 15277312	-----				
	gi 6933864	-----				
	gi 16758634	FSAPGQLCISMTSNMGSTPISAASATSLGHFTKSMCPPPQQYGFPAAPFG				
	gi 12711660	FSAPGQLCISMTSNLGGSAPIASAASATSLGHFTKSMCPPPQQYGFPAATPFG				
2360 2370 2380 2390						
10	NOV2 COR87940554	-----
	gi 15212448	-----
	gi 15277312	-----
	gi 6933864	-----
	gi 16758634	TQWSGTGGPAPQPLGQFQPVGTTSLQNFNISNLQKSISNPSSNLRTT				
	gi 12711660	AQWSGTGGPAPQPLGQFQPVGTASLQNFNISNLQKSISNPSPGSNLRTT				

Tables 2E, 2F and 2G list the domain description from DOMAIN analysis results against NOV2. This indicates that the NOV2 sequence has properties similar to those of other proteins known to contain these domains.

Table 2E. Domain Analysis of NOV2

gnl|Smart|smart00220, S_TKc, Serine/Threonine protein kinases, catalytic domain; Phosphotransferases. Serine or threonine-specific kinase subfamily.

(SEQ ID NO:41)

CD-Length = 256 residues, 98.0% aligned

Score = 221 bits (562), Expect = 1e-58

NOV 2 : 176 EIGRGSFKTVYRG LTD TDTTVEAWCELQTRKLSRAERQRFS EEVEMLKGLQHPNI VR F YD 235

Sbjct: 6 VLKGKAEGKVKYLARDKKTGKLVIAJKVIKKEKLKKKKRERILEREIKILKKLDHPNIVKLYD 65

NOV. 2: 236 SWKSVLRGOVCLVLYTELMTSGTLKTYLRREFREMKPRVLRQWSRQTLRGLHLHSRVRPTI 295

SWANSEA, 11.12.1911. SIR JAMES GUTHRIE, 11.12.1911. SIR JAMES GUTHRIE, 11.12.1911.

LHDLKCDNVFTGPTGSVKGDLGLATL--KRASFAKSVIGTPEFMAPEMY-EERYDEA

VDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGRKPNNSFHKVKI - PEVKEIIEGCIR

TDKNERFTIQDLLAHAFF 429

| + | | ++ | | | |

Sbjct: 239 KDPEKRLTAAEALEHPFF 256

Table 2F. Domain Analysis of NOV2

gnl|Pfam pfam00069, pkinase, Protein kinase domain.

(SEQ ID NO:42)

CD-Length = 256 residues, 98.0% aligned

Score = 197 bits (500), Expect = 2e-51

Subjct: 6 KLGSAGFKVYKGKHKDTGEIVAIKILKKRSLS-EKKKRFLRETIQILRRLSHPNIVRLLG 64

Subject: 65 VFEE----DDHLYLVMEYMEGGDLFDYLRRNGLLLSEKEAKKIALOILRGLLEYLHSRG-- 118

NOV 2: 295 ILHRDLKCDNVFITGPTGSVKIGDLGLATLKRA--SFAKSVIGTPEFMAPE-MYEEKYD 350

Shict: 118 IVHDLKPERNTILDEN-GTVKLADEGLARKLESSSYEKLITTEVGTPREYMAPPEVLEGRGYS 177

NOV 2: 351 EAVDVYAFGMCMLEMATSEYPYSECQNAAQIYRKVTSGRKPNFSHKVKIPEVKEIIEGCI 410

Skripsi 172. GUNUNG GUNUNG KELITOKI PERGURUAN FELI KEPERIBEDALI PENGSEKOLAHAN 227

NOV 2: 411 RTDKNERFTIQDLLAHAF F 429

Table 2G. Domain Analysis of NOV2

gnl|Smart smart00219, TyrKc, Tyrosine kinase, catalytic domain; Phosphotransferases. Tyrosine-specific kinase subfamily.

(SEQ ID NO:43)

CD-Length = 258 residues, 98.4% aligned

Score = 143 bits (361), Expect = 2e-35

NOV 2:	171	LKF DIE IGR GSFK TVY RGL --- DTD TTV EVA CEL QTR KLS RAER QRF SEE VEM LKGLQH	227
		+ + + + + + + + + + + + +	
Sbjct:	1	LTL GKKL GEG AFGE VY KGT LKG KGG VEV AVK TLKEDA-SEQ QIE F LRE AR LMR KLDH	59
NOV 2:	228	PNIV RFY DSW KSV LRG QVC IVL VTEL MTS GTL KTY LR -- RFREM KPR VLQR WSR QI LRG L	285
		+ + + + + + + + + +	
Sbjct:	60	PNIV KLL --- GVCT EEE P L MIV MEY MEGG DLL DYL RKN RPK EL SLS DLL S FAL QI ARG M	115
NOV 2:	286	HFL HSR VPP I LHR DLK C DN V FIT GPT GSV KI GDL GLA TLK RAS FAK S VIG TPE --- FMA	341
		+ + + + + + + + + + + + + + +	
Sbjct:	116	EY LESK -- NFV HRDL AAR NCL VGEN - KTV KI AD FGL A RD LY DDD YY RKK KSP RL P I RW MA	172
NOV 2:	342	PE MYEE - KY DE A VD VY A FG MCM L E M A T - SE Y PY SEC Q N A Q I Y R K V T S G -- R K P N S F H K	396
		+ + + + + + + + + + + + + + + + + + +	
Sbjct:	173	PES LK DG KFT SKSD VWS FG VLL W E I F TL G E S P Y P G M S N - E E V L E Y L K K G Y R L P Q P P N C P -	230
NOV 2:	397	V KI P E V K E I I E G C I R T D K N E R F T I Q D L	423
		+ + + + + + + +	
Sbjct:	231	--- D E I Y D L M L Q C W A E D P E D R P T F S E L	254

The protein similarity information, expression pattern, and map location for the NOV2 protein and nucleic acid disclosed herein suggest that it may have important structural and/or physiological functions characteristic of the family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

The nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: Hypercalceimia, Ulcers, Hemophilia, hypercoagulation, 5 idiopathic thrombocytopenic purpura, autoimmune disease, allergies, immunodeficiencies, transplantation, Graft versus host disease (GVHD), Lymphaedema, Systemic lupus erythematosus , Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, 10 Cardiovascular disease, Hypercalceimia, Lesch-Nyhan syndrome, Fertility, Cancer and other diseases, disorders and conditions of the like.

15 Protein phosphorylation is a fundamental process for the regulation of cellular functions. The coordinated action of both protein kinases and phosphatases controls the levels of phosphorylation and, hence, the activity of specific target proteins. One of the predominant roles of protein phosphorylation is in signal transduction, where extracellular signals are amplified and propagated by a cascade of protein phosphorylation and dephosphorylation events. Eukaryotic protein kinases are enzymes that belong to a very extensive family of proteins which share a 20 conserved catalytic core common with both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. In the N-terminal extremity of the catalytic domain there is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. In the central part of the catalytic domain there is a conserved aspartic acid residue which is important for the catalytic 25 activity of the enzyme.

NOV3

25 A disclosed NOV3 nucleic acid (designated as CuraGen Acc. No. COR100339661), which encodes a novel GPCR-like protein and includes the 2646 nucleotide sequence (SEQ ID NO:13) shown in Table 3A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 800-802 and ending with a TAA codon at nucleotides 1766-1768. Putative untranslated regions downstream from the termination codon and upstream from the 30 initiation codon are underlined in Table 3A, and the start and stop codons are in bold letters.

Table 3A. NOV3 Nucleotide Sequence (SEQ ID NO:13)

```

AAACTCACTAAAATAACAAAAGGACAGAATGTGTCGGTCCAAGGCAAAGCATGGTCGTTGCTCCAGAT
ATGGTGCAGTCTTCAGCTGCACTGAAGTCCCTCTGGCAGGAACGGTCTAGATGGGTTTGTCATCTAG
ATAAACTTTAATGGTTACAGTAGATTCTATATTGCACTGAGATTATAAAATACATAATGTATATACAGT
CTATATATTGAAAAAAATTAAGATATTCTAGTAACACCAGTCTGCTTGAATTACAAATTTCAAA
GTCTCTAAAGAAAACCCAGCAAATTATTCAAATACATCTGTGTGAGCCAATCCAAGTGGGCTCACATGGG
TGATGTCCACATTCCCATCTGCTGTGGCATGTCATGCTGGGTTGATTATGCAGGGCTGGATGCTGG
GCATGTTCAAATGCTGGGTGATTATGCAGGGCTGGATTGCTCTTGCTTGCCTTGGACAGGAGCTGGGATT
GTGGGCTGGAGAGAATCAAATCTGGACACAGCACAGTCATCTTGCTTCAATGAAATTAGAGGAAGACTAG
AGCAAGTGAAGCAGAAACAAAGCATCAATTGCTAGGTCAAAGACAACCATGCTCTGGTCTCCGTATGACATCTG
ACTGCCATATACATGACGCAGTTGCTTATGTCAGAGTTACTACATGGTTGTTGAACTAAACAAGTAATAAA
TAATTGAAGTTCTGCTCTCCCACACTGTCAGTATTGATGTCAGTCAGTGCAGTAGAGATGGGAGCAACCA
ATGACAGCACCTCAGCCATTTCATCCTTATAGGCTCTGACCGGCCGAGCTGGAGAGGGCTCTTCGCCAT
CATCCTGCCGCCCTACCTCCTAACCCCTGCTGGCAACAGCATCATCCTGGTATCCAGGCTGGACCCGACCTT
CACACCCCCATGTAACCTCAGCGGGCCGACAAGACCATCAGCTATGTGGCTGTGCTCTGAGCTGGCCTGTTCTGGG
TACTCTATAACCTCAGCGGGCCGACAAGACCATCAGCTATGTGGCTGTGCTCTGAGCTGGCCTGTTCTGGG
CCTGGGGGGTGTGGAGTGCCTGCTGGCTGTGATGGCTATGACCGCTTGTGGCGGTCTGCAAGGCCCTGAC
TACATGGTCATCATGAACCCCCAGCTCTGCCGGGCTTGGTGTCACTGACCTGGGCTGTGGGTGGCCAACCTC
TGGCCATGTCCTGTGACCCCTGCCCTTACCCCGCTGTGGGACCCAGAGGTGGACACTCCTGCGTGAGATGCC
CGCCCTGATCCGGATGGCCTGCGTCAGCACTGTGGCCATNGAAGGCACCGTCTTGTCTGGCGGTGGGTGCTGCC
CTGTCCCCCTGGTGTATCATGATATCTTACAGCTACATTGTGAGGGCTGTGTTACAAATTGGTCAGCATCAG
GAAGGCAGAAGGCCCTGGCACCTGCCGCTCCATCTCACTGTGGCTCCCTTTCTATGAAACATCATCTACAT
GTACATGCAGGCCAGGAGCCAGTTCTCCCAGGACCAGGGCAAGTCTCCTCACGCTCTCTACAACATTGTCACCCCC
CTCCTCAATCCTCTCATCTACACCCCTCAGAAACAGAGAGGTGAAGGGGGCACTGGGAAGGTTGCTCTGGGAAAGA
GAGAGCTAGAAAGGAGTAAAGGCATCTCCACCTGACTCACCTCCATCCAGGGCACTGGCAGCATCTGGAACGG
CTGAATTCCAGCTGATATTAGCCCACGACTCCAACTTGCCTTTCTGGACTTTGTGAGGCTGTTCAAGTTCTG
ACATTATGTGTTTTGTGCTCTAAAATTGAGACGGGTCTCACTCTGTCACCTAGGGTGGAGTCAGTGG
GCCACCATAGCTCCTCGACTATTGGCTTAAGCGATCTCCCCACCTCAGCTTCAAGTAACTGGGACTACAG
GTGTGCATCACTGGCAGTGGAAATTGGCTTTCTGCTCTATGGAGACGGGCTTGCTGTGACCTGG
GGCCCCAAACTCCTGCCCATGTGATCCTCTGCCATGGCCTCTAAAGTCTGGGATTACAAGTGTGACTCAC
TGTGACTGGCAACATTATGTGATTATGTGACTATATAACACAAATCATCCCCAAACCCATCATGATCTGT
AAAGCAGCTGCAAAGAATGAAGTGAAGAGAAACAGTTGAAAGATGAGTTCCACCTACTTATACCAAGAGTGTCAAG
AGGAAATAACTCTCTCAATCAGAGCTTGTGTTGTGTTGCTTAAAGTCTAACACACCTGACATGT
TTCAAGTGCAGCACAGTTGATATTTCTATATTCCAAATTCCCTACCCAAACCTTTCTGAAATCGTAGAGTTG
TTTACCTTATCTGGTAAAGATTCTGCATAAACCAAGAAGTGAACCTGTAATATCTATC

```

The nucleic acid sequence of NOV3 maps to chromosome 1 and 629 of 918 bases (68%) identical to a gb:GENBANK-ID:AF098664|acc:AF098664.1 mRNA from Homo sapiens (Homo sapiens olfactory receptor-like protein (OR2C1) gene, complete cds).

5 The NOV3 polypeptide (SEQ ID NO:14) is 322 amino acid residues in length and is presented using the one-letter amino acid code in Table 3B. The SignalP, Psort and/or Hydropathy results predict that NOV3a has a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.6000. In alternative embodiments, a NOV3a polypeptide is located to the Golgi body with a certainty of 0.4000, the endoplasmic reticulum (membrane) with a certainty of 0.3000, or the microbody (peroxisome) with a certainty of 0.3000. The

10

SignalP predicts a likely cleavage site for a NOV3a peptide between amino acid positions 58 and 59, i.e., at the dash in the sequence VSR-LD.

Table 3B. Encoded NOV3 Protein Sequence (SEQ ID NO:14)

MSSSGAVEMGATNDSTFSHFILIGFSDRPELERVLFAIILPAYLLTLLGNSIIILVSRLDPHLHTPMYFFLTH
LSFLDLSFTSSSIPQLLYNLSPDKTISYVGCALQLVFLGLGGVECLLLAVMAYDRFVAVCKPLHYMVIMNP
QLCRGLVSVTWGCGVANSLAMSPVTLRLPRCGHHEVDHFLREMPALIRMACVSTVAXEGTVFVLAVGAALSPL
VFIMISYSYIVRAVLQIRSASGRQKAFTCGSHLTVVSLFYGNIIYMYMQPGASSSDQGKFLTLFYNIVTPL
LNPLIYTLRNREVKGALGRLLLGKRELGKE

5 The NOV3 amino acid sequence has 281 of 314 amino acid residues (89%) identical to, and 295 of 314 amino acid residues (93%) similar to, the 314 amino acid residue gi|17445344|ref|XP_060558.1| XM_060558 protein from Homo sapiens (Human) (similar to OLFACtORY RECEPTOR) (E = e-149).

NOV3 is expressed in at least the following tissues: liver, spleen. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.

NOV3 has homology to the amino acid sequences shown in the BLASTP data listed in Table 3C.

Table 3C. BLAST results for NOV3

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<u>gi 17445344 ref XP_060558.1 (XM_060558)</u>	similar to olfactory receptor (H. sapiens) [Homo sapiens]	314	281/314 (89%)	295/314 (93%)	e-149
<u>gi 5901478 gb AAD55304.1 AF044033 (AF044033)</u>	olfactory receptor [Marmota marmota]	237	196/237 (82%)	216/237 (90%)	e-102
<u>gi 13624329 ref NP_112165.1 (NM_030903)</u>	olfactory receptor, family 2, subfamily W, member 1	320	178/305 (58%)	236/305 (77%)	3e-97
<u>gi 12054431 emb CAC20523.1 (AJ302603)</u>	olfactory receptor [Homo sapiens]	320	178/305 (58%)	236/305 (77%)	4e-97
<u>gi 12054429 emb CAC20522.1 (AJ302602)</u>	olfactory receptor [Homo sapiens]	320	178/305 (58%)	236/305 (77%)	5e-97

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 3D.

Table 3D. ClustalW for NOV3

- 1) NOV3 (SEQ ID NO:14)
- 2) gi|17445344 ref XP_060558.1 (XM_060558) similar to olfactory receptor (H. sapiens) [Homo sapiens] (SEQ ID NO:44)
- 3) gi|5901478|gb|AAD55304.1|AF044033_1 (AF044033) olfactory receptor [Marmota marmota] (SEQ ID NO:45)
- 4) gi|13624329|ref|NP_112165.1| (NM_030903) olfactory receptor, family 2, subfamily W, member 1 [Homo sapiens] (SEQ ID NO:46)
- 5) gi|12054431|emb|CAC20523.1| (AJ302603) olfactory receptor [Homo sapiens] (SEQ ID NO:47)
- 6) gi|12054429|emb|CAC20522.1| (AJ302602) olfactory receptor [Homo sapiens] (SEQ ID NO:48)

NOV3 COR100339661

25

30

40

50

		10	20	30	40	50		
							
	NOV3 COR100339661	MSSSGAVE	GAT D	TFSH	I	DR EL RV	FAAILPA L L	
	<u>gi 17445344 </u>	-----	GT G	TQTH		DR HL R	FV IL A L	
	<u>gi 5901478 </u>	-----						
	<u>gi 13624329 </u>	-----	QS Y	SLHG		NH KM M	SG VA F I	
	<u>gi 12054431 </u>	-----	QS Y	SLHG		NH KM M	SG VA F I	
	<u>gi 12054429 </u>	-----	QS Y	SLHG		NH KM M	SG VA F I	
		60	70	80	90	100		
							
	NOV3 COR100339661	SI V R	PH	TH	S S S	L Y S		
	<u>gi 17445344 </u>	T V R	PH	AH	S S	L Y N C		
	<u>gi 5901478 </u>	-----		L G	S S	L H S R		
	<u>gi 13624329 </u>	A A L	SQ	R	C I	M V W		
	<u>gi 12054431 </u>	A A L	SQ	R	C I	V V W		
	<u>gi 12054429 </u>	A A L	SQ	R	C I	M V W		
		110	120	130	140	150		
							
	NOV3 COR100339661	AL VLFLG	G	A V V	M I	Q R		
	<u>gi 17445344 </u>	M A	FLFLG	G	A CV	M I	R R	
	<u>gi 5901478 </u>	VV	FLFLG	G	A V V	T I	SSR	
	<u>gi 13624329 </u>	I	YVYMW	S	S T	F V	H	
	<u>gi 12054431 </u>	I	YVYMW	S	S T	F V	H	
	<u>gi 12054429 </u>	I	YVYMW	S	S T	F V	H	
		160	170	180	190	200		
							
	NOV3 COR100339661	GLVSVT	GCGV	LAMSPV	R R	HHEV	R M	IRM S
	<u>gi 17445344 </u>	GLVSVT	GCGV	LAMSPV	R R	HHEV	R M	IRM S
	<u>gi 5901478 </u>	GLVSA	GCGM	L MSPV	Q R	H KV	M	IRM N
	<u>gi 13624329 </u>	KMIIIMI	SISL	V LCTL	N T N	IL	L	VKI D
	<u>gi 12054431 </u>	KMIIIMI	SISL	V LCTL	N T N	IL	L	VKI D
	<u>gi 12054429 </u>	KMIIIMI	SISL	V LCTL	N T N	IL	L	VKI D
		210	220	230	240	250		
							
	NOV3 COR100339661	VAX GT	V AVGAA	S VF M	S VR	QIR ASGRQ	FG	
	<u>gi 17445344 </u>	VAI GT	V KKGV	S VF	L S	VR	QIR ASGRQ FG	
	<u>gi 5901478 </u>	VAI GT	V AVG	S VF	V H	VR F	IQ SSGRHRIF	
	<u>gi 13624329 </u>	TTV MS	A GII	T IL		AK	TK KASQR M	
	<u>gi 12054431 </u>	TTV MS	A GII	T IL		AK	TK KASQR M	
	<u>gi 12054429 </u>	TTV MS	A GII	T IL		AK	TK KASQR M	
		260	270	280	290	300		
							

5	NOV3 COR100339661 gi 17445344 gi 5901478 gi 13624329 gi 12054431 gi 12054429	L N M ASS Q L N M ASS Q L N M S S Q M T L N A K M T L N A K M T L N A K	M M	NIV L NIV L NIV L F S TVI S TVI S TVI S
10	NOV3 COR100339661 gi 17445344 gi 5901478 gi 13624329 gi 12054431 gi 12054429	310 320 REV G GR LLGKRELG E----- REV G GR LLGKRELG E----- ----- KDM D KK MRFHHKST IKRNCKS KDM D KK MRFHHKST IKRNCKS KNM D KK MRFHHKST IKRNCKS		
15				

Table 3E lists the domain description from DOMAIN analysis results against NOV3. This indicates that the NOV3 sequence has properties similar to those of other proteins known to contain these domains.

Table 3E. Domain Analysis of NOV3

gnl|Pfam|pfam00001 7tm_1, 7 transmembrane receptor (rhodopsin family)

(SEQ ID NO:49)

CD-Length = 254 residues, 100.0% aligned

Score = 82.0 bits (201), Expect = 5e-17

G-protein-coupled receptors (GPCRs) constitute a vast protein family that encompasses a wide range of functions (including various autocrine, paracrine and endocrine processes). They show considerable diversity at the sequence level, on the basis of which they can be separated into distinct groups. The term “clan” is used to describe the GPCRs, as they embrace a group of families for which there are indications of evolutionary relationship, but between which there is no statistically significant similarity in sequence. The currently known clan members include the rhodopsin-like GPCRs, the secretin-like GPCRs, the cAMP receptors, the fungal mating pheromone receptors, and the metabotropic glutamate receptor family. The metabotropic glutamate receptors are functionally and pharmacologically distinct from the ionotropic glutamate receptors. They are coupled to G-proteins and stimulate the inositol phosphate/Ca²⁺ intracellular signalling pathway. The amino acid sequences of the receptors contain high proportions of hydrophobic residues grouped into seven domains, in a manner reminiscent of the rhodopsins and other receptors believed to interact with G-proteins. However, while a similar 3D framework has been proposed to account for this, there is no significant sequence identity between these and receptors of the rhodopsin-type family: the metabotropic glutamate receptors thus bear their own distinctive '7TM' signature. This 7TM signature is also shared by the calcium-sensing receptors, and GABA (gamma-amino-butyric acid) type B (GABA(B)) receptors.

The protein similarity information, expression pattern, and map location for the NOV3 protein and nucleic acid disclosed herein suggest that it may have important structural and/or physiological functions characteristic of the GPCR family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration *in vitro* and *in vivo* (vi) biological defense weapon.

The NOV3 nucleic acid and protein are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for

treatment of patients suffering from: Cardio-vascular diseases, Von Hippel-Lindau (VHL) syndrome, Cirrhosis, Transplantation, Hemophilia, Hypercoagulation, Idiopathic thrombocytopenic purpura, Immunodeficiencies, Graft versus host disorders and other diseases, disorders and conditions of the like.

5 NOV4

NOV4 includes two novel ankyrin repeat containing proteins. The disclosed proteins have been named NOV4a and NOV4b.

NOV4a

10 A disclosed NOV4a nucleic acid (designated as CuraGen Acc. No. COR87934767), encodes a novel ankyrin repeat containing protein and includes the 2381 nucleotide sequence (SEQ ID NO:15) shown in Table 4A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 849-851 and ending with a TAA codon at nucleotides 1965-1967. Putative untranslated regions downstream from the termination codon and upstream from the initiation codon are underlined in Table 4A, and the start and stop codons are in bold letters.

15

Table 4A. NOV4a Nucleotide Sequence (SEQ ID NO:15)

GGAAAATTGACGGGAGGGAAAGAGGGTGGAGAGCAGGACAGAGAGGGCGGTGCAGAAGGGAAATATCCCTCCTGAG TTCCTGGAAGAGCGTCAGCCTGGACCTGGCTTGGCTCTCTGCTGGAATCCTGGCAGCCCCGGTGTGCG GCGAGGGTCAAGGCCACACAAAGGCAGGCAGGAGCAGACGAGCCAGTCACATGGGGCAGTCAGCTGCCTGCGTGA ATGCTAGGCCGGACAATGGCAACTCCGGGACAAAGTGCAGGGAGACTCTGAAGAGATAAGAGGAAGGGCGAA GGAAGGGGGCGGGGACCCAGAGCTCGGAGCTCCAGGACCGCGTTGGAGACCGTGGCTGGAAGCCGAGCTCGG CCCGCTCGGAAGGGCGCCCTCGGCCCTACACTCTAGCCCCGGCTGGATGCTGAGAACCGCGCTTCCAGGG CCGCAGCGAGCTCCAGCCAGTCCCGGCCCTCGGTCTGGAGGCGGGCTGCCAGCTCACCTGGCC TTGGGGTGGGACCGCCCGACCCGGGGAGCTGCAAGAGCGGGTACCCAGGGAAAGTGGAGCTGGCTTGCC TGGGGACTGGCTGGAGCTCACACCCCTCCACGCCCCCAAGGCCCTGCGCGGGGGCCCTCCCTAGCTCCCTCCCT CCT ACGCCAGCGCCAGTTCTCTCCCGTTGGGGCCGGAAAGGCAGCTAACGCTGGACACTGGACGGCCGCGGGCG AGCTTCAAGACCATGGCCAGCTGGAGGGGGCCGAACCGGGCACCCACGGCTCTCTCGGCCGACCTCGCAGA GCTCGGGTGCAGCCCGCAGCCCCCCCCTCGAGAGCGGACACTGGTAGCCTGGCAGGTACTGGGCAAAGCCG AGCCGCCGCTCCCGGGAGCACCCCTCCACGGCACGCTGATGCACCTCTGCAGCGGGCTCAGGGGCCGGGG GCGCTCGGGAACTGCTGGGCTGCAGCGGGCGCTCCCGGGGTGGCTGGAGGAGCTGCTGAGGGCGACCCGATCACCGC GCGGGCGAGTGGCCGGCAGCAGCAGGCTGTGCTGGAACCGCGGGAGCACCGCTGGATTCTGGCAGCCGCG GGCCCGCTATGAGGTGCTGCGGGAGCTGGAGGCTGAGCCGGAGCTGCTGAGGGCGACCCGATCACCGC TACTCGGTTCTGCACTGGCTGGCCAAGCACGGCGCCACGAGGAGCTCATTCTGGTACACGACTTCGCCCTACGCC GGGGGCTGAGGCTGACGTGAGCGCCCCAGGCAGCGGGCGCTCACGCCCTCCACCTGGCGGCCCTCAGGGCA CGACATGGTCATCAAGGTGCTGGTGGCGCCCTGGGTGCTGACGCTACCGCCCGCACACAGCGGCCACCGGGCC TGCCACTACCTGCGGCCGACGCCCTGGAGGTTGCGGGAGCTGCTGGAGGCCAGGAATGGGAGATGGAGAGCG GCAGCGGGTGCACCAACCTGAACAAACAACAGCAGCGGCCACCACTGCGTGGAGGGCCCGAGCGCAGTGGGGCGCGA ACGGCTGTGAGACAAGCAGGAGAGTGGCAGCGTCGCCGACCAAGGCGAAGGACACCGCGGGCAGCCGGGTGGCGC

```

AAATGCATAGCCTTCCGCATCTGTTCCCTCATTCCAGGACCGTTGACAGGGACAGAGACTGGAGAGCTAGGA
GGGGCTGTGACACTGTGGCGATGGCTAGGTCTGGGTTGTCGGGGTCCACCGAAGGAGAGGCGCCTGGACGCT
GCTTGGGCCTGCAAGGAACAGAACACGTCGGGTCCGACTCAGGTACTTGTCTCAGGTCTCCGTAAACCACGGG
TGGAGGACCCGGGACTCGGGCACCACNTCACCAAGAGAGACTGAAGGACCAAGCTGGCCTGGCTCCGAGTTCAA
AGCTACAGGACTAAGGAGTTGGGAGCAGGGAGCGTGGTCTGCTTGGAGAGGGCAAGTTAAGCTTCAAGGGCCA
TTCTGGGCAGGCCACGCGCTGGTTATTAGAAACATCGCTAGAAGAATGAGTTAAGATTGTAACCACCAA
TGCAGAGAAAACGCCTAACTCTGCCGGCTCGCTGGCCATTAATGGTCTTGGGTGCGGGTAGAGTCAGCCTCT
GACAACCTCCTCTGAGACGACCCAGCCTACTGGTACTTTCTCATGTATCACAGGTTACTTCTTATGTATATT
AAAGTGAATATGTGTCTTTCAC

```

The nucleic acid sequence of NOV4a maps to chromosome X and has 764 of 1297 bases (58%) identical to a gb:GENBANK-ID:AK025523|acc:AK025523.1 mRNA from Homo sapiens (Homo sapiens cDNA: FLJ21870 fis, clone HEP02445).

The NOV4a polypeptide (SEQ ID NO:16) is 372 amino acid residues in length and is presented using the one-letter amino acid code in Table 4B. The SignalP, Psort and/or Hydropathy results predict that NOV4a has a signal peptide and is likely to be localized to the microbody (peroxisome) with a certainty of 0.4763. In alternative embodiments, a NOV4a polypeptide is located to the nucleus with a certainty of 0.3000, the lysosome (lumen) with a certainty of 0.2592, or the mitochondrial matrix space with a certainty of 0.1000.

Table 4B. Encoded NOV4a Protein Sequence (SEQ ID NO:16)

```

MAQLGGAANRAPTASLAPTSQSLRCAQPRPSRADTGSIGRYWGKAAAASREHPFPGTLHSAAGSGRRRGA
LRELLGLQRAAPAGWLSEERAELGGPSGPSSRLCLEPREHAWILAAAEGRYEVLRLEAEPELLRGDPI
TGYSVLHWLAKHGRHEELILVHDFAIRRGLRLDVSAPGSGGLTPLHLAALQGHDMVIKVLVGALGADATRRDH
SGHRACHYLRPDAPWRLRELSGAAEWEMESGSGCTLNNNSSGTTAWRAASAVGRERLWRQAGEWQRQGPRRR
TPRAAGWRKCIAFSAICSPHSRTVDRDRDWRARRGCDTVAMARSVVPGSTEGEAPWTLLGPARNRTRRGPTQ
VILVSGLL

```

The NOV4a amino acid sequence has 273 of 273 amino acid residues (100%) identical to, and 273 of 273 amino acid residues (100%) similar to, the 314 amino acid residue
15 gi|17486018|ref|XP_066736.1| XM_066736 protein (similar to LD31582p, H. sapiens) ($E = e^{-125}$).

NOV4a is predicted to be expressed in the following tissues because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:AK025523|acc:AK025523.1) a closely related Homo sapiens cDNA: FLJ21870 fis, clone HEP02445 homolog in species Homo sapiens: uterus, lung, kidney, brain and placenta.

20

NOV4b

A disclosed NOV4b nucleic acid (designated as CuraGen Acc. No. CG57238-01), a variant of NOV4a, includes the 1209 nucleotide sequence (SEQ ID NO:17) shown in Table 4C.

Table 4C. NOV4b Nucleotide Sequence (SEQ ID NO:17)

```
AGCTAACGCTGGACACTGGGACGGCGCGCGAGCTCAAGACCAGGCCAGCTCGGAGGGCCGCG  
AACCGGGCACCCACGGCCTCTCGCGCCGACCTCGCAGAGCTCGGGTGCAGCCCGCAGCCCCCCCCT  
CGAGAGCGGACACTGGTAGCTGGCAGGTACTGGGCAAAGCCGAGCCGCCCTCCGGAGCACCC  
CTTCCCAGGCACGCTGATGCACTCTGCAGCGGCTCAGGGGCCGGCGGGAGCGCTCGGAACTGCTG  
GGGCTGCAGCGGGCGCTCTGCCGGTGGCTGTCGGAGGAGCGCGCCGAGGAGCTGGCGGGCGAGTG  
GGCGGGCAGCAGCAGGCTGTGCTGGAACCGCGGGAGCACCGTGGATTCTGGCAGCCGCCAGGGCG  
CTATGAGGTGCTGCGGGAGCTGCTGGAGGCTGAGCCGGAGCTGCTGAGGGCGACCCGATACCGGC  
TACTCGGTTCTGCACTGGCTGGCAAGCACGGGCCACGAGGAGCTCATTCTGGTACACGACTTCGCC  
TACGCCGGGGCTGAGGCTGACGTGAGCGCCCCAGCGAGCGGCCCTACGCCCTCACGCCGC  
CCTTCAGGGCACGACATGGTCATCAAGGTGCTGGTGGCGCCCTGGGTGCTGACGCTACGCCGC  
CACAGCGGCCACCGGGCCTGCCACTACCTGCGGCCGACGCCCTTGGAGGTTGCGGGAGCTGCGGAG  
CCGAGGAATGGGAGATGGAGAGCGCAGCGGGTGCACCAACCTGAACAAACACAGCAGCGCACCACTGC  
GTGGAGGGCCCGAGCGCAGTGGCGCACGGCTGAGGAGACAAGCAGGAGAGTGGCAGCGTCGCGGACC  
AAGGCGAAGGACACCGCGGGCAGCCGGGTGGCGAAATGCATAGCCTTTCCGCCATCTGTTCCCTCAT  
TCCAGGACCGTTGACAGGGACAGAGACTGGAGAGCTAGGAGGGCTGTGACACTGTGGCGATGGCTAGGT  
CCTGGGTTGCCCGGGTCCACCGAAGGAGAGGCGCCCTGGACGCTGCTGGCCTGCAAGGAACAGAAC  
ACGTCGGGGTCCGACTCAGGTACTTGTCTCAGGTCTCCTGTAACCACCGCCCTGGAGGACCCGGGACTC  
GGGCACCACTTCACCAAGA
```

The nucleic acid sequence of NOV4b maps to chromosome X and has 764 of 1297 bases (58%) identical to a gb:GENBANK-ID:AK025523|acc:AK025523.1 mRNA from Homo sapiens (Homo sapiens cDNA: FLJ21870 fis, clone HEP02445).

The NOV4a polypeptide (SEQ ID NO:18) is 315 amino acid residues in length and is presented using the one-letter amino acid code in Table 4D. The SignalP, Psort and/or Hydropathy results predict that NOV4b has a signal peptide and is likely to be localized to the microbody (peroxisome) with a certainty of 0.4763. In alternative embodiments, a NOV4b polypeptide is located to the nucleus with a certainty of 0.3000, the lysosome (lumen) with a certainty of 0.2592, or the mitochondrial matrix space with a certainty of 0.1000.

Table 4D. Encoded NOV4b Protein Sequence (SEQ ID NO:18)

```
MAQLGGAANRAPTASLAPTSQSLRCAQPQPRPSRADTGSILGRYWGKAAAASREHPFPGTLMHSAGSGRRRGALRE  
LLGLQRAAPAGWLSEERAELGGPSGPSSRLCLEPREHAWILAAAEGRYEVILRELLEAPELLRGDPITGYSVL  
HWLAKHGRHEELILVHDFAIRRGLRLDVAPGSGGLTPLHLAALQGHDMVIKVLVGALGADATRRDHSGHRACHYL  
RPDAPWRLRELSGAEEWEMESGSGCTNLNNNSGTTAWRAASAVGATAVETSRRVAASRTKAKDTAGSRVAQMHS  
FRHLFPSFQDR
```

The NOV4b amino acid sequence has 273 of 273 amino acid residues (100%) identical to, and 273 of 273 amino acid residues (100%) similar to, the 314 amino acid residue [gi|17486018|ref|XP_066736.1| XM_066736](#) protein (similar to LD31582p, H. sapiens) (E = e-125).

NOV4b is predicted to be expressed in the following tissues because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:AK025523|acc:AK025523.1) a closely related Homo sapiens cDNA: FLJ21870 fis, clone HEP02445 homolog in species Homo sapiens: uterus, lung, kidney, brain and placenta.

5 NOV4a and NOV4b are very closely homologous as is shown in the amino acid alignment in Table 4E.

Table 4E. Amino Acid Alignment of NOV4a and NOV4b

		10	20	30	40	50
	COR87934767				
10	CG57238-01					
		60	70	80	90	100
	COR87934767				
	CG57238-01					
		110	120	130	140	150
	COR87934767				
	CG57238-01					
		160	170	180	190	200
	COR87934767				
	CG57238-01					
		210	220	230	240	250
	COR87934767				
30	CG57238-01					
		260	270	280	290	300
	COR87934767				
35	CG57238-01	RERLWRQ G WQ GPRR PRAAGWR				
		-----AT V TS VAAS -----				
		310	320	330	340	350
	COR87934767				
40	CG57238-01	KCIAFSAICSPHSRTVDRDR WRAR GCDT MAR WVVPGSTEGEAPWT				
		-----KAK TAGS ----- QMH LFR -----H				
		360	370			
	COR87934767				
45	CG57238-01	LGPARN TRRGPTQVLVSGLL				
		FPSFQD -----				

Homologies to any of the above NOV4 proteins will be shared by the other NOV4 proteins insofar as they are homologous to each other as shown above. Any reference to NOV4 is assumed to refer to both of the NOV4 proteins in general, unless otherwise noted.

NOV4a also has homology to the amino acid sequence shown in the BLASTP data listed 50 in Table 4F.

Table 4F. BLAST results for NOV4

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 17486018 ref XP_066736.1 (XM_066736)	similar to LD31582p (H. sapiens) [Homo sapiens]	315	273/273 (100%)	273/273 (100%)	e-125

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 4G.

Table 4G. ClustalW Analysis for NOV4

1) NOV4a (SEQ ID NO:16)
 2) NOV4b (SEQ ID NO:18)
 3) gi|17486018 ref XP_066736.1| (XM_066736) similar to LD31582p (H. sapiens) [Homo sapiens] (SEQ ID NO:50)

10 20 30 40 50
 NOV4a COR87934767 |.....|.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4b CG57238-01
 gi|17486018|

60 70 80 90 100
 NOV4a COR87934767 |.....|.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4b CG57238-01
 gi|17486018|

110 120 130 140 150
 NOV4a COR87934767 |.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4b CG57238-01
 gi|17486018|

160 170 180 190 200
 NOV4a COR87934767 |.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4b CG57238-01
 gi|17486018|

210 220 230 240 250
 NOV4a COR87934767 |.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4b CG57238-01
 gi|17486018|

260 270 280 290 300
 NOV4a COR87934767 |.....|.....|.....|.....|.....|.....|.....|.....|
 NOV4b CG57238-01
 gi|17486018|

310 320 330 340 350
 NOV4a COR87934767 KCIASFSAICSPHSRTVDRDR WRAR GCDT MAR WVVPGSTEGEAPWT
 NOV4b CG57238-01
 gi|17486018|

360 370
 NOV4a COR87934767 LGPARN TRRGPTQVLVSGLL

Table 4H lists the domain description from DOMAIN analysis results against NOV4.

5 This indicates that the NOV4 sequence has properties similar to those of other proteins known to contain these domains.

Table 4H. Domain Analysis of NOV4

gnl|Pfam(pfam00023, ank, Ank repeat). Ankyrin repeats generally consist of a beta, alpha, alpha, beta order of secondary structures. The repeats associate to form a higher order structure.

(SEQ ID NO:51)

CD-Length = 33 residues, 97.0% aligned
Score = 35.4 bits (80), Expect = 0.006

The protein similarity information, expression pattern, and map location for the NOV4 proteins and nucleic acids disclosed herein suggest that it may have important structural and/or physiological functions characteristic of the family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

20 The nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: Cardio-vascular disorders, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect

5

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95

(ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus , Pulmonary stenosis , Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Obesity, Transplantation, Systemic lupus erythematosus , Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Hypercalceimia, Lesch-Nyhan syndrome and other diseases, disorders and conditions of the like. Ankyrin repeats are tandemly repeated modules of about 33 amino acids. They occur in a large number of functionally diverse proteins mainly from eukaryotes. The few known examples from prokaryotes and viruses may be the result of horizontal gene transfers. The conserved fold of the ankyrin repeat unit is known from several crystal and solution structures, e.g., from: p53-binding protein 53BP2, cyclin-dependent kinase inhibitor p19Ink4d, transcriptional regulator GABP-beta, and NF-kappaB inhibitory protein I kB-alpha. It has been described as an L-shaped structure consisting of a beta-hairpin and two alpha-helices. Many ankyrin repeat regions are known to function as protein-protein interaction domains.

NOV5

20

A disclosed NOV5 nucleic acid (designated as CuraGen Acc. No. COR100396092), encodes a novel ankyrin repeat containing protein and includes the 6272 nucleotide sequence (SEQ ID NO:19) shown in Table 5A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 7-9 and ending with a TGA codon at nucleotides 6181-6183. Putative untranslated regions downstream from the termination codon and upstream from the initiation codon are underlined in Table 5A, and the start and stop codons are in bold letters.

Table 5A. NOV5 Nucleotide Sequence (SEQ ID NO:19)

AGGACGATGCCAAGGGTGGGTGCCCTAAAGCACACAGCAGGAAGAGCTTCCCCTCAGCAGCGACATGGTGGAGA AGCAGACTGGAAAAAGAAAGATAAAAGTTCTCTAACCAAGACCCAAAATGGAGCGTGGCGATGGGGAAAGGA GGTAGGGAGCGAGCCAGCAAGCGGAAGCTGCCCTCACCGCGGGGCCAATGGGAGCAGAAGGACTCGGACACA GGTACCGCCGACAGCCTTACCTCTGTGTGACCCCTTCACATACTGCGGAAGAAGCCAAAGCTGAAAGGAGA AGCAGGGCCCTGAGCGGAAGAGGATTAAGAAGGAGCCTGTACCCCGAAGGCCGGCTGTCTGGAATCCGAGCCGG CTACCCCTCTCCGAGCGCCAGCAGGTGGCCCTCTCATGCAGATGACGGCCGAGGAGTCTGCCAACAGCCCAGTG GACACAAACACCAAAGCACCCCTCCAGTCTACAGTGTCTAGAAGGGAACGCCAACTCTGCCTAAAAACCAAAG ATAAAAGTGAACAAGAGAAACGAGCGTGGAGAGACCCGCTGCACCGAGCCCATCCGCGGGACGCCGGCGCAT CAAAGAGCTCATCAGCGAGGGGAGACGTCACGTCAAGGACTTCGCAGGCTGGACGGCGCTGCACGAGGCCTGT AACCGGGGCTACTACGACGTCGCGAAGCAGCTGCTGGCTGCAGGTGCGGAGGTGAACACCAAGGGCCTAGATGACG ACACGCCTTGCACGACGCTGCCAACACGGGCACCAGGTGGTGAAGGCTGCTGCTGCCGGTACGGAGGGAACCCGA GCAGAGCAACAGGAAAGGGAGACGCCGCTGAAAGTGGCCAACCTCCCCACCGATGGTGAACCTCCTGTTAGGCAAA
--

GGCACTTACACTTCCAGCGAGGAGAGCAGCTCAGAAGAGGAAGACGCACCACCTTCGCACCTTCAGTCG
 ACGGCAACAAACCGACTCCGAGTCGAAAAAGGCCCAAGCACAAGGCCAACAGGCCACAGAAGGCCAC
 GGCCTCCGTCAGGACGAGTATGAGTTGATGAGGACGACGAGCAGGACAGGTTCTCCGGTGGACACAAGCAC
 CTATTGAAAAGGACTACAGAAAAGAAACGAAATCCAATAGTTTATCTCTATACCCAAATGGAGGTTAAAAGTT
 ACACAAAAATAACACGATTGCACCAAAGAAAGCGTCCATCGTATCCTGTCAAGACACGTCGGACGAGGAGGACG
 GAGTGTCAACCGTGGGACAGGAGAGAAGCTGAGACTCTCGGCACATACGATATTGCTGGTAGTAAGACACGAGAG
 CCTCTAATGCCAAGCAGCAGAAGGAAAAAATAAAGTAAAAAGCAGAAAGAAAGAAACAAAGGCAGAGAGG
 TTCGCTCGGAAAGCGGAGCGACAAGTCTGCTCCTCGAGTCGGAGAGCAGTCTCAGAGAGTGGGAGGATGA
 CAGGGACTCTCTGGGAGCTGGCTGCCTCAAGGGGCTCCCGCTGGTAGAAGGACCCCTCCCTGTCAGCTCC
 CTCTGCCTCCTCACCTCGTCAAGGGAGCTGCGCCAGAACGACAGCAGCACACCAAGCAGTC
 AAACCATTTCTCCCCGGCTGGTCAGAGGTCAGTTTATCAGACTCCACAAGGACGAGACTGACAAGCGAGTC
 TGACTACTCCTCTGAGGGCTCAGTGTGAATCGCTGAAGCCAGTGAAGGAGAGGACAGGAAGCGAGCC
 TCCCTGCGAGAAGAAGAGCCCTCTGTCAGCGGGAGGGCCTGTCAGGAAACTGGACAAGGAGGGAAAG
 TTGTCAAAAACATAAAACAAAACACAAACACAAAACAAGGAGAAGATCAGGCAAGAGCTGAAGTTGAAAAGTT
 TACTTACGAATATGAGGACTCCAAGCAGAAGTCAGATAAGGCTATACTGTTAGAGAATGATCTTCACTGAAAAC
 AAGCTAAAAGTGTAAAGCACGATCGCACCCTTAAAAGAAGAGAAACTTAGCAAATGAAATTAGAAGAAA
 AAGAATGGCTTTAAAGATGAAAATCACTGAAGAGAATCAAAGACAAACTGAGACTGTACAAAGAGGAGAGAGA
 CAAAATTCTAAAAGAGAAGGAGAAGATTTTAAAGAAGATAAAGAAAAACTCAAAAGAAAAGGTTATAGGAA
 GATAGCCTTCTGACCGGGATTCATCCTTGATTCAAGGGGCAAGCTCATCTGGAGACGGTGAAGGAGGACA
 GCAAGGAGAGGAGGCGGGACAGCCGGCCGGAGAACGACCCAGCAGGAGAAGGAGAACCCGATAAGAGGAA
 GAGATACAAAGAGAAAGACAAGGACAAAAGTGAAGAAATCAATCCTGAAAATGTCAGAAGGACAAGAGGAA
 GAAAACATAAAAGACACACATGGCAAAGACAAAGAAGAAAGGAAAGCCTGAGTCAGGAGGACACACTCCTCATCTCAG
 ATAAAGACTCCACAGAAAAGTACAAGGACAGAGCCTCAGTGGACTCCACGCAAGATAAGAAAATAACAGGAGAA
 GGCCTGAAAAGAACGACGCTGCCAGAACGACAAGGCTAAAGCAAACACAAAGAGAAGTCGGACAAGAACATTCCAAG
 GAGAGGAAGTCCTCGAGAAGTGCAGCAGGAAATCAGAGAAAGCAGGTCCTCTGACAGCTTCACGGACCGAG
 AGGACGACAAGAGCCTGCTCCCTGAGAAGCTGAAAGAGAGGACAGACACTCCTCATCTCAG
 GAGCCACGACCGAGAGGAGAAGAAAGAGGATTACAAGGAGGGCAGGAAGGGCAGTACGAAAAGGACCTGGAGGCG
 GATGCTTACGGAGTTCTTACAACATGAAAGCTATTGAAATTGTTGAAAAGAAAAGATAAAATGATGAAACCTCTAA
 AAGAGAAGAAGAAGAGAGAAACACAGGGAGAAATGGAGAGACGAGAAGGAGAGGACCCGGAGACAGGCATGGGA
 TAGGCCGAAGCCATCAAAGACCCAGGCAAGAAAGACGCCAGGCCAGGGAGAAGCTCCTGGGGAGCGGCACCTG
 ATGATGACCAAGCTCGAGAGGATGCTGTCCTCAGAAGGACCTGGAGATCGAGGAGCGCCACAAGCGGCACAAGGAGA
 GGATGAAGCAAATGGAGAAGCTGAGGCACGGTCCGGAGACCCAGCTCAAGGAGAAGCGAAGCCGGCAGACGA
 CGGGCGGAAGAAGGCTGGACATTCTGCTAAGAAACGCCGGGCTGGACCTCCATTAAAGACAAAAGCTC
 AAAGAGTCGACTCCTATTCCACCTGCCCGGAAAATAAGCTACACCCAGCATCAGGTGAGACTCCTAAAGACTGGC
 TGGCAGGCCCTCACATGAAAGAGGCTCTGCCGTCCCCCAGGCCAGCACAGGCCACTGGCGTGCCTC
 CCTACGTGGCTATCCTGCCAGCTACGAGGAGGTGATGCACACGCCAGGACCCGCTCTGCAGCGCCGAT
 GACTACGCGACCTCGTGTGACTGCGCCACTCGCAGCACTCCACGCCCGCTGCCACCGCTCCACCGCGCCT
 GCTCCCCCTCTTTTCGACAGGTTCTCGTGGCTTCAAGTGGCTTGGAAAACGCCAGGCCAGGCTCTGCCAG
 GCCTCTCTCACAAACCTTACCGCTCGGTCTGACATTGACAAGCTCTCAGGCAGCAGAGCGTCTGCT
 GCCTCCAGCTACGACTCTCCATGCCACCCCTGATGGAAGACAGGGGCCCTGCCCGGTTCCCGCGGAGAAGT
 TTGCTGCTGTCGCCAGGGTACTACTCCCCAGACTATGGCTCCCGTCCAGCTGGAGTCTGACTGCC
 ACCGGCTGCCGTTGTCAGTACCCCGTCTCCAGAGGGCGTCTCTCAAGTTACAAGAAAACCTCCCTCC
 CCCCCCTCCCTGGACACCTCCGAGGACCAGCAGGCCGCGCATCATTCCCCCGGAGGCCAGCTACCTGGAGC
 CGCTGGACGAGGGTCCCTCAGGCCGTCATCACCAGGGAGGCCCTGAGTGGGCCACCCCTCCGAGCAGGCCGCT
 TGCTCTAGCCTGATCGGGGACCTCTGAAAACCCCTGAGCTGGCTCTGAGCTGGGCCACCTCTGCTGAAGTCT
 CCACAGAGATTCCCCGAGTCCCCAAAGCTTCTGCCCGCGGACCCCTCCACTCTGCCGCCCCAGGGCCCTCA
 GGGCCTCGGAGGCCTGACCCCGCTCTGCCGCTCTGCCGCTACGCCCTCCCTCCGGAGCAGCTGGAGGA
 CGTCAGGACGCTCCCGCCGACCTCCACCTCAGAGGCCGCTCCCTACGCCCTCCCTCCGGAGTCTGAGCTCC
 TTCAGCAACTGCAAGTCACTTCCGAAGGCCGCTGGACGTGGCCCCCGAGGCTCTGGGGCCCTGAAAATAGCT
 TCTCTGGACGGCAGCCGCCCTGTCACCTCCGGCAGGTGGAGGCCGCTGGCCCTGGGGAGCGCCTCGCCGCC
 CGAGGACGACCTGGACCTGGGCCCTCTCCCTGCCGAGCTTCCCTGAGCTTCCCTGAGACTAAAGATGCCGAGATGGTGA
 GCGGAACCGTGGAAAGAAAGTCTGCTCTCCAGAAGAGATGCCCTCAGGGGCCCGGGAGCTCGAGCCTGAGC
 CCTCAGGGGAGCCAAAGCTGGACGTGGCTCTAGAAGCTGCCGAGGCCGAGCGGTGCCGGAGAGAGGCCG
 TGGGGATCCGACTCCAGCGTGGAGGCCGCCCCGTTCCCTGCCGAGCTTCCCTGAGCTTCCCTGAGACTAAAGATGCCGAGATGGTGA
 GCCCCTGACGGCCCCGCCGAACACTGTGGCACAAGCTCAGGCCGAGGCCGAGCGGTGCCGGAGACGCCCTCCCTG
 AGGCCCTCCCGTCCGCCGCCCCAGCCGAAGGCCCTCTGGCCAGCCGAAGCCGAGAACACAAAACCCACGCCGA
 AGCCCCGAAGGCCCGAGAGATCCCTCAGCGCATGACCAGGAACCGGCCAGATGCTCGGAACCAAGAGCAAG

```

CAGGGCCGCCCTCCGAGAAGGAGTGCGCCCCCACCCCTGCCCGTCACCAGGGCAAGGCCCGGGCTCCG
AGGACGACGACGCCAGGCCAGCATCCGCGCAAACGCCCTTCAGCGCTCCACCCAGCAGCTGCAGCTGAACAC
GTCCACGCGAGCACGCCAGGTGATCCAGCAGCAGCTGCCATCGTGACGCCATCAAGCTGGATGCCATC
GAGCCCTACCACAGCAGGGCAACCCCTACTTCGAATACCTGCAGATCAGGAAGAAGATCGAGGAGAACGCA
AGATCCTGTGCTGTATCACGCCAGGCCAGTGTACGCCAGTACGTACCTACACGGCTCTACCTC
GGACGGCAAGCCGCTCAGCAAGCTCCACATCCCGTATCGCACCCCTCCCTGGGGAGGCCCTGAAGGAG
CTGTTCAAGGCCAGCAGGAGGCCCTGGGGAAAGCTGCCTACAGCACAGCATCGAGCAGGGAGAACGCTGATCGT
CCTGTGAGCAGGAGATTCTGCCGGTTCACTGCCGGCGGCCAGGACCATGCCAACCAGGCAGTGCCATTAGCGC
CTGCACGATGCTGACTCCGAGGTCTACAACATGCCCTGGAGAGCCAGGGTGACGAGAACAGTCAGTGCGC
GACCGTTCAACGCCGCCAGTTATCTCCTGGCTCCAGGACGTGATGACAAGTATGACCGCATGAAGGCTGCC
TCCTCATGCGGCAGCAGCACGAGGCCCGGCCCTGAACGCCGTGAGGATGGAGTGGAGCTGAAGGTCAGGA
ACTGGACCCGCCGGGACAAGTCCCTGTGCGTGAACGAGGTGCCCTCTACGTGCCATGGTCAGTCAC
GACGACTTTGATTGTCGCCGATGACACCCGGGACGGCCGAGGACGCAGGCAGGGCCGACGGCTGCCAG
GACTGCTGAGCCCCAGGGCGAGGAGGGAGCGCCCT

```

The nucleic acid sequence of NOV5 maps to chromosome 16 and has 555 of 857 bases (64%) identical to a gb:GENBANK-ID:AF317425|acc:AF317425.1 mRNA from Homo sapiens (Homo sapiens GAC-1 (GAC-1) mRNA, complete cds).

The NOV5 polypeptide (SEQ ID NO:20) is 2058 amino acid residues in length and is presented using the one-letter amino acid code in Table 5B. The SignalP, Psort and/or Hydropathy results predict that NOV5a has a signal peptide and is likely to be localized in the nucleus with a certainty of 0.9800. In alternative embodiments, a NOV5a polypeptide is located to the microbody (peroxisome) with a certainty of 0.3000, the mitochondrial matrix space with a certainty of 0.1000, or the lysosome (lumen) with a certainty of 0.1000.

Table 5B. Encoded NOV5 Protein Sequence (SEQ ID NO:20)

```

MPKGGCPKAPQQEELPLSSDMVEQTGKKDKVSLTKTPKLERGDDGKERVRRASKRKLPTAGANGEQKDSD
TGTSPALPLCDPFTYTAEEAKAERQKQGPERKRIKKEPVTRKAGLSGIRAGYPLSERQQVALLMQMTAEEESA
NSPVDTTPKHPQSSTVCQKGTPNSASKTDKVNKRNERGETRLHRAAIRGDARRRIKELISEGADVNVKDFAGW
TALHEACNRGYDVAKQLLAAGAEVNTKGDDDTPLHDAANNHGVVKLLRYGGNPQQSNRKGETPLKVANS
PTMVNLLLGKGTYSSESSSEEDAPSFAPSSVDGNNTDSEFEKGLKHAKNPEPQKATAPVKDEYEFDED
DEQDRVPPVDDKHLLKDYRKETKSNSFISIPKMEVKSYTNNIAPKKASHRILSDTSDEEDASVTVGTGEK
LRLSAHTILPGSKTREPSNAKQQKEKNVKKKRKETKGREVFRGKRSDFCSESESESSEGEDDRDSLGS
SGCLKGSPLVLKDPSLFSSLSASSTSSHGSSAAQKQNDQHTKHWKTISSPAWSEVSSLSDSTRTRLTSESDYS
SEGSSVESLKPVRKRQEHRKRALSEKKSPFLSSAEGAVPKLDKEGVVKKHKTKHKNKEKISQELKLKSFT
TYEYEDSKQKSDKAILLENDLSTENKLKVLKHDRDHFKKEEKLSKMKELEKEWLKDEKSLKRIKDKLRLYKE
ERDKISKEKEKIFKEDKEKLKEKVYREDLSLSDRDSFDKGAKLILETVKEDSKERRDRSRAREKHPAREKE
KPDKRKRYKEKDKDSEKSILEKCQKDKEKEKHDTGKDKERKASVFEKHKKEKKDESTEKYKDRASVDST
QDKKNQEKAEKKHAAEDAKSKHKEKSDKEHSKERKSSRSADAERYRESEVSSDSFTDREDDKSACLPEKLKE
KRHRHSSSSKKSHDREKKEDYKEGRKGQYEKDLEADAYGVSYNMKAIELFEKKDKNDEPLKEKKREKRE
KWRDEKERHRDRHADRPKSKDPGKKDARPREKLLGDGLMMTSFERMLSQKLEIEERHKRHKERMKQMEKL
RHRSGDPKLKEKAKPADDGRKKGLDIPAKKPPGLDPFKDKKLKESTPIPPAAENKLHPASGADSKDWLAGPH
MKEVLPASPRPDQSRPTGVPTPTSVLSCPSYEEVMHTPRTPCSADDYADLVFDCADSQHSTPVPTAPTSACS
PSFFDRFSVASSGLSENASQAPARPLSTNLYRSVSDIDKLFRQQSVPAASSYDSPMPPSMEDRAPLPPVPAE
KFACLSPGYSPDYGLPSPKVDALHCPAAVVTVTPSPEGFSSLQAKPSPSPPSLDTSEDQQATAAIIPPEP
SYLEPLDEGPFSAVITEEPVEWAHPSEQALASSLIGGTSENVPVSPVGSDELLKSPQRFPESPKRFCPADPLH
SAAPGPFSAEAPYPAPPASPAPYALPVAELEDVKDVPAIASTSEAAPYAPPSGLESFFSNCKSLPEAPLDVA
PEALGPLENSFLDGSRGLSHLGQVEPVPWADAFAGPEDIIDLGPFSLPELPLQTKDAADGEAEPVEESLAPPE

```

```

EMPPGAPRELEPEPSGEPKLDVALEAAVEAETVPEERARGDPDSSVEPAPVPPEQLSGDPSLCAPDGPAPNT
VAQQAQADGAGPEDDTTEASRAAAPAEGPPGQPEAAEPKPTAEAPKAPREIPQRMTRNRAQMLANQSKQGPPPS
EKECAPTPAPVTRAKARGSEDDDAQQAQHPRKRRFQRSTQQQLQLNTSTQQTREVIQQTLAAIVDAIKLDAIEPY
HSDRANPYFEYLQIRKKIEEKRKILCCITPQAPQCYAEYVTYTGSYLLDGKPLSKLHIPVIAPPSLAEPLKE
LFRQQEAVRGKLRQLQHSIEREKLIVSCEQEILRVHCRAARTIANQAVPFSACTMLLDSEVYNMPLESQGDENK
SVRDRFNARQFISWLQDVDDKYDRMKVCLLMRQQHEAAALNAVQRMWQLKVQELDPAGHKSLCVNEVPSFYV
PMVDVNDDFVLLPA

```

The NOV5 amino acid sequence has 373 of 398 amino acid residues (93%) identical to, and 376 of 398 amino acid residues (93%) similar to, the 399 amino acid residue
gi|17486077|ref|XP_066756.1| XM_066756 protein from Homo sapiens (Human) (similar to
5 KIAA0874 PROTEIN) (E =0.0).

NOV5 is expressed in at least the following tissues: Heart, liver, Blood, Gall Bladder, Adrenal Gland/Suprarenal gland, Amygdala, Ascending Colon, Bone, Bone Marrow, Brain, Cervix, Dermis, Hippocampus, Kidney, Lung, Lymph node, Lymphoid tissue, Mammary gland/Breast, Ovary, Parotid Salivary glands, Pituitary Gland, Placenta, Prostate, Small Intestine, Spinal Chord, Spleen, Synovium/Synovial membrane, Testis, Thymus, Thyroid, Urinary Bladder, Vulva. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.

NOV5 has homology to the amino acid sequences shown in the BLASTP data listed in Table 5C.

Table 5C. BLAST results for NOV5

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<u>gi 14140238 ref NP_056023.1 (NM_015208)</u>	KIAA0874 protein [Homo sapiens]	2062	804/2109 (38%)	1142/2109 (54%)	0.0
<u>gi 17486077 ref XP_066756.1 (XM_066756)</u>	similar to KIAA0874 protein (H. sapiens) [Homo sapiens]	399	373/398 (93%)	376/398 (93%)	0.0
<u>gi 7019449 ref NP_037407.1 (NM_013275)</u>	nasopharyngeal carcinoma susceptibility protein [Homo sapiens]	366	308/366 (84%)	315/366 (85%)	e-141

gi 5690397 gb AAF24125.1 AF121775.1 (AF121775)	nasopharyngeal carcinoma susceptibility protein LZ16 [Homo sapiens]	366	308/366 (84%)	315/366 (85%)	e-141
gi 4240237 dbj BAA74897.1 (AB020681)	KIAA0874 protein [Homo sapiens]	601	283/600 (47%)	365/600 (60%)	e-120
gi 17445427 ref XP_065820.1 (XM_065820)	similar to putative (H. sapiens) [Homo sapiens]	999	248/517 (47%)	301/517 (57%)	8e-80

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 5D.

Table 5D. ClustalW Analysis of NOV5

- 1) NOV5 (SEQ ID NO:20)
- 2) gi|14140238|ref|NP_056023.1| (NM_015208) KIAA0874 protein [Homo sapiens] (SEQ ID NO:52)
- 3) gi|17486077|ref|XP_066756.1| (XM_066756) similar to KIAA0874 protein (H. sapiens) [Homo sapiens] (SEQ ID NO:53)
- 4) gi|7019449|ref|NP_037407.1| (NM_013275) nasopharyngeal carcinoma susceptibility protein [Homo sapiens] (SEQ ID NO:54)
- 5) regi|6690397|gb|AAF24125.1|AF121775.1 (AF121775) nasopharyngeal carcinoma susceptibility protein LZ16 [Homo sapiens] (SEQ ID NO:55)
- 6) gi|4240237|dbj|BAA74897.1| (AB020681) KIAA0874 protein [Homo sapiens] (SEQ ID NO:56)
- 7) gi|17445427|ref|XP_065820.1| (XM_065820) similar to putative (H. sapiens) [Homo sapiens] (SEQ ID NO:57)

5 NOV5 COR100396092

10

gi|14140238|

10 20 30 40 50
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

NOV5 COR100396092

gi|14140238| MPKSGFTKPIQSENSDSDSNMVEKPYGRKSKDKIASYSKTPKIERSDVSK

gi|17486077|

gi|7019449|

gi|4240237|

gi|17445427|

15

NOV5 COR100396092

gi|14140238|

gi|17486077|

gi|7019449|

gi|4240237|

gi|17445427|

60 70 80 90 100
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

NOV5 COR100396092

gi|14140238| EMKEKSSMKRKLPFTISPSRNEERDSDTDSDPGHTSENWGERLISSYRTY

20

NOV5 COR100396092

gi|14140238|

gi|17486077|

gi|7019449|

gi|4240237|

gi|17445427|

110 120 130 140 150
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

NOV5 COR100396092

gi|14140238| SEKEGPEKKTKKEAGNKKSTPVSILFGYPLSERKQMALLMQMTARDNSP

25

NOV5 COR100396092

gi|14140238|

160 170 180 190 200
.....|.....|.....|.....|.....|.....|.....|.....|.....|.....|

NOV5 COR100396092

gi|14140238| DSTPNHPSQTTPAQKKTPSSSRQDKVNKRNERGETPLHMAAIRGDVKQ

5	gi 17486077	-----					
	gi 7019449	-----					
	gi 4240237	-----					
	gi 17445427	-----					
10	NOV5 COR100396092	-----	210	220	230	240	250
	gi 14140238	VKELISLGANVNVKDFAGWTPLHEACNVGYYDVAKILIAAGADVNTQGLD	-----				
	gi 17486077	-----					
	gi 7019449	-----					
	gi 4240237	-----					
	gi 17445427	-----					
15	NOV5 COR100396092	-----	260	270	280	290	300
	gi 14140238	DDTPLHDSASSGHHRDIVKLLLRHGGNPFOANKHGERPVDVAETEELELLL	-----				
	gi 17486077	-----					
	gi 7019449	-----					
	gi 4240237	-----					
	gi 17445427	-----					
20	NOV5 COR100396092	-----	310	320	330	340	350
	gi 14140238	KREVPLSDDESYTDSEEAQSVNPSSVDENIDSETEKDSLICESKQILPS	-----				
	gi 17486077	-----					
	gi 7019449	-----					
	gi 4240237	-----					
	gi 17445427	-----					
25	NOV5 COR100396092	-----	360	370	380	390	400
	gi 14140238	KTPPLPSALDEYEFKDDDDEEINKMIDDRHILRKEQRKENPEAEKTHLFA	-----				
	gi 17486077	-----					
	gi 7019449	-----					
	gi 4240237	-----					
	gi 17445427	-----					
30	NOV5 COR100396092	-----	410	420	430	440	450
	gi 14140238	KQEKFYPKSFKSKKQKPSRVLYSSTESSDEALQNKKISTCSVIPETS	-----				
	gi 17486077	-----					
	gi 7019449	-----					
	gi 4240237	-----					
	gi 17445427	-----					
35	NOV5 COR100396092	-----	460	470	480	490	500
	gi 14140238	NSDMQTKKEYVVSGEHKQKGKVKRKLKNQNQNKENQELKQEKGKENTRI	-----				
	gi 17486077	-----					
	gi 7019449	-----					
	gi 4240237	-----					
	gi 17445427	-----					
40	NOV5 COR100396092	-----	510	520	530	540	550
	gi 14140238	TNLTVNTGLDCSEKTREEGNFRKSFSPKDDTSLHLFH1STGKSPKHSCGL	-----				
	gi 17486077	-----					
	gi 7019449	-----					
	gi 4240237	-----					
	gi 17445427	-----					
45	NOV5 COR100396092	-----	560	570	580	590	600
	gi 14140238	SEKQSTPLKQEHKTCLSPGSSEMSLQPDILVRYDNTESFLEPESSSVKSC	-----				
	gi 17486077	-----					
	gi 7019449	-----					
	gi 4240237	-----					
	gi 17445427	-----					
50	NOV5 COR100396092	-----					
55	NOV5 COR100396092	-----					
60	NOV5 COR100396092	-----					
65	NOV5 COR100396092	-----					
70	NOV5 COR100396092	-----					

5	gi 17486077 gi 7019449 gi 4240237 gi 17445427	----- ----- ----- -----
10	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	610 620 630 640 650
15	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	660 670 680 690 700
20	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	710 720 730 740 750
25	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	760 770 780 790 800
30	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	810 820 830 840 850
35	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	860 870 880 890 900
40	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	910 920 930 940 950
45	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	960 970 980 990 1000
50	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	----- ----- ----- -----
55	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	----- ----- ----- -----
60	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	----- ----- ----- -----
65	NOV5 COR100396092 gi 14140238 gi 17486077 gi 7019449 gi 4240237 gi 17445427	----- ----- ----- -----
70	NOV5 COR100396092 gi 14140238	----- -----

5	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
10	NOV5 COR100396092	1010 1020 1030 1040 1050			
	gi 14140238	KEKTKDEPLKTPDGKEKDKKDIDRYKERDKHKDKIQINSLLKLKSEAD	-----			
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
15	NOV5 COR100396092	1060 1070 1080 1090 1100			
	gi 14140238	KPKPKSSPASKDTRPKERKLVNDDLMQTSFERMLSLKDLIEEQWHKKHE	-----			
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
20	NOV5 COR100396092	1110 1120 1130 1140 1150			
	gi 14140238	KIKQKEKERLRNRNCLELKIKDKEKTKHTPTESKNKELTRSKSSEVTDAY	-----			
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
25	NOV5 COR100396092	1160 1170 1180 1190 1200			
	gi 14140238	TKEKQPKDAVSNRSQSVDTKNVMTLGKSSFVSDNSLNRSPRSENEKPGLS	-----			
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
30	NOV5 COR100396092	1210 1220 1230 1240 1250			
	gi 14140238	SRSVSMISVASSEDSCHTTVTPRPPVEYDSDFMLESSESQMSFSQSPFL	-----			
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
35	NOV5 COR100396092	1260 1270 1280 1290 1300			
	gi 14140238	SIAKSPALHERELDSLADLPERIKPPYANRLSTSHLRSSSVEDVKLISE	-----			
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
40	NOV5 COR100396092	1310 1320 1330 1340 1350			
	gi 14140238	GRPTIEVRRCMSMPSVICEHTKQFQTISEESENQGSLLTVPGDTSPSPKPEV	-----			
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
45	NOV5 COR100396092	1360 1370 1380 1390 1400			
	gi 14140238	FSNVPERDLSNVSNIHSSFATSPPTGASNSKYVSADRNLIKNTAPVNTVMD	-----			
	gi 14140238	-----				

5	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
10	NOV5 COR100396092	1410 1420 1430 1440 1450			
	gi 14140238	SPVHLEPSSQVGVIQNKSWE MPVDRLETLSTRDFICPNSNIPDQESSLQS	-----			
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
15	NOV5 COR100396092	1460 1470 1480 1490 1500			
	gi 14140238	FCNSENKVLKENADFLSLRQTELPGNSCAQDPASFMPPQQPCSFPSQSL	-----			
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
20	NOV5 COR100396092	1510 1520 1530 1540 1550			
	gi 14140238MPKGGCPK P QEELPLSSDM EKQTGKK-K KV LTK PKLER	-----			
	gi 17486077	DAESISKHMSLSYV N EPGILQQKNA QIISALDT NE TKD ENTFV	-----			
	gi 7019449	-----				
	gi 4240237	-----MPKGGCPK P QEELPLSSDM EKQTGKKDK KV LTK PKLER	-----			
	gi 17445427	DAESISKHMSLSYV N EPGILQQKNA QIISALDT NE TKD ENTFV	-----			
		KDCSNTAEKEKSLKEKSSKEEKLRLYKEERKTPKRQK KEPKDKRKDTGA	-----			
25	NOV5 COR100396092	1560 1570 1580 1590 1600			
	gi 14140238	GDGGKE-----VRERASKR FTAG-----	-----			
	gi 17486077	LGDVQKTDFAFV-P-VYSDSTIQEASPNEFKEYT VL PSE DFNGSDASTQ	-----			
	gi 7019449	-----M QS-SA DYLG-----	-----			
	gi 4240237	GDGGKE-----VRERASKR FTAG-----	-----			
	gi 17445427	LGDVQKTDFAFV-P-VYSDSTIQEASPNEFKEYT VL PSE DFNGSDASTQ	-----			
		ADGVTDKKEKVKLEKHKEKKVKEYQKNNKQK EKAEK QSAEDK-----	-----			
30	NOV5 COR100396092	1610 1620 1630 1640 1650			
	gi 14140238NGEQ DSDTGTSP TAL-----PLCDPFTYTAE	-----			
	gi 17486077	LNTHY FSKLTYKSSSGHEV NSTTDTQV ISHEKENKLES LVLTHLSRC	-----			
	gi 7019449	-----EYCIL AQAADGAGP DDTEASRAA PAE-----	-----			
	gi 4240237	-----NGEQ DSDT-----	-----			
	gi 17445427	LNTHY FSKLTYKSSSGHEV NSTTDTQV ISHEKENKLES LVLTHLSRC	-----			
		-----NSKH EKSDKEYSK R KSLRSADMEKS LLEKLE ALHEYR DSS	-----			
35	NOV5 COR100396092	1660 1670 1680 1690 1700			
	gi 14140238	EAKAERQKQG ERKRIKKE VTRKA-----GLSG RAGYPLS	-----			
	gi 17486077	SDLCEMNAGM KGNLNEQD KHC PES-EKCLLSIEDEESQQS LSSLEN	-----			
	gi 7019449	-----GP CG-----IQPEAAE-----	-----			
	gi 4240237	-----EKQG ERKRIKKE VTRKA-----LLFGMGLSG RAGYPLS	-----			
	gi 17445427	SDLCEMNAGM KGNLNEQD KHC PES-EKCLLSIEDEESQQS LSSLEN	-----			
		DKIT TTERDSQERKVPEEKGRDYKEGGSRKDTGQYKDFLEM VAYGVSY	-----			
40	NOV5 COR100396092	1710 1720 1730 1740 1750			
	gi 14140238	ER QVALL QMTAEE SANSPVDTTPKHP S QVC KG P S SKTKDKVN	-----			
	gi 17486077	SQ STQPE HKYQLVKVELEENA EDDK TENQIP RM R K NTMANQSK	-----			
	gi 7019449	-----P-----KPTAEAPKA PRV EIP RM R R QMLANQSK	-----			
	gi 4240237	ER QVALL QMTAEE SANSPVDTTPKHP S QVC KG P S SKTKDKLN	-----			
	gi 17445427	SQ STQPE HKYQLVKVELEENA EDDK TENQIP RM R K NTMANQSK	-----			
		MKA VIEDR LNK TVELFSTEKKDKN D SERETSK KIE KELK PYG SRT KQK P	-----			
45	NOV5 COR100396092	1760 1770 1780 1790 1800			
	gi 14140238	KRNERGETRLHRAIRGDA -----KELISEG DVNVKDFAGWTALHE	-----			
	gi 17486077	QILASCTLLSEKDSESSSP -----G RLTED DPQIHHPRKRKV SRVPQ	-----			
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
50	NOV5 COR100396092	1760 1770 1780 1790 1800			
	gi 14140238	KRNERGETRLHRAIRGDA -----KELISEG DVNVKDFAGWTALHE	-----			
	gi 17486077	QILASCTLLSEKDSESSSP -----G RLTED DPQIHHPRKRKV SRVPQ	-----			
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
55	NOV5 COR100396092	1760 1770 1780 1790 1800			
	gi 14140238	KRNERGETRLHRAIRGDA -----KELISEG DVNVKDFAGWTALHE	-----			
	gi 17486077	QILASCTLLSEKDSESSSP -----G RLTED DPQIHHPRKRKV SRVPQ	-----			
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
60	NOV5 COR100396092	1760 1770 1780 1790 1800			
	gi 14140238	KRNERGETRLHRAIRGDA -----KELISEG DVNVKDFAGWTALHE	-----			
	gi 17486077	QILASCTLLSEKDSESSSP -----G RLTED DPQIHHPRKRKV SRVPQ	-----			
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
65	NOV5 COR100396092	1760 1770 1780 1790 1800			
	gi 14140238	KRNERGETRLHRAIRGDA -----KELISEG DVNVKDFAGWTALHE	-----			
	gi 17486077	QILASCTLLSEKDSESSSP -----G RLTED DPQIHHPRKRKV SRVPQ	-----			
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
70	NOV5 COR100396092	1760 1770 1780 1790 1800			
	gi 14140238	KRNERGETRLHRAIRGDA -----KELISEG DVNVKDFAGWTALHE	-----			
	gi 17486077	QILASCTLLSEKDSESSSP -----G RLTED DPQIHHPRKRKV SRVPQ	-----			
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				

5	gi 17486077	QGPPPSEKECAP-TPAPVT	-----AKARGSED D QAQHPRKRQRFQRSTQ			
	gi 7019449	KRNERGETRLHRAIRGDA	-----KELISEG DVNVKDFAGWTALHE			
	gi 4240237	QILASCTLLSEKDSESSSP	-----G RLTED DPQIHHPRKRKVSVPQ			
	gi 17445427	ARDKDSPPRALKDKSRDEDPRLRKAKLKEKFK	S EKEKDDDSVKMSKGDD			
		1810	1820	1830	1840	1850
10	NOV5 COR100396092	ACN-----			
	gi 14140238	PVQVSP-----			
	gi 17486077	QLQQQLN-----			
	gi 7019449	ACN-----			
	gi 4240237	PVQVSP-----			
	gi 17445427	KVSPSKDPGKKNARPREKLRGDGDMMIISFQRMFSQKDLEIEERHKGHKE			
15		1860	1870	1880	1890	1900
20	NOV5 COR100396092	-----RGYYDVA QLLAAG E NTKG			
	gi 14140238	-----SLLQAKE TQQS A I DSL			
	gi 17486077	-----TSTQQQTREVIQQT A I DAI			
	gi 7019449	-----RGYYDVA QLLAAG E NTKG			
	gi 4240237	-----SLLQAKE TQQS A I DSL			
	gi 17445427	RMKQMEKLRHQSRDPNLKERAKPADDGRKKGLEIPA KPPG DPPFKDK			
25		1910	1920	1930	1940	1950
30	NOV5 COR100396092	DDT LHDAAN GH-----QVV LL RYGGN QS-----			
	gi 14140238	EIQ YSSERA PYFEYLHIRK -----IEE RK LCSVI AP-----			
	gi 17486077	AIE YHSDRA PYFEYLQIRK -----IEE RKILCCIT AP-----			
	gi 7019449	DDT LHDAAN GHY-----KVV LL RYGGN QS-----			
	gi 4240237	EIQ YSSERA PYFEYLHIRK -----IEE RK LCSVI AP-----			
	gi 17445427	KELT IPPAAE KPRPGSGADS DWLAGPHM EV PASPR DQSRPVCP			
35		1960	1970	1980	1990	2000
40	NOV5 COR100396092	-----NRK ETP KVANS-----			
	gi 14140238	-----QYYDEYV FN SYL D NPLSKICIPIT-----			
	gi 17486077	-----QWYAQYV YT SYL D KPLSKLHIPVIA-----			
	gi 7019449	-----NRK ETP KVANS-----			
	gi 4240237	-----QYYDEYV FN SYL D NPLSKICIPIT-----			
	gi 17445427	PLRRCCPASA RR HSPAP RHRGPAGYSPHH GAQLPGAAGRGLIGSA			
45		2010	2020	2030	2040	2050
50	NOV5 COR100396092	-----TMVNL LG-----KGTYTSE-----			
	gi 14140238	-----SLSDP KELFRQ-----QEVRVRMKLRLQH IEREK I			
	gi 17486077	-----SЛАЕР KELFRQ-----QEAVRGKLRLQH IEREK I			
	gi 7019449	-----TMVNL LG-----KGTYTSE-----			
	gi 4240237	-----SLSDP KELFRQ-----QEVRVRMKLRLQH IEREK I			
	gi 17445427	SENPVSW VGSEL LKSPQRFPESPEYFCSADSLHSAAPGPF ASENT L			
55		2060	2070	2080	2090	2100
60	NOV5 COR100396092	-----ES-----SSEEED PS APSSSVDGNN-----			
	gi 14140238	VSN--- QEVL HYRA RTLANQTL SACTV LDAEVYNVP D-----			
	gi 17486077	VSC--- QEIL HCRA RTIANQ V STCTM LDSEVYNMP E-----			
	gi 7019449	-----ESSTESSEEED PS APSSSVDGNN-----			
	gi 4240237	VSN--- QEVL HYRA RTLANQTL SACTV LDAEVYNVP D-----			
	gi 17445427	IAEPGL DVKD EAIP TISTSE A YAPPSG ESFFNNCKS PESLLD			
65		2110	2120	2130	2140	2150
70	NOV5 COR100396092	-----TD EFE GLKHKAKNPEPKATAPVKDEYEFD-----			
	gi 14140238	-----Q DS T-----			
	gi 17486077	-----QG EN-----			
	gi 7019449	-----TD EFE G-----			
	gi 4240237	-----Q DS T-----			
	gi 17445427	MAPEACNHCGSDAFAG ED LDLGSFSLPELPLQTKDVPDVETEPEESL			
75		2160	2170	2180	2190	2200
80	NOV5 COR100396092	-----DEQDRVPP-----VDDKHLKKDYRKET-----			
	gi 14140238	-----			

5	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----	APSEKIPPGAPVVLPTELEPEPSEEPKLDVALEATEAEAVPEERASGDLD			
10	NOV5 COR100396092	2210	2220	2230	2240	2250
	gi 14140238				
	gi 17486077	K NSFISIPKMEVKSYTKNN-----	-----	-----	-----	-----
	gi 7019449	- VR-----DRFNA -----	-----	-----	-----	QFMS L DVDD
	gi 4240237	- VR-----DRFNA -----	-----	-----	-----	QFIS L DVDD
	gi 17445427	- VR-----S---T -----	-----	-----	-----	-----
						PRT SHR-
						- VR-----DRFNA -----

						QFMS L DVDD
						S MEPTPVRPEQQLGS DQGAEAEHLLPPAASLCAPDTPCPP TLWHKP
15	NOV5 COR100396092	2260	2270	2280	2290	2300
	gi 14140238				
	gi 17486077	LS TSDEEDASVTVGTGEKLRLSAHT-----	-----	-----	-----	-----
	gi 7019449	KF KLKT-----	-----	-----	-----	CLLM QQHE A LN VQ L
	gi 4240237	KY RMKT-----	-----	-----	-----	CLLM QQHE A LN VQ M
	gi 17445427	-----	-----	-----	-----	-----
						PRPPS----- T
						KF KLKT-----
						CLLM QQHE A LN VQ L
						RLRTVLAPTTTLRASRAAAPAEGPPCGIDPEATESEPCKPT E PK PRHS
20	NOV5 COR100396092	2310	2320	2330	2340	2350
	gi 14140238				
	gi 17486077	KVKK RKKETKGREVRFKGKRSDFCSSESESSESSESSED RDSLGS	-----	-----	-----	-----
	gi 7019449	EW LQELDP-----	-----	-----	-----	ATYKSI
	gi 4240237	EW VQELDP-----	-----	-----	-----	AGHKS
	gi 17445427	SMS MRTTS-----R-----	-----	-----	-----	TGF
						EW LQELDP-----
						ATYKSI
						TQ NTSTQQT-----
						-----REVIQQTLATIVDAIKLDIAIYPYHSDRANPYFEEF
25	NOV5 COR100396092	2360	2370	2380	2390	2400
	gi 14140238				
	gi 17486077	KGSPVLKDPSLFLSSLSASSTSSHGSSAAQKQNDQHTKHWKTISSPAWSE	-----	-----	-----	-----
	gi 7019449	SIY-----	-----	-----	-----	EIQFF VPL DVNDDFE TPI-----
	gi 4240237	CVN-----	-----	-----	-----	EVPDF VPM DVNDDFV LPA-----
	gi 17445427	R-----	-----	-----	-----	-----
						WTTST-----
						SIY-----
						EIQFF VPL DVNDDFE TPI-----
						HIRKKIEEKRKILCCITPQATQW AEY TYTGSYL DGKSLSKLHMPMIA
30	NOV5 COR100396092	2410	2420	2430	2440	2450
	gi 14140238				
	gi 17486077	VSSLSDSTRTRLTSESDYSSSEGSSVESLKVVRKRQEHRKRASLSKKSPF	-----	-----	-----	-----
	gi 7019449	-----	-----	-----	-----	-----
	gi 4240237	-----	-----	-----	-----	-----
	gi 17445427	PPPSLRASATRTSQCATGSTPASSSPGSMITWTTIQPHEDLLTWQQHEAAA	-----	-----	-----	-----
35	NOV5 COR100396092	2460	2470	2480	2490	2500
	gi 14140238				
	gi 17486077	LSSAEGAVPKLDKEGKVVKHHKTKHHKHNKEKISQELKLKSFTYBYESDK	-----	-----	-----	-----
	gi 7019449	-----	-----	-----	-----	-----
	gi 4240237	-----	-----	-----	-----	-----
	gi 17445427	LNAMQRMEWQLKVQKLDPAGH-----	-----	-----	-----	-----
40	NOV5 COR100396092	2510	2520	2530	2540	2550
	gi 14140238				
	gi 17486077	QKSDKAILLENDLSTENKLKVLDKHDHFKEEKLSKMKLEEKEWLKD	-----	-----	-----	-----
	gi 7019449	-----	-----	-----	-----	-----
	gi 4240237	-----	-----	-----	-----	-----
	gi 17445427	-----	-----	-----	-----	-----
45	NOV5 COR100396092	2560	2570	2580	2590	2600
	gi 14140238				
	gi 14140238	KSLKRIKDKLRLYKEERDKISKEKEKIFKEDKEKLKKEKVYREDSLSDRD	-----	-----	-----	-----

5	gi 17486077	-----
	gi 7019449	-----
	gi 4240237	-----
	gi 17445427	-----
10	NOV5 COR100396092	2610 2620 2630 2640 2650
	gi 14140238	SSFDFKGAKLILETVKEDSKERRDSRAREKHPAREKEKPDKRKRYKEKD
	gi 17486077	-----
	gi 7019449	-----
	gi 4240237	-----
	gi 17445427	-----
15	NOV5 COR100396092	2660 2670 2680 2690 2700
	gi 14140238	DKDKSEKSILEKCQKDKEKKEKHKDTHGKDKERKASVFEKHKEKKDKESTE
	gi 17486077	-----
	gi 7019449	-----
	gi 4240237	-----
	gi 17445427	-----
20	NOV5 COR100396092	2710 2720 2730 2740 2750
	gi 14140238	KYKDRASVDSTQDKKNQEKAKKHAEDAKSKHKEKSDKEHSKERKSS
	gi 17486077	-----
	gi 7019449	-----
	gi 4240237	-----
	gi 17445427	-----
25	NOV5 COR100396092	2760 2770 2780 2790 2800
	gi 14140238	RSADAEYRESEVSSDSFTDREDDKSACLPEKLKEKRHRHSSSSSKSHDR
	gi 17486077	-----
	gi 7019449	-----
	gi 4240237	-----
	gi 17445427	-----
30	NOV5 COR100396092	2810 2820 2830 2840 2850
	gi 14140238	EEKKEDYKEGRKGQYEKDLEADAYGVSYNMKAIELFEKDKNDEPLKEKK
	gi 17486077	-----
	gi 7019449	-----
	gi 4240237	-----
	gi 17445427	-----
35	NOV5 COR100396092	2860 2870 2880 2890 2900
	gi 14140238	KREKHREKWRDEKERHRDRHADRPKPSKDPGKDKDARPREKLLGDGDLMMT
	gi 17486077	-----
	gi 7019449	-----
	gi 4240237	-----
	gi 17445427	-----
40	NOV5 COR100396092	2910 2920 2930 2940 2950
	gi 14140238	SFERMLSQKDLEIEERHKRHKERMQMEKLRHRSGDPKLKEKAKPADDGR
	gi 17486077	-----
	gi 7019449	-----
	gi 4240237	-----
	gi 17445427	-----
45	NOV5 COR100396092	2960 2970 2980 2990 3000
	gi 14140238	KKGLDIPAKKPPGLDPFPFDKKLKESTPIPPAAENKLHPASGADSKDWLA
	gi 14140238	-----

5	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
10	NOV5 COR100396092	3010	3020	3030	3040	3050
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
15	NOV5 COR100396092	3060	3070	3080	3090	3100
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
20	NOV5 COR100396092	3110	3120	3130	3140	3150
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
25	NOV5 COR100396092	3160	3170	3180	3190	3200
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
30	NOV5 COR100396092	3210	3220	3230	3240	3250
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
35	NOV5 COR100396092	3260	3270	3280	3290	3300
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
40	NOV5 COR100396092	3310	3320	3330	3340	3350
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
45	NOV5 COR100396092	3360	3370	3380	3390	3400
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
50	NOV5 COR100396092	3410	3420	3430	3440	3450
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
55	NOV5 COR100396092	3490	3500	3510	3520	3530
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
60	NOV5 COR100396092	3540	3550	3560	3570	3580
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
65	NOV5 COR100396092	3620	3630	3640	3650	3660
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
70	NOV5 COR100396092	3710	3720	3730	3740	3750
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				

5	gi 17486077	3410	3420	3430	3440	3450
10	gi 14140238	NOV5 COR100396092	FAGPEDDLGLPFSLPELPLQTKDAADGEAEPVEEESLAPPEEMPPGAPRE			
15	gi 17486077					
20	gi 7019449					
25	gi 4240237					
30	gi 17445427					
35		3460	3470	3480	3490	3500
40	gi 14140238	NOV5 COR100396092	LEPEPSGEPKLDVALEAAVEAETVPEERARGDPDSSVPAPVPPEQLGSG			
45	gi 17486077					
50	gi 7019449					
55	gi 4240237					
60	gi 17445427					
65		3510	3520	3530	3540	3550
70	gi 14140238	NOV5 COR100396092	DPSLCAPDGPAPNTVAQQAQAADGAGPEDDTEASRAAAPAEGPPGQPEAAE			
75	gi 17486077					
80	gi 7019449					
85	gi 4240237					
90	gi 17445427					
95		3560	3570	3580	3590	3600
100	gi 14140238	NOV5 COR100396092	PKPTAEEPKAPEIIPQRMTTRNRAQMLANQSKQGPPPSEKECAPTPAPVTR			
105	gi 17486077					
110	gi 7019449					
115	gi 4240237					
120	gi 17445427					
125		3610	3620	3630	3640	3650
130	gi 14140238	NOV5 COR100396092	AKARGSEDDDAQAQHPRKRRFQRSTQQQLQLNTSTQQTREVQQTLAAIVD			
135	gi 17486077					
140	gi 7019449					
145	gi 4240237					
150	gi 17445427					
155		3660	3670	3680	3690	3700
160	gi 14140238	NOV5 COR100396092	AIKLDAIEPYHSDRANPYFEYLQIRKKIEEKRKILCCITPQAPOCYAEYV			
165	gi 17486077					
170	gi 7019449					
175	gi 4240237					
180	gi 17445427					
185		3710	3720	3730	3740	3750
190	gi 14140238	NOV5 COR100396092	TYTGSYLLDGKPLSKLHIPVIAPPSLAEPLKELFRQQEAVRGKLRLQHS			
195	gi 17486077					
200	gi 7019449					
205	gi 4240237					
210	gi 17445427					
215		3760	3770	3780	3790	3800
220	gi 14140238	NOV5 COR100396092	IEREKLIKIVSCEQEILRVHCRARTIANQAVPFSACTMLLDSEVYNMPLS			
225						

5	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
10		3810	3820	3830	3840	3850
	NOV5 COR100396092	QGDENKSVRDRFNRQFISWLQDVDDKYDRMKVCLLMRQHAAALNAVQ			
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				
15		3860	3870	3880	3890	
	NOV5 COR100396092	RMEWQLKVQELDPAGHKSLCVNEVPSFYVPMVDVNDDFVLLPA			
	gi 14140238	-----				
	gi 17486077	-----				
	gi 7019449	-----				
	gi 4240237	-----				
	gi 17445427	-----				

Tables 5E, 5F, 5G, 5H, 5I and 5J list the domain description from DOMAIN analysis results against NOV5. This indicates that the NOV5 sequence has properties similar to those of other proteins known to contain these domains.

Table 5E. Domain Analysis of NOV5

gnl|Pfam|pfam00023, ank, Ank repeat. Ankyrin repeats generally consist of a beta, alpha, alpha, beta order of secondary structures. The repeats associate to form a higher order structure.

(SEQ ID NO:58)

CD-Length = 33 residues, 84.8% aligned

Score = 45.8 bits (107), Expect = 2e-05

NOV 5: 218 GWTALHEACNRGYDVAKQLLAAGAEVN 245

|| || | | + + | | || || + ||

Sbjct: 2 GNTPLHLAARNGHLEVVKLLLEAGADVN 29

Table 5F. Domain Analysis of NOV5

gnl|Pfam|pfam00023, ank, Ank repeat. Ankyrin repeats generally consist of a beta, alpha, alpha, beta order of secondary structures. The repeats associate to form a higher order structure.

(SEQ ID NO:59)

CD-Length = 33 residues, 100.0% aligned

Score = 43.1 bits (100), Expect = 2e-04

NOV 5: 250 DDDTPLHDAANNGH-QVVKLLRYGGNPQQSNR 281

| +| ||| || ||| +| ||||| | + ++

Sbjct: 1 DGNTPLHLAARNGHLEVVKLLLEAGADVNDAR 33

Table 5G. Domain Analysis of NOV5

gnl|Pfam|pfam00023, ank, Ank repeat. Ankyrin repeats generally consist of a beta, alpha, alpha, beta order of secondary structures. The repeats associate to form a higher order structure.

(SEQ ID NO:60)

CD-Length = 33 residues, 93.9% aligned

Score = 42.0 bits (97), Expect = 3e-04

NOV 5: 185 GETRLHRAAIRGDARRIKELISEGADVNVKD 215

| | ||| | | +| | + | ||||| +|

Sbjct: 2 GNTPPLHLAARNGHLEVVKLLLEAGADVNDAR 32

Table 5H. Domain Analysis of NOV5

gnl|Smart|smart00248, ANK, ankyrin repeats; Ankyrin repeats are about 33 amino acids long and occur in at least four consecutive copies. They are involved in protein-protein interactions. The core of the repeat seems to be an helix-loop-helix structure.

(SEQ ID NO:61)

CD-Length = 30 residues, 93.3% aligned

Score = 43.1 bits (100), Expect = 2e-04

NOV 5: 218 GWTALHEACNRGYYDVAKQLLAAGAEVN 245

| | ||| | | +| | | | ||++|

Sbjct: 2 GRTPLHAAENGNLEVVKLLDKGADIN 29

Table 5I. Domain Analysis of NOV5

gnl|Smart|smart00248, ANK, ankyrin repeats; Ankyrin repeats are about 33 amino acids long and occur in at least four consecutive copies. They are involved in protein-protein interactions. The core of the repeat seems to be an helix-loop-helix structure.

(SEQ ID NO:62)

CD-Length = 30 residues, 93.3% aligned

Score = 41.2 bits (95), Expect = 6e-04

NOV 5: 250 DDDTPLHDAANNGH-QVVKLLLRYGGNP 276

| | | | | | | + + | | | | | | +

Sbjct: 1 DGRTPPLHAAENGNGLEVVKLLDKGADI 28

Table 5J. Domain Analysis of NOV5

gnl|Smart|smart00248, ANK, ankyrin repeats; Ankyrin repeats are about 33 amino acids long and occur in at least four consecutive copies. They are involved in protein-protein interactions. The core of the repeat seems to be an helix-loop-helix structure.

(SEQ ID NO:63)

CD-Length = 30 residues, 96.7% aligned

Score = 39.3 bits (90), Expect = 0.002

NOV 5: 185 GETRLHRAAIRGDARRIKELISEGADVNV 213

| | | | | | | + + | | + + | | | + | +

Sbjct: 2 GRTPLHAAENGNGLEVVKLLDKGADINL 30

Ankyrin repeats are tandemly repeated modules of about 33 amino acids. They occur in a large number of functionally diverse proteins mainly from eukaryotes. The few known examples from prokaryotes and viruses may be the result of horizontal gene transfers. The conserved fold of the ankyrin repeat unit is known from several crystal and solution structures, e.g., from: p53-binding protein 53BP2, cyclin-dependent kinase inhibitor p19Ink4d, transcriptional regulator GABP-beta, and NF-kappaB inhibitory protein I kB-alpha. It has been described as an L-shaped structure consisting of a beta-hairpin and two alpha-helices. Many ankyrin repeat regions are known to function as protein-protein interaction domains.

The protein similarity information, expression pattern, and map location for the NOV5 protein and nucleic acid disclosed herein suggest that it may have important structural and/or physiological functions characteristic of the family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or

prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

The nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: Cardio-vascular disorders, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus, Pulmonary stenosis, Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Obesity, Transplantation, Systemic lupus erythematosus, Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Hypercalceimia, Lesch-Nyhan syndrome and other diseases, disorders and conditions of the like.

20 NOV6

A disclosed NOV6 nucleic acid (designated as CuraGen Acc. No. COR87941483), encodes a novel TNF intracellular domain interacting protein and includes the 1749 nucleotide sequence (SEQ ID NO:21) shown in Table 6A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 103-105 and ending with a TAG codon at nucleotides 1579-1581. Putative untranslated regions downstream from the termination codon and upstream from the initiation codon are underlined in Table 6A, and the start and stop codons are in bold letters.

Table 6A. NOV6a Nucleotide Sequence (SEQ ID NO:21)

```

AGAACGCGGAGAGTCGCCGCTGGCCGGCGTAGACGCGGTGGCAGAGCCCGCGCGCTGGAA
GCGAGTGGCGGAGCGCGGGACCTCGCGGACTCGCCATGGAGGAGGGTGTGAAGGAAGCCG
GTGAGAAGCCTCGGGGAGCACAGATGGTGGACAAGGCTGGCTGGATCAAGAAGAGCAGTGGGGC
CTCCTGGGTTCTGAAAGACCGATATCTGCTCCTCTGCCAGGCCAGCTGCTGGTCTATGAGAATG
AGGATGATCAGAAGTGTGGAGACTGTGGAGCTGGCAGCTATGAGAAGTGCCAGGACCTCGTG
CCCTCCTCAAGCGAAAACACCGCTTATCCTGCTGCGATCCCCAGGAACAAGGTCAAGCGACATCA
AATTCCAGGCACCCACCGGGAGGAGAAGGAATCCTGGATCAAAGCCCTCAATGAAGGGATTAAC
CGAGGCAAAAACAAGGCTTCGATGAGGTAAAGGTGGACAAGAGCTGCGCCCTGGAGCATGTGAC
ACGGGACCGGGTGCAGGGGGCCAGCGACGCCGCCACCAACGAGAGTCCACCTGAAGGAGGTGG
CCAGTCAGCTCTGACGGCTCTGCGCCTGGATCTGATGTTCCGGACAGTGGGCCACCGAGTGT
TGCCCCCAGCAATCATGTCAGTGAAGCCAACCTCGGGAGACACCCCGCCCTCATGCCTCCTACC
AAGCCTTCCTAGCACCTGAGACCACCAAGCCCTGGTACAGGGTGGAGACCCCTGTGGGGGAGAGA
GCCCAACCCCTGTCTCAGCAAGCTCTGAGGTCTCCCTGAGAGCCAAGAGGACTCAGAGACCCCA
GCAGAGGAGGACAGTGGCTCTGAGCAGCCTCCAAACAGCGTCCGCTGACAAACTGAAGGTGAGC
TGGGAGAACCCAGCCCCAGGAGGCCCCCTGCTCAGAGAGTCAGAACCGTCCAGGACCCCTGT
TCTGAGACTTCTGAGGCTGCCCTAGGGTGGAGATGCAGGCTTCTGGGCCACCTGCTCCAGGCACA
TCAGAAGAACACTTGAAGCCTCCATGGGTGGAGATGCAGGCTTCTGGGCCACCTGCTCCAGGCACA
GTGAAAGGTCTCAGTCAAATGGCAAGAAATGGAAGGACTGAGCATTCCAAGCACTTAAGGCTGA
AGGCACCCAAAGAACTTCTCAAAGGATGACTAACACACCAAGCACTGCCCCCTGGGACCTGCC
ACCTCAGTCCATCACCGCTGCTCCCTGGGACTTGCCTGGGAAGCCCCCTACACCCCAAGATCTTA
CAGCCCAGGCAACGGCTATATCGGGCCCAGCTGGAGGTGAAGGTGGCCTCGGAACAGACGGAGAA
ACTGTTGAACAAGGTGCTGGCAGTGAAGCCGGCCCTGTTAGTGCCTGGAAACATTGCTCAGGCCAGG
TGTGGAGCAGCTGAGGCAGGCCACCCAGGTCTGCAGGAAATGAGAGATTGGGAGAGCTGAGCC
AGGAAGCACCTGGCTAAGGGAGAACGGGAAGGAGCTGGTGCACCCCTACAGGAGAACGTGCACCC
TAGGGCCTCTGGCCAGAGGCACCATCCCTCTGGCCATCCATCAAGTCATCAAGGCCAGCCCT
GCTGAGAAATGTGCTCTGCTACAGCAATGGCTGCAGGAGGGCCATTGGCATGTCAGGGTTT
GCCCATGACCGAAGAGACTCCTGGCGCCTCCTACT

```

The nucleic acid sequence of NOV6 maps to chromosome 15 and has 360 of 631 bases (57%) identical to a gb:GENBANK-ID:AF168676|acc:AF168676.1 mRNA from Homo sapiens (Homo sapiens TNF intracellular domain-interacting protein mRNA, complete cds).

The NOV6 polypeptide (SEQ ID NO:22) is 492 amino acid residues in length and is presented using the one-letter amino acid code in Table 6B. The SignalP, Psort and/or Hydropathy results predict that NOV6 has a signal peptide and is likely to be localized to the nucleus with a certainty of 0.7000. In alternative embodiments, a NOV6 polypeptide is located to the mitochondrial matrix space with a certainty of 0.1000 or the lysosome (lumen) with a certainty of 0.1000.

Table 6B. Encoded NOV6 Protein Sequence (SEQ ID NO:22)

```

MEEEGVKEAGEKPRGAQMVDKAGWIKKSSGGLGFWKDRYLLCQAQLLVYENEDDQKCVERVE
LGSYEKCQDLRALLKRKHRFILLRSPGNKVDIKFQAPTGEEKESWIKALNEGINRGKNKAFDEVKV
DKSCALEHVTDRVRGGQRRRPTRVHLKEVASAASDGLLRLDLDVPSGPPVFAFSNHVSEAQPRT
TPRPLMPPTKFLAPETTSPGDRVETPVGERAPTPVSASSEVSPEQEDSETPAEEDSGSEQPPNSVLPD
KLKVSWENPSPQEAPAAESAEPQACSETSEAAPREGGKPPTPPPILSEEHLKASMGEMQASGPPA
PGTVKGLSQMARMEGLSIAKHSKAEGTQRTSPKDALTHQALPPWDLPPQFHRCSSLGDLLGEGPR
HPLQPRQRLYRAQLEVKVASEQTEKLLNKVLGSEPAVSAETLLSQAVEQLRQATQLQEMRDLGE
LSQEAPGLREKRKELVTLYRRSAP

```

The NOV6 amino acid sequence has 263 of 289 amino acid residues (91%) identical to, and 269 of 289 amino acid residues (93%) similar to, the 399 amino acid residue gi|18027838|gb|AAL55880.1|AF318373_1| AF318373 protein from Homo sapiens (Human) (UNKNOWN) (E = e⁻¹⁰²).

5 NOV6 has homology to the amino acid sequences shown in the BLASTP data listed in Table 6C.

Table 6C. BLAST results for NOV6					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<u>gi 18027838 gb AAL55880.1 AF318373_1 </u> (AF318373)	unknown [Homo sapiens]	287	263/289 (91%)	269/289 (93%)	e-102

10 The homology of this sequence is shown graphically in the ClustalW analysis shown in Table 6D.

Table 6D. ClustalW Analysis of NOV6

1) NOV6 (SEQ ID NO:22)
 2) gi|18027838|gb|AAL55880.1|AF318373_1| (AF318373) unknown [Homo sapiens] (SEQ ID NO:64)

	10	20	30	40	50
15	NOV6 COR87941483	MEEEGVKEAGEKPRGAQMVDKAGWIKKSSGGLLGFWKDRYLLLCQAQLIV	gi 18027838	-----
	60	70	80	90	100
20	NOV6 COR87941483	YENEDDQKCVETVELGSYEKCQDLRALLKRKHRFILLRSPGNKVSDIKFQ	gi 18027838	-----
	110	120	130	140	150
25	NOV6 COR87941483	APTGEEKESWIKALNEGINRGKKNKAFDEVKVDKSCALEHVTRDRVRGGQR	gi 18027838	-----
	160	170	180	190	200
30	NOV6 COR87941483	RRPPTTRVHLKEVASAASDGLLRLDLVVDGPPVFAPSNIHVSEAQPRTP	gi 18027838	-----
	210	220	230	240	250
35	NOV6 COR87941483	RPL	gi 18027838	---
	260	270	280	290	300
40	NOV6 COR87941483	P	gi 18027838	S
	310	320	330	340	350

NOV6 COR87941483 gi 18027838	EH K-	KGL QMARME Q-V VNGMDD
5	360 370 380 390 400	
NOV6 COR87941483 gi 18027838	GLSI H K QR S L HQ SPEP P Q PG P T ST	H P
10	410 420 430 440 450	
NOV6 COR87941483 gi 18027838	Q E	
15	460 470 480 490	
NOV6 COR87941483 gi 18027838	

Tables 6E and 6F list the domain description from DOMAIN analysis results against NOV6. This indicates that the NOV6 sequence has properties similar to those of other proteins known to contain these domains.

Table 6E. Domain Analysis of NOV6

gnl|Pfam|pfam00169, PH, PH domain. PH stands for pleckstrin homology

(SEQ ID NO:65)

CD-Length = 100 residues, 99.0% aligned

Score = 57.8 bits (138), Expect = 1e-09

NOV 6: 19 VDKAGWIKSSGGLLGFWKDRYLLLQQAQLLVYENE-DDQKCVETVELGSYEKCQDLRAL 77

+ | ||+ | | || || | + |++ + ++ | +

Sbjct: 1 IVKEGWLLKKSTVKKRKKRYFFLFNDVLIYYKDKKKSYEPKGSIPLSGCSVEDVPDSE 60

NOV 6: 78 LKRKHRFILLRSPGNKVSDIKFQAPTGEEKESWIKALNEGI 118

|| + | | | + || + ||++ ||| | + |

Sbjct: 61 FKRPNCFQLRSRDGKET--FILQAESEEERQDWIKAIQSAI 99

Table 6F. Domain Analysis of NOV6

gnl|Smart|smart00233, PH, Pleckstrin homology domain.; Domain commonly found in eukaryotic signalling proteins. The domain family possesses multiple functions including the abilities to bind inositol phosphates, and various proteins. PH domains have been found to possess inserted domains (such as in PLC gamma, syntrophins) and to be inserted within other domains. Mutations in Brutons tyrosine kinase (Btk) within its PH domain cause X-linked agammaglobulinaemia (XLA) in patients. Point mutations cluster into the positively charged end of the molecule around the predicted binding site for phosphatidylinositol lipids.

(SEQ ID NO:66)
CD-Length = 104 residues, 99.0% aligned
Score = 57.8 bits (138), Expect = 1e-09

NOV 6: 19 VDKAGWIKKSSGGLLGFWKDRYLLLQCQAQLLVYENE -- DDQKCVCETVELGSYEKCQDLR 75
| | | | + | | | | | | | + | | | | + + + | | | + + | + + +
Sbjct: 1 VIKEGWLLKKSSGGKKSWKKRYFVLFNGVLLYYKSKKKKSSSKPKGSIPLSGCTVREAPD 60

NOV 6: 76 ALLKRKHRFILLRSPGNKVSDIKFQAPTGEEKESWIKALNEGINR 120
+ + | + + | | + | | + | | + + | + + | | + | +
Sbjct: 61 SDSKKKNCFEIVTPDRKT -- LLLQAESEEERKEWAEALRKIAK 103

The protein similarity information, expression pattern, and map location for the NOV6 protein and nucleic acid disclosed herein suggest that it may have important structural and/or physiological functions characteristic of the family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

The NOV6 nucleic acid and protein are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: Cardio-vascular disorders, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD),

Atrioventricular (A-V) canal defect, Ductus arteriosus , Pulmonary stenosis , Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Obesity, Transplantation, Systemic lupus erythematosus , Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis,

5 Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Hypercalceimia, Lesch-Nyhan syndrome and other diseases, disorders and conditions of the like.

The 'pleckstrin homology' (PH) domain is a domain of about 100 residues that occurs in a wide range of proteins involved in intracellular signaling or as constituents of the cytoskeleton.

10 The function of this domain is not clear, several putative functions have been suggested:

- binding to the beta/gamma subunit of heterotrimeric G proteins,
- binding to lipids, e.g. phosphatidylinositol-4,5-bisphosphate,
- binding to phosphorylated Ser/Thr residues,
- attachment to membranes by an unknown mechanism.

15 It is possible that different PH domains have totally different ligand requirements. The 3D structure of several PH domains has been determined. All known cases have a common structure consisting of two perpendicular anti-parallel beta sheets, followed by a C-terminal amphipathic helix. The loops connecting the beta-strands differ greatly in length, making the PH domain relatively difficult to detect. There are no totally invariant residues within the PH domain.

20 Proteins reported to contain one more PH domains belong to the following families:

- Pleckstrin, the protein where this domain was first detected, is the major substrate of protein kinase C in platelets. Pleckstrin is one of the rare proteins to contains two PH domains.
- Ser/Thr protein kinases such as the Act/Rac family, the beta-adrenergic receptor kinases, the mu isoform of PKC and the trypanosomal NrkA family.
- Tyrosine protein kinases belonging to the Btk/Itk/Tec subfamily.
- Insulin Receptor Substrate 1 (IRS-1).
- Regulators of small G-proteins like guanine nucleotide releasing factor

NOV7

30 A disclosed NOV7 nucleic acid (designated as CuraGen Acc. No. COR101716725) encodes a novel secretory protein and includes the 1491 nucleotide sequence (SEQ ID NO:23) shown in Table 7A. An open reading frame for the mature protein was identified beginning with

an ATG codon at nucleotides 31-33 and ending with a TGA codon at nucleotides 1324-1326. Putative untranslated regions are underlined in Table 7A, and the start and stop codons are in bold letters.

Table 7A. NOV7 Nucleotide Sequence (SEQ ID NO:23)

GGGCCCCGCAGCCCCGGGAACCCACATCGGGCGGCTCGGCCCTGGCGACCTGGTGCTTC
TTCTGCCCCTCTCCAAGCGCCTGCAGGGCGGCTCCCAGGCCTCAGGGTCCCGCTGCATCTTCCCTGG
CCTGGCTGGGCGTCTTCAGGCAGCTGGCTGGTTACGTGACTACTCGCCTACTCGGGAGCGCTGC
TCGCGGCCATGTCTGCAGGTGGTCATTGTGACCAGTACCGCAAGGGGATCATCTCGGGCTCCGTC
TGCCAGGACCTGTGAGCTGCATATGGTGGAGGTGGAGGACCTGCCTCTCGTGGGGCCCCGGGCAAG
CAGGTGTACAGCGGGCTCTGGCGGACAAGGATGTTAACCATCAAGTGTGGCATTGAGGAGACCCCT
GACTCCAAGGCCCGGTCGGATGCGGCCCCCCGGCGGGAGCTGGTACTGTTTGACAAGCCCACCCGG
GGCACCTCCATCAAGGAATTCCGGGAGAGTGACCCCTCGGCTCTCAAGGCGAACCTGGGAGACCTGT
CCTCCCTGCCGGCTGGTGGCCAGGTCCCTGCTCATGGCTGACTTCACTAACAAGGACACCGGGTGT
CCCTGGCGGAAGCCAAGTCCGTGGGCCTGCTGCAGCGTAACGAGTTCCGTCTGCTGTCCCT
GCAGGAGAAAGGAGACGCCCCTCCAGACTGCTGGGCTACTGTGGGACCTTACCACCGAGGGCGGT
GCCGCATGGCCCCTGGACGCGGCCCCCTCCACCCCTGTGCGCCACTGTGCCCTGGCCTGTG
CAGGGTGTCTCCAGCAGTGGCTGGGCCTGCGCTGGCGCCAAAGATCGCCATCGGCTGT
CTGGAGTTCGTGGAGGAGCTCTCCACGGCTCTTACGGGACTITCTACATGTGTGAGACCACACTGG
CCAACGTGGGCTACACAGCCACCTACGACTCAAGATGGCCGACTGCAGCAGGGTGGCACCCGAGG
CCACCGGTCGCCCTCCCTGCAGGGCCCCGCTGCGAGACAGCACCGACTGCACCTACGGCGCG
ACTGCAGGGGCCCCGGTGTGAAGGCTATGAGGCAGTGAAGGGCACCTATCCAGCCAAACCTGG
CCAAGGGTGTGCGACTGCTACGGGCTACCTGCTGCCTGGCGCCCCGGACTCCCGGAGGAGC
TGGGCACACACAGGTCGCCACTGTACACGCTGAGCGGCTGGCCAGGTGGAGGCCATCACT
CGCTGGGCTCAGGCCACCTCAAGACTGTCTGGAAGAAGAGTCTCCAAACCCAAAGTACTCTTGAT
GGGGCAGTGGAGGGCCCTGGCCACCCTTCTGGAGGCTGGCCAGGTGGCCAGGGTCCAACCCCTCCCTCA
AGGAGAGTCCCTCCAAGGGTTGTACTCTGAAGAACGTAAGTCAATAAACAGCTTTATGTAAAT
GCCCAGGGGTGAGCACCCCTGAGCCCCCCATCA

5 The nucleic acid sequence of NOV7 has 1137 of 1347 bases (84%) identical to a
gb:GENBANK-ID:AB030186|acc:AB030186.1 mRNA from *Mus musculus* (*Mus musculus*
mRNA, complete cds, clone:1-82).

The NOV7 polypeptide (SEQ ID NO:24) is 431 amino acid residues in length and is
presented using the one-letter amino acid code in Table 7B. The SignalP, Psort and/or
10 Hydropathy results predict that NOV7 has a signal peptide and is likely to be located outside of
the cell with a certainty of 0.6615. In alternative embodiments, a NOV7 polypeptide is located to
the microbody (peroxisome) with a certainty of 0.1215, the endoplasmic reticulum (membrane)
with a certainty of 0.1000, or the endoplasmic reticulum (lumen) with a certainty of 0.1000. The
SignalP predicts a likely cleavage site for a NOV7 peptide between amino acid positions 59 and
15 60, i.e., at the dash in the sequence CRG-HV.

Table 7B. Encoded NOV7 Protein Sequence (SEQ ID NO:24)

MRRRLRRLAHLVLFCPFSKRLQGRLPGLRVRCAIFLAWLGVFAGSWLVYVHYSSYSERCRGHVCQVVI
 CDQYRKGIISGSVCQDLCELMVEWRTCLSVAPGQQVYSGLWRDKDVTIKCGIEETLDSKARSDAAPRRELVLFDPTRGTSIKEFREMTLGFLKANLGDPLSLPALVGQVLLMADFNKDNRVSLAEAKSVW
 ALLQRNEFLLLSLQKEHASRLLGYCGDLYLTEGVPHGAWHAAALPPLLRLPPLQGALQQWL
 GPAWPWRAKIAIGLLEFVEELFHGSYGTFCYMCETTLANVGYTATYDFKMADLQQVAPEATVRRFLQ
 GRRCEHSTDCTYGRDCRAPCDRLMRQCKGDLIQPNLAKVCALLRGYLLPGAPADLREELGTQLRTC
 TTLSGLASQVEAHSLVLSHLKTLWKKISNTKYS

The NOV7 amino acid sequence has 255 of 256 amino acid residues (99%) identical to, and 255 of 266 amino acid residues (99%) similar to, the 266 amino acid residue
gi|18027802|gb|AAL55862.1|AF318355_1 AF318355 protein from Homo sapiens (Human)
 (UNKNOWN) (E = e^{-136}).

NOV7 is expressed in at least the following tissues: Adipose, Adrenal Gland/Suprarenal gland, Amygdala, Aorta, Bone, Bone Marrow, Brain, Cerebral Medulla/Cerebral white matter, Cervix, Chorionic Villus, Colon, Coronary Artery, Dermis, Epidermis, Foreskin, Frontal Lobe, Heart, Hippocampus, Kidney, Liver, Lung, Lymph node, Lymphoid tissue, Mammary gland/Breast, Muscle, Ovary, Pancreas, Parathyroid Gland, Parotid Salivary glands, Peripheral Blood, Pineal Gland, Pituitary Gland, Placenta, Prostate, Respiratory Bronchiole, Retina, Skin, Small Intestine, Spinal Chord, Stomach, Substantia Nigra, Synovium/Synovial membrane, Testis, Thalamus, Thyroid, Tonsils, Umbilical Vein, Uterus and Vein. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.

NOV7 also has homology to the amino acid sequences shown in the BLASTP data listed in Table 7C.

Table 7C. BLAST results for NOV7

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<u>gi 13272520 gb AAK1_7190.1 AF332189_1</u> (AF332189) pancreatitis-	induced protein 49 [Mus musculus]	431	382/431 (88%)	397/431 (91%)	0.0
<u>gi 9790001 ref NP_062807_1</u> (NM_019833)	hypothetical protein 1-82 [Mus musculus]	428	313/348 (89%)	322/348 (91%)	e-176
<u>gi 18027802 gb AAL55862.1 AF318355_1</u> (AF318355)	unknown [Homo sapiens]	266	255/256 (99%)	255/256 (99%)	e-136

gi 12850997 dbj BAB28914.1 (AK013580)	putative [Mus musculus]	428	199/412 (48%)	280/412 (67%)	e-121
gi 17433824 ref XP_028387.2 (XM_028387)	hypothetical protein XP_028387 [Homo sapiens]	403	194/403 (48%)	275/403 (68%)	e-119

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 7D.

Table 7D. ClustalW Analysis of NOV7

- 1) NOV7 (SEQ ID NO:24)
- 2) gi|13272520 gb|AAK17190.1|AF332189_1 (AF332189) pancreatitis-induced protein 49 [Mus musculus] (SEQ ID NO:67)
- 3) gi|9790001|ref|NP_062807.1| (NM_019833) hypothetical protein 1-82 [Mus musculus] (SEQ ID NO:68)
- 4) gi|18027802|gb|AAL55862.1|AF318355_1 (AF318355) unknown [Homo sapiens] (SEQ ID NO:69)
- 5) gi|12850997 dbj|BAB28914.1| (AK013580) putative [Mus musculus] (SEQ ID NO:70)
- 6) gi|17433824 ref|XP_028387.2| (XM_028387) hypothetical protein XP_028387 [Homo sapiens] (SEQ ID NO:71)

	10	20	30	40	50	
					
	NOV7 COR101716725	MRRRLRLAHLVLFCPFSKRLQGRLPGLRVRCIFLA	GV A	LV	H	
	gi 13272520	MRRRLRLVHLVLLCPFSKGLQGRLPGLRVKYVLLV	GI V	MV	H	
	gi 9790001	-----	-----	MV	H	
	gi 18027802	-----	-----	-----	-----	
	gi 12850997	---MARSICAGAWLRKPHYLQARLSYMVRVKYLFFS	VV V	II	Q	
	gi 17433824	-----MKYLFFS	VV V	II	Q	
	60	70	80	90	100	
					
15	NOV7 COR101716725	S S R	H V Q V V	Q R K I S S V Q D	E L H M	V
	gi 13272520	S S	H V Q V V	Q R K I S S V Q D	E L Q K	S
	gi 9790001	S S	H V Q V V	Q R K I S S V Q D	E L Q K	S
	gi 18027802	-----	-----	-----	M	V
	gi 12850997	T T	K D K K I	K K T V D P A N S	V T E T L Y F G K	N K S
20	gi 17433824	T T	K D K K I	K K T V D P A N S	V T E T L Y F G K	T K N
	110	120	130	140	150	
					
25	NOV7 COR101716725	R D	T D	RS		
	gi 13272520	Q E	N	W P		
	gi 9790001	Q E	N	W P		
	gi 18027802	R D	T D	RS		
	gi 12850997	N M L V D N L P G V V	Q M Q	H L D F G T E L E	K I	T V Q
30	gi 17433824	N M L I D N L P G V V	Q M Q	H L D F G T E L E	K I	T V Q
	160	170	180	190	200	
					
35	NOV7 COR101716725	G	G V	N		
	gi 13272520		D	S		
	gi 9790001		D	S		
	gi 18027802	G	G V	N		
	gi 12850997	K K V Y L F K	Q G N S E	N L T V	G D R G Q	G A
	gi 17433824	K K V Y L F K	Q G N S E	N L T V	G D G Q	G A
40		210	220	230	240	250
					
	NOV7 COR101716725		A A A	L		
	gi 13272520		I	V L A		

5	gi 9790001		I	V L A		
	gi 18027802	L	MVI D TPK M F	VM S EYT LY IS	WVMEL	
	gi 12850997	L	MVI D TPK M F	VM S EYT LY IS	WVIEL	
	gi 17433824					
		260	270	280	290	300
	NOV7 COR101716725	PA QG	L			
10	gi 13272520	V H				
	gi 9790001	V H				
	gi 18027802	PA QG	L			
	gi 12850997	FI GFR SMD L T S RK		DV	P N L D SA	
	gi 17433824	FI GFR SMD L T S RK		DV	P N L D SA	
15		310	320	330	340	350
	NOV7 COR101716725			R H T T R AP		
	gi 13272520			Q S I R AP		
	gi 9790001			Q S I R AP		
20	gi 18027802			R H T TT -----		
	gi 12850997	K L NEK L V MRKIV	TNLKELIKD	SDL V T TS		
	gi 17433824	K L NDK L V MRKIV	TNLKELIKD	SDL V T TS		
25		360	370	380	390	400
	NOV7 COR101716725	RLMRQ KGDL	V A RG P ADLR	GT RT TT S		
	gi 13272520	RLMRQ KGDL	V E R P AGLY	G RT TT S		
	gi 9790001	RLMRQ KGDL	V E R P AGLY	G CAPAPQKV		
30	gi 18027802	-----	TAGPRTGTS	-----		
	gi 12850997	LSTMK TSEV	A Q K H SEIR	E YS IA K		
	gi 17433824	QSTMK TSEV	A Q K R SEIR	E YS IA K		
35		410	420	430	440	450
	NOV7 COR101716725	GL S V AH V SH	KK N -----	KY -----		
	gi 13272520	GL S I AH V SH	RE N -----	NY -----		
	gi 9790001	DWPRLRLTIHW	AT RPYSGGRSPTPTPRAAGSRHY	SQVAPPHSLO		
40	gi 18027802	-----	-----	-----		
	gi 12850997	VT N M ME I NN	KK Y -----	ND -----		
	gi 17433824	VT N M ME I NN	KK Y -----	ND -----		
45		460	470			
	NOV7 COR101716725	-----	-----			
	gi 13272520	-----	-----			
	gi 9790001	QLSRGARGPYQRWPTGPNNP	-----			
	gi 18027802	-----	-----			
	gi 12850997	-----	-----			
50	gi 17433824	-----	-----			

Many calcium-binding proteins belong to the same evolutionary family and share a type of calcium-binding domain known as the EF-hand. This type of domain consists of a twelve residue loop flanked on both side by a twelve residue alpha-helical domain. In an EF-hand loop the calcium ion is coordinated in a pentagonal bipyramidal configuration. The six residues involved in the binding are in positions 1, 3, 5, 7, 9 and 12; these residues are denoted by X, Y, Z, -Y, -X and -Z. The invariant Glu or Asp at position 12 provides two oxygens for liganding Ca (bidentate ligand).

The protein similarity information, expression pattern, and map location for the NOV7 protein and nucleic acid disclosed herein suggest that it may have important structural and/or

physiological functions characteristic of the EF-hand family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

The NOV7 nucleic acid and protein are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: Cardio-vascular diseases, Cardiomyopathy, Atherosclerosis, Hypertension, Congenital heart defects, Aortic stenosis, Atrial septal defect (ASD), Atrioventricular (A-V) canal defect, Ductus arteriosus, Pulmonary stenosis, Subaortic stenosis, Ventricular septal defect (VSD), valve diseases, Tuberous sclerosis, Scleroderma, Obesity, Transplantation, Systemic lupus erythematosus, Autoimmune disease, Asthma, Emphysema, Scleroderma, allergy, Diabetes, Autoimmune disease, Renal artery stenosis, Interstitial nephritis, Glomerulonephritis, Polycystic kidney disease, Systemic lupus erythematosus, Renal tubular acidosis, IgA nephropathy, Hypercalceimia, Lesch-Nyhan syndrome and other diseases, disorders and conditions of the like.

NOV8

NOV8 includes two GPCR-like proteins. They have been designated NOV8a and NOV8b.

NOV8a

A disclosed NOV8a nucleic acid (designated as CuraGen Acc. No. CG56663-01), encodes a novel GPCR-like protein and includes the 1062 nucleotide sequence (SEQ ID NO:25) shown in Table 8A. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 10-12 and ending with a TAA codon at nucleotides 948-950. Putative untranslated regions are underlined in Table 8A, and the start and stop codons are in bold letters.

Table 8A. NOV8a Nucleotide Sequence (SEQ ID NO:25)

TAGAGATGGATGGAACCAATGGCAGCACCAAACCCATTCTACTGGGATTCTCTGACCGAC
CCCATCTGGAGAGGATCCTTTGTGGTACATCGCTACCTCTGACCCCTGTAGGCAACAC
CACCATCATCCTGGTCCCAGCTGGACCCCCACCTCCACACCCCCATGACTTCTCTGCCACC
TTTCCTTCCTGGACCTCAGTTCACCAACAGCTCCATCCCCAGCTGCTCTACAACCTTAATGGATGT
GACAAGACCATCAGCTACATGGGCTGTGCCATCCAGCTCTCCTGTTCTGGGTCTGGGTGGTGG
AGTGCCTGCTTCTGGCTGTATGGCCTATGACCGGTGTGGCTATCTGCAAGCCCTGACTACAT
GGTATCATGAACCCCAGGCTCTGCCGGGCTTGGTGTAGTGACCTGGGCTGTGGGTGGCAA
CTCCTGGGCATGTCTCTGTGACCCCTGCGCTTACCCGCTGTGGCACCAACGAGGTGGACCACTTC
CTGCGTGAAGATGCCGCCCTGATCCGGATGCCCTGCGTCAGCACTGTGGCATCGAAGGCACCGTC
TTTGTCTGAAAAAAGGTGTTGTGCTGCCCCCTGGTTATCCTGCTCTTACAGCTACATTGT
GAGGGCTGTGTTACAAATTCCGTAGCATCAGGAAGGCAGAAGGCCCTCGCACCTGCGGCTCCCA
TCTCACTGTGGTCTCCCTTCTATGAAACATCATCTACATGTACATGCAGCCAGGAGCCAGTTCT
CCCAGGACCAGGGCATGTTCTCATGCTCTTCTACAACATTGTCACCCCCCTCCTCAATCCTCTCATC
TACACCCTCAGAAACAGAGAGGTGAAGGGGCACTGGGAAGGTTGCTCTGGGAAGAGAGAGCT
AGGAAAGGAGTAAAGGCATCTCACCTGACTTCACCCATCCAGGGCACTGGCAGCATCTGGAA
CGGCTGAATTCCAGCTGATATTAGCCCACGACTCCAACTTGCCTTTCTGGACTTT

The NOV8a polypeptide (SEQ ID NO:26) is 314 amino acid residues in length and is presented using the one-letter amino acid code in Table 8B.

Table 8B. Encoded NOV8a Protein Sequence (SEQ ID NO:26)

MDGTNGSTQTHFILLGFSDRPHLERILFVVILIA^{YLL}TVGN^{TTI}LVSRLD^{PHL}H^{TPM}YFFLA^{HL}SFLD
LSFTTSSIPQLLYNLNGCDKTISYMGCAIQ^{FL}FLGLGGVECLL^{LA}VMAYDRCVAICKPLHYMVIMNP
RLCRGLVSVTWGCVANSLAMSPVTLRLPRCGH^{HE}VDHFLREMPALIRMACVSTVAIEGT^VFVLKK
GVVLSPLVFILL^{SYSY}IVRAVLQIRSASGRQKA^FGTCGSHLT^VSLFYGN^{IY}YMQPGASSSQDQGM
FLMLFYNI^VTPLL^NPLIYTLRNREVKGALGRLLL^GKREL^GKE

5

NOV8b

A disclosed NOV8b nucleic acid (designated as CuraGen Acc. No. CG56663-02), which is a variant of NOV8a, includes the 1062 nucleotide sequence (SEQ ID NO:27) shown in Table 8C. An open reading frame for the mature protein was identified beginning with an ATG codon at nucleotides 6-8 and ending with a TAA codon at nucleotides 948-950. The start and stop codons of the open reading frame are highlighted in bold type. Putative untranslated regions are underlined and found upstream from the initiation codon and downstream from the termination codon.

Table 8C. NOV8b Nucleotide Sequence (SEQ ID NO:27)

```

TAGAGATGGATGGAACCAATGGCAGCACCCAAACCCATTCTACTGGGATTCTCTGAC
CGACCCCATCTGGAGAGGATCCTCTTGTCATCGCGTACCTCCTGACCCTCGTA
GGCAACACCACCATCATCCTGGTGTCCCGCTGGACCCCCACCTCCACACCCCCATGTACTT
CTTCCTCGCCACCTTCCTGGACCTCAGTTACACCAGCTCCATCCCCAGCTGCTC
TACAACCTTAATGGATGTGACAAGACCATCAGCTACATGGGCTGTGCCATCCAGCTTCCCT
GTTCTGGGTCTGGGTGGTGTGGAGTGCCTGCTTCTGGCTGTATGGCCTATGACGGGTGTGT
GGCTATCTGCAAGCCCCCTGCACTACATGGTATCATGAACCCAGGCTCTGCCGGGGCTGG
TGTCAGTGACCTGGGGCTGTGGGCAACTCCTGGCCATGTCTCTGTGACCCCTGCGCT
TACCCCGCTGTGGGCAACACGAGGTGGACCACTCCTGCGTGAGATGCCGCCCTGATCCGG
ATGGCCTGCGTCAGCACTGTGCCATCGACGGCACCGCTTTGCTCTGGCGTGGGTGT
GCTGCCCCCTGGTGTATCCTGCTCTTACAGCTACATTGTGAGGGCTGTGTTACAAAT
TCGGTCAGCATCAGGAAGGCAGAAGGCCCTGGCACCTGCGGCTCCATCTACTGTGGTCT
CCCTTTCTATGGAACACATCATCTACATGTACATGCAGCCAGGAGCCAGTTCTCCCAGGAC
CAGGGCATGTTCTCATGCTCTTACAACATTGTCACCCCCCTCTCAATCCTCTCATCTAC
ACCCTCAGAAACAGAGAGGTGAAGGGGGCACTGGGAAGGTTGTTGGGAAGAGAGAGC
TAGGAAAGGAGTAAAGGCATCTCACCTGACTTCACTTCCATCCAGGGCACTGGCAGCATC
TGGAACGGCTGAATTCCAGCTGATATTAGCCCACGACTCCAACTGCCTTTCTGGACTTT
T

```

A NOV8b polypeptide (SEQ ID NO:28) is 314 amino acid residues and is presented using the one letter code in Table 8D.

Table 8D. Encoded NOV8b Protein Sequence (SEQ ID NO:28)

```

MDGTNGSTQTHFILLGFSDRPHLERILFVILIAYLLTIVGNTHILVSRLDPHLHTPMYFFLAHSFLDSL
TTSSIPQLLYNLNGCDKTISYMGCAIQLFLFLGLGGVECLLLAVMAYDRCVAICKPLHYMVIMNPRLCR
GLVSVTWGCVANSLAMSPVTLRLPRCGHHEVDHFLREMPALIRMACVSTVAIDGTVFVLAVGVVLSP
LVFILLSYSIVRAVLQIRSASGRQKAFGTGSHLTVVSLFYGNIIYMYMQPGASSSQDQGMFLMLFYNI
VTPLLNPLIYTLRNREVKGALGRLLLKGRELGKE

```

5

The nucleic acid sequence of NOV8 has 600 of 710 bases (84%) identical to a
gb:GENBANK-ID:AX008326|acc:AX008326.1 mRNA from Marmota marmota (Sequence 24
from Patent WO9967282).

A NOV8 amino acid sequence has 314 of 314 amino acids (100%) identical to, and 314 of
10 314 amino acids (100%) similar to, a [gi|17445344|ref|XP_060558.1|](#) XM_060558 protein from
Homo sapiens (Human) (similar to OLFACTORY RECEPTOR) ($E = e^{-164}$).

NOV8 is expressed in at least the following tissues: Apical microvilli of the retinal
pigment epithelium, arterial (aortic), basal forebrain, brain, Burkitt lymphoma cell lines, corpus
callosum, cardiac (atria and ventricle), caudate nucleus, CNS and peripheral tissue, cerebellum,
15 cerebral cortex, colon, cortical neurogenic cells, endothelial (coronary artery and umbilical vein)
cells, palate epithelia, eye, neonatal eye, frontal cortex, fetal hematopoietic cells, heart,

hippocampus, hypothalamus, leukocytes, liver, fetal liver, lung, lung lymphoma cell lines, fetal lymphoid tissue, adult lymphoid tissue, Those that express MHC II and III nervous, medulla, subthalamic nucleus, ovary, pancreas, pituitary, placenta, pons, prostate, putamen, serum, skeletal muscle, small intestine, smooth muscle (coronary artery in aortic) spinal cord, spleen, stomach, 5 taste receptor cells of the tongue, testis, thalamus, and thymus tissue. This information was derived by determining the tissue sources of the sequences that were included in the invention including but not limited to SeqCalling sources, Public EST sources, Literature sources, and/or RACE sources.

NOV8a and NOV8b are very closely homologous as is shown in the amino acid alignment in Table 8E.

Table 8E. Amino Acid Alignment of NOV8a and NOV8b

15 20 25

30

35

40

45

10 20 30 40 50

NOV8a CG56663-01
NOV8b CG56663-02

60 70 80 90 100

NOV8a CG56663-01
NOV8b CG56663-02

110 120 130 140 150

NOV8a CG56663-01
NOV8b CG56663-02

160 170 180 190 200

NOV8a CG56663-01
NOV8b CG56663-02

210 220 230 240 250

NOV8a CG56663-01
NOV8b CG56663-02

260 270 280 290 300

NOV8a CG56663-01
NOV8b CG56663-02

310

NOV8a CG56663-01
NOV8b CG56663-02

Homologies to any of the above NOV8 proteins will be shared by the other NOV8 proteins insofar as they are homologous to each other as shown above. Any reference to NOV8 is assumed to refer to both of the NOV8 proteins in general, unless otherwise noted.

The SignalP, Psort and/or Hydropathy results predict that a NOV8 has a signal peptide and is likely to be localized to the plasma membrane with a certainty of 0.6000. In alternative embodiments, a NOV8 polypeptide is located to the Golgi body with a certainty of 0.4000, the endoplasmic reticulum (membrane) with a certainty of 0.3000, or the microbody (peroxisome) 5 with a certainty of 0.3000. The SignalP predicts a likely cleavage site for a NOV8 peptide between amino acid positions 41 and 42, i.e., at the dash in the sequence LVG-NT.

NOV8a also has homology to the amino acid sequences shown in the BLASTP data listed in Table 8F.

Table 8F. BLAST results for NOV8a					
Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
<u>gi 17445344 ref XP_060558.1 (XM_060558)</u>	similar to olfactory receptor (H. sapiens) [Homo sapiens]	314	314/314 (100%)	314/314 (100%)	e-164
<u>gi 5901478 gb AAD55304.1 AF044033.1 (AF044033)</u>	olfactory receptor [Marmota marmota]	237	194/237 (81%)	215/237 (89%)	2e-99
<u>gi 13624329 ref NP_112165.1 (NM_030903)</u>	olfactory receptor, family 2, subfamily W, member 1 [Homo sapiens]	320	184/305 (60%)	236/305 (77%)	1e-94
<u>gi 12054431 emb CAC20523.1 (AJ302603)</u>	olfactory receptor [Homo sapiens]	320	184/305 (60%)	236/305 (77%)	1e-94
<u>gi 12054429 emb CAC20522.1 (AJ302602)</u>	olfactory receptor [Homo sapiens]	320	184/305 (60%)	236/305 (77%)	2e-94

10 The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 8G.

Table 8G. ClustalW Analysis for NOV8a

- 1) NOV8a (SEQ ID NO:26)
- 2) NOV8b (SEQ ID NO:28)
- 3) gi|17445344 ref XP_060558.1| (XM_060558) similar to olfactory receptor (H. sapiens) [Homo sapiens] (SEQ ID NO:72)
- 4) gi|5901478|gb|AAD55304.1|AF044033.1| (AF044033) olfactory receptor [Marmota marmota] (SEQ ID NO:73)
- 5) gi|13624329 ref NP_112165.1| (NM_030903) olfactory receptor, family 2, subfamily

W, member 1 [Homo sapiens] (SEQ ID NO:74)

6) gi|12054431|emb_CAC20523.1 (AJ302603) olfactory receptor [Homo sapiens] (SEQ ID NO:75)

7) gi|12054429|emb_CAC20522.1 (AJ302602) olfactory receptor [Homo sapiens] (SEQ ID NO:76)

		10	20	30	40	50
		
	5	NOV8a Cura 559 CG56663-01	GT G TQTH	DR HL R FV IL A L		T V R
		NOV8b Cura-559B CG56663-02	GT G TQTH	DR HL R FV IL A L		T V R
		gi 17445344	GT G TQTH	DR HL R FV IL A L		T V R
		gi 5901478				
	10	gi 13624329	QS Y SLHG	NH KM M SG VA F I		A A L
		gi 12054431	QS Y SLHG	NH KM M SG VA F I		A A L
		gi 12054429	QS Y SLHG	NH KM M SG VA F I		A A L
		60	70	80	90	100
					
	15	NOV8a Cura 559 CG56663-01	PH	AH S S L Y N C		M A
		NOV8b Cura-559B CG56663-02	PH	AH S S L Y N C		M A
		gi 17445344	PH	AH S S L Y N C		M A
		gi 5901478				
	20	gi 13624329	L GN	S S L H S R		V VV
		gi 12054431	SQ RN	C I M V W P		V I
		gi 12054429	SQ RN	C I V V W P		V I
			SQ RN	C I M V W P		V I
		110	120	130	140	150
					
	25	NOV8a Cura 559 CG56663-01	FLFLG G	A CV	M I R	RGLVSVT G
		NOV8b Cura-559B CG56663-02	FLFLG G	A CV	M I R	RGLVSVT G
		gi 17445344	FLFLG G	A CV	M I R	RGLVSVT G
		gi 5901478	FLFLG G	A FV V	T I SSR	LGLVSVA G
	30	gi 13624329	YVYMW S	S FT	F V H	LKMIIMI S
		gi 12054431	YVYMW S	S FT	F V H	LKMIIMI S
		gi 12054429	YVYMW S	S FT	F V H	LKMIIMI S
		160	170	180	190	200
					
	35	NOV8a Cura 559 CG56663-01	CGV LAMSPV R R HHEV	R M IRM	S VAI GT	
		NOV8b Cura-559B CG56663-02	CGV LAMSPV R R HHEV	R M IRM	S VAI GT	
		gi 17445344	CGV LAMSPV R R HHEV	R M IRM	S VAI GT	
		gi 5901478				
	40	gi 13624329	CGM LVMSPV Q R HNKV	C M IRM	N VAI GT	
		gi 12054431	ISL VVLCTL N T NNIL	C L VKI	D TTV MS	
		gi 12054429	ISL VVLCTL N T NNIL	C L VKI	D TTV MS	
			ISL VVLCTL N T NNIL	C L VKI	D TTV MS	
		210	220	230	240	250
					
	45	NOV8a Cura 559 CG56663-01	V KKGV S VF L S VR	QIR ASGRQ FG		L
		NOV8b Cura-559B CG56663-02	V AVGV S VF L S VR	QIR ASGRQ FG		L
		gi 17445344	V KKGV S VF L S VR	QIR ASGRQ FG		L
		gi 5901478	V AVGI S VF V GH VR	FRIQ SSGRHRIFN		L
	50	gi 13624329	A GIII T IL I G AK	RTK KASQR MN		M
		gi 12054431	A GIII T IL I G AK	RTK KASQR MN		M
		gi 12054429	A GIII T IL I G AK	RTK KASQR MN		M
		260	270	280	290	300
					
	55	NOV8a Cura 559 CG56663-01	N M ASS Q M M	NIV L	REV G	
		NOV8b Cura-559B CG56663-02	N M ASS Q M M	NIV L	REV G	
		gi 17445344	N M ASS Q M M	NIV L	REV G	
		gi 5901478				
	60	gi 13624329	T L NRA K K T	TVI S	KDM D	
		gi 12054431	T L NRA K K T	TVI S	KDM D	
		gi 12054429	T L NRA K K T	TVI S	KNM D	
		310	320			
					
	65	NOV8a Cura 559 CG56663-01	GR LLGKRELG E-----			
		NOV8b Cura-559B CG56663-02	GR LLGKRELG E-----			
		gi 17445344	GR LLGKRELG E-----			
		gi 5901478				

gi 13624329	KK MRFHHKST IKRNCKS
gi 12054431	KK MRFHHKST IKRNCKS
gi 12054429	KK MRFHHKST IKRNCKS

5

Table 8H lists the domain description from DOMAIN analysis results against NOV8.

This indicates that the NOV8 sequence has properties similar to those of other proteins known to contain these domains.

Table 8H. Domain Analysis of NOV8

gnl|Pfam|pfam00001, 7tm_1, 7 transmembrane receptor (rhodopsin family).

(SEQ ID NO: 77)

CD-Length = 254 residues, 100.0% aligned

Score = 95.1 bits (235). Expect = 5e-21

NOV 8: 41 GNTTIILVSRLDPHLHTPMYFFLAHLSFLDSFTTSSIPQLLYNLNGCDKTISYMGCAIQ 100

Sbjct: 1 GNLLVILVILRTKKLRPTNIFLLNLAVADLLFLLTPWALYYLVGGDWVFGDALCKLV 60

NOV 8: 101 LFLFLGLGGVECLLLAVMAYDRCVAICKPLHYMVIMNPRLCRGVLVS梧CGVANSIAMS 160

SOURCE: 81 GAIFFVNGTIASTELATISIDKLTAVIPEKTRKRTFRIKAVTEELVWEALESEI 118

o o

NOV 8: 161 PVTLRPLRCGHHEVDHFLREMPALIRMACVSTVAIEGTVFVLKKGVVLSPLVFILLSY 220

Sbjct: 119 PLLFSLWLRTEEGNTVCLIDFPEESVKRSYVLLSTLVGFVL-----PLLVLVLCYTR 171

NOV 8 : 221 IVRAV-----LQIIRSASGRQKAFGTCGSHLTVVSLFYG---NIIYMYMOPGASSS 267

NOV 8 : 268 QDQGMFLMLFYNIVTPLLNPLIY 290

Subj: 232 LPTALLITLWLAYVNSCLNPIIY 254

G-Protein Coupled Receptor (GPCRs) have been identified as extremely large subfamily of G protein-coupled receptors in a number of species. These receptors share a seven transmembrane domain structure with many neurotransmitter and hormone receptors, and are likely to underlie the recognition and G-protein-mediated transduction of various signals. Previously, GPCR genes cloned in different species were from random locations in the respective

genomes. The human GPCR genes are intron less and belong to four different gene subfamilies, displaying great sequence variability. These genes are dominantly expressed in olfactory epithelium.

Olfactory receptors (ORs) have been identified as extremely large subfamily of G protein-coupled receptors in a number of species. These receptors share a seven transmembrane domain structure with many neurotransmitter and hormone receptors, and are likely to underlie the recognition and G-protein-mediated transduction of odorant signals. Previously, OR genes cloned in different species were from random locations in the respective genomes. The human OR genes are intron less and belong to four different gene subfamilies, displaying great sequence variability. These genes are dominantly expressed in olfactory epithelium.

The protein similarity information, expression pattern, and map location for the NOV8 proteins and nucleic acids disclosed herein suggest that it may have important structural and/or physiological functions characteristic of the GPCR family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

The NOV8 nucleic acid and protein are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: developmental diseases, MHCII and III diseases (immune diseases), Taste and scent detectability Disorders, Burkitt's lymphoma, Corticoneurogenic disease, Signal Transduction pathway disorders, Retinal diseases including those involving photoreception, Cell Growth rate disorders; Cell Shape disorders, Feeding disorders; control of feeding; potential obesity due to over-eating; potential disorders due to starvation (lack of appetite), noninsulin-dependent diabetes mellitus (NIDDM1), bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not

limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies, benign

5 prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation. Dentatorubro-pallidoluysian atrophy(DRPLA) Hypophosphatemic rickets, autosomal dominant (2) Acrocallosal syndrome and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders of the like.. The polypeptides can be used as immunogens to produce

10 antibodies specific for the invention, and as vaccines. They can also be used to screen for potential agonist and antagonist compounds. For example, a cDNA encoding the OR -like protein may be useful in gene therapy, and the OR-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from bacterial, fungal, protozoal and viral infections (particularly infections caused by HIV-1 or HIV-2), pain, cancer (including but not limited to Neoplasm; adenocarcinoma; lymphoma; prostate cancer; uterus cancer), anorexia, bulimia, asthma, Parkinson's disease, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, Crohn's disease; multiple sclerosis; and Treatment of Albright Hereditary Osteodystrophy, angina pectoris, myocardial infarction, ulcers, asthma, allergies,

20 benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles de la Tourette syndrome and/or other pathologies and disorders. The novel nucleic acid encoding OR-like protein, and the OR-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the

25 presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.and other diseases, disorders and conditions of the like.

NOV9

30 A disclosed NOV9 is nucleic acid (designated as CuraGen Acc. No. CG56787-01, encodes a novel dual specificity phosphatase and includes the 624 nucleotide sequence (SEQ ID NO:29)

shown in Table 9A. An open reading frame for the mature protein was identified beginning at nucleotide 1 and ending with a TAA codon at nucleotides 805-807. Putative untranslated regions downstream from the termination codon are underlined in Table 9A, and the stop codon is in bold letters.

5

Table 9A. NOV9 Nucleotide Sequence (SEQ ID NO:29)

```
CTTGAGCTCTCTGACTGCTGACCACTGACCCACCGACTTGATGACAGCACCCCTCGTGTGCCTTCC
CAGTTCAAATCCGGCAGCCCTCAGTCAGCGGCCTCTCGCAGATAACCAAAAGCCTGTATATCAGCA
ATGGTGTGGCCGCCAACAAACAAGCTCATGCTGTAGCAACAGATCACCATGGTCATCAATGTCTC
AGTGGAGGTAGTGAACACCTGTATGAGGATATCCAGTACATGCAGGTACCTGTGGCTGACTCCCC
TAACTCACGTCTGTGACTCTTGACCCATTGCTGACCATAATCCACAGCGTGGAGATGAAGCAG
GGCGTACTTGTGCACTGTGCTGCTGGTGTGAGCGCTCAGCTGCCCTGTGCCTCGCCTACCTCA
TGAAGTACCACGCCATGTCCCTGCTGGACGCCAACACGTGGACCAAGTCATGCCGGCCCACATCC
GACCCAACAGCGGCTTGGAGCAGCTCATCCACTATGAGTTCAATTGTTGGCAAGAACACTGT
GCACATGGTCAGTCCCCAGTGGGAATGATCCCTGACATCTATGAGAAGGAAGTCCGTTGATGATT
CCACTGTGAGCCATCCACGAGCC
```

The nucleic acid sequence of NOV9 maps to chromosome 22 and has 363 of 563 bases (64%) identical to a gb:GENBANK-ID:AF120032|acc:AF120032.1 mRNA from Homo sapiens (Homo sapiens MAP kinase phosphatase 6 (MKP6) mRNA, complete cds).

The NOV9 polypeptide (SEQ ID NO:30) is 188 amino acid residues in length and is presented using the one-letter amino acid code in Table 9B. The SignalP, Psort and/or Hydropathy results predict that NOV9 has a signal peptide and is likely to be localized to the cytoplasm with a certainty of 0.4500. In alternative embodiments, a NOV9 polypeptide is located to the microbody (peroxisome) with a certainty of 0.3000, the lysosome (lumen) with a certainty of 0.1955, or the mitochondrial matrix space with a certainty of 0.1000.

Table 9B. Encoded NOV9 Protein Sequence (SEQ ID NO:30)

```
MTAPSCAFPVQIRQPSVGLSQITKSLYISNGVAANNKMLSSNQITMVINVSVVNTLYEDIQYMQ
VPVADSPNSRLCDFFDPIADHIHSVEMKQGRTLLHCAAGVSRSAALCLAYLMKYHAMSLDAHTWT
KSCRPIIRPNNSGFWEQLIHYEFQLFGKNTVHMVSSPVGMPDIYEKEVRLMIPL
```

The NOV9 amino acid sequence has 187 of 188 amino acid residues (99%) identical to, and 187 of 188 amino acid residues (99%) similar to, the 188 amino acid residue [gi|17485142|ref|XP_038481.2| XM_038481](#) protein from Homo sapiens (Human) (HYPOTHETICAL PROTEIN XP_038481) ($E = e^{-102}$).

NOV9 is expressed in at least the following tissues: Brain, Brown adipose, Cartilage, Colon, Dermis, Epidermis, Hair Follicles, Hippocampus, Hypothalamus, Kidney, Lung, Lymph node, Lymphoid tissue, Ovary, Oviduct/Uterine Tube/Fallopian tube, Parotid Salivary glands, Peripheral Blood, Pituitary Gland, Prostate, Right Cerebellum, Skin, Substantia Nigra, Testis, 5 Thyroid, Tonsils, Umbilical Vein, Uterus, Vulva, Whole Organism. Expression information was derived from the tissue sources of the sequences that were included in the derivation of the sequence of NOV9. The sequence is predicted to be expressed in the following tissues because of the expression pattern of (GENBANK-ID: gb:GENBANK-ID:AF120032|acc:AF120032.1) a closely related Homo sapiens MAP kinase phosphatase 6 (MKP6) mRNA, complete cds homolog in species Homo sapiens : breast and ovarian tissue, pancreas, brain, liver, kidney, spleen, testis, ovary, and peripheral blood leukocytes.

NOV9 has homology to the amino acid sequences shown in the BLASTP data listed in Table 9C.

Table 9C. BLAST results for NOV9

Gene Index/ Identifier	Protein/ Organism	Length (aa)	Identity (%)	Positives (%)	Expect
gi 17485142 ref XP 038481.2 (XM_038481)	hypothetical protein XP_038481 [Homo sapiens]	188	187/188 (99%)	187/188 (99%)	e-102
gi 18043293 gb AAH2 0036.1 AAH20036 (BC020036)	Unknown (protein for MGC:28218) [Mus musculus]	188	156/188 (82%)	171/188 (89%)	4e-86
gi 13278657 gb AAH0 4110.1 AAH04110 (BC004110)	Unknown (protein for IMAGE:3689593) [Homo sapiens]	151	148/148 (100%)	148/148 (100%)	2e-81
gi 12840422 dbj BAB 24847.1 (AK007061)	putative [Mus musculus]	189	137/186 (73%)	158/186 (84%)	1e-76
gi 10334445 emb CAC 10195.1 (AL133545)	bA386N14.1 (novel protein similar to a dual specificity phosphatase) [Homo sapiens]	190	131/190 (68%)	164/190 (85%)	6e-72

The homology of these sequences is shown graphically in the ClustalW analysis shown in Table 9D.

Table 9D. ClustalW Analysis of NOV9

- 1) NOV9 (SEQ ID NO:38)
- 2) gi|17485142|ref XP_038481.2 (XM_038481) hypothetical protein XP_038481 [Homo sapiens] (SEQ ID NO:78)
- 3) gi|18043293|gb|AAH20036.1 AAH20036 (BC020036) Unknown (protein for MGC:28218) [Mus musculus] (SEQ ID NO:79)
- 4) gi|13278657|gb|AAH04110.1 AAH04110 (BC004110) Unknown (protein for IMAGE:3689593) [Homo sapiens] (SEQ ID NO:80)
- 5) gi|12840422|dbj|BAB24847.1| (AK007061) putative [Mus musculus] (SEQ ID NO:81)
- 6) gi|10334445|emb|CAC10195.1| (AL133545) ba386N14.1 (novel protein similar to a dual specificity phosphatase) [Homo sapiens] (SEQ ID NO:82)

	10	20	30	40	50
NOV9				
gi 17485142	APSCA	-V IR P- VS	K Y	N M	M
gi 18043293	APSCA	-V FR P- VS	K Y	N M	M
gi 13278657	SPWSA	-V IP P- IR	K F	N L	T
gi 12840422	TASCI	-S AT QDNIY	A F	SAV	D T N H T
gi 10334445	ASASS	SSS GV QP IYSF	R FL	D L	R A
	60	70	80	90	100
NOV9				
gi 17485142	L	M	A S	C	K
gi 18043293	L	M	A S	C	K
gi 13278657	A F	V	V A VA	SN	SV R
gi 12840422	L	M	A S	C	K
gi 10334445	I A	FF	V S A	Y Y	G RN
	IV A	VFF G	IK	T ARD Y	L TID R
	110	120	130	140	150
NOV9				
gi 17485142					
gi 18043293			V		
gi 13278657					
gi 12840422	M	T	N T	T	N
gi 10334445	S	S	S	R	N
	160	170	180	190	
NOV9				
gi 17485142	H VS	M	V		
gi 18043293	L	MQ MD	M R	T	
gi 13278657	H VS	M	V		
gi 12840422	K SR	R IY	I L N	AY ELM	
gi 10334445	N K NN	R IN	N	DL M SM	

Tables 9E, 9F and 9G list the domain description from DOMAIN analysis results against NOV9. This indicates that the NOV9 sequence has properties similar to those of other proteins known to contain these domains.

Table 9E. Domain Analysis of NOV9

gnl Smart smart00195, DSPc, Dual specificity phosphatase, catalytic domain

(SEQ ID NO:83)

CD-Length = 139 residues, 100.0% aligned

Score = 134 bits (336), Expect = 6e-33

NOV 9: 19 GLSQITKSLYI SNGVAANNKMLSSNQITMVINVSVEVNNTLYEDIQYMQVPVADSPNSR 78

Spict: 1 GPSEIILPHIYLGSYSQDASNLALLKKLIGITHVINVTTEEVPSNSKSGELYLGLPVDDNTETK 60

NOV 9: 79 LCDFFDP IADHIHSVEMKQGR TLLHCAAGVRSAA CLAYLMKYHAMSLLDAHTWT KSCR 138

Слайд 61 ІСРУХ ВІДЧУВЕЛЕННЯ ПІДСІДІТЬ НІЗКО СОНЧЕСНОСТЬ І ВІДМІННОСТЬ ПІДЧУВЕЛЕННЯ 100

NOV 9 1988 BIBLIOGRAPHY OF HYDRO 157

Sheet: 121 PIISPNEGELBOLIEYERK 139

Table 9F. Domain Analysis of NOV9

gnl.Pfam|pfam00782, DSPc, Dual specificity phosphatase, catalytic domain.

Ser/Thr and Tyr protein phosphatases. The enzyme's tertiary fold is highly similar to that of tyrosine-specific phosphatases, except for a "recognition" region.

(SEO ID NO: 84)

CD-Length = 139 residues, 100.0% aligned

Score = 134 bits (336), Expect = 6e-33

NOV 9: 19 GLSQITKSLYISNGVAANNKMLSSNQITMVINVSVVVNTLYEDIQYMQVPVADSPNSR 78

BRGEEL, BUL, XI, CGXPTA, SNI, AEL, SKI, GLTHW, VNTSE, ENCKNS, GEL, XI, UU, EVDEN, KETP, 63

NOV 9: 79 LCDFFDP IADHIHSVEMKQGR TLLHCAAGV RSAALCLAYLMKYHAMSLLDAHTWT KSCR 138

NOV 6 1968 BIRMINGHAM LIBRARIES 157

卷之三

Skjært. 121. BILSNEGEKPOLJERVERK. 129

Table 9G. Domain Analysis of NOV9

gnl_Smart:smart00194, PTPc, Protein tyrosine phosphatase, catalytic domain

(SEQ ID NO:85)

CD-Length = 264 residues, 12.5% aligned

Score = 35.0 bits (79), Expect = 0.004

NOV 9: 88 DHIHSVEMKQGRTLLHCAAGVSRSAALCLAYLM 120

| | ++ || + || | + ++

Sbjct: 187 RKSQSTLRNSGPIVVHCSAGVGRGTGTFIAIDIL 219

Mitogen-activated protein (MAP) kinase phosphatases constitute a growing family of dual specificity phosphatases thought to play a role in the dephosphorylation and inactivation of MAP kinases and are therefore likely to be important in the regulation of diverse cellular processes such as proliferation, differentiation, and apoptosis. For this reason it has been suggested that MAP kinase phosphatases may be tumor suppressors. DUSP6 (alias PYST1), one of the dual-specificity tyrosine phosphatases, is localized on 12q21, one of the regions of frequent allelic loss in pancreatic cancer. This gene is composed of three exons, and two forms of alternatively spliced transcripts are ubiquitously expressed. Although no mutations were observed in 26 pancreatic cancer cell lines, reduced expressions of the full-length transcripts were observed in some cell lines, which may suggest some role for DUSP6 in pancreatic carcinogenesis. PMID: 9858808

The mitogen-induced gene, DUSP2, encodes a nuclear protein, PAC1, that acts as a dual-specific protein phosphatase with stringent substrate specificity for MAP kinase. MAP kinase phosphorylation and consequent enzymatic activation is a central and often obligatory component in signal transduction initiated by growth factor stimulation or resulting from various types of oncogenic transformation. DUSP2 downregulates intracellular signal transduction through the dephosphorylation/inactivation of MAP kinases. PMID: 7590752

Keyse and Emslie (1992) isolated and characterized a cDNA, which they designated CL100, corresponding to an mRNA that is highly inducible by oxidative stress and heat shock in human skin cells. The cDNA was obtained by differential screening of a library made from normal human skin fibroblasts stressed for 2 hours in a solution of hydrogen peroxide. The cDNA contains an open reading frame specifying a 367-residue protein of 39.3 kD predicted molecular mass with the structural features of a nonreceptor type protein-tyrosine phosphatase. It has significant amino acid sequence similarity to a tyr/ser-protein phosphatase encoded by the late gene H1 of vaccinia virus. The purified protein encoded by the open reading frame expressed in

bacteria has intrinsic phosphatase activity. Given the relationship between the levels of protein-tyrosine phosphorylation, receptor activity, cellular proliferation, and cell-cycle control, Keyse and Emslie (1992) concluded that induction of this gene may play an important regulatory role in the human cellular response to environmental stress. Alessi et al. (1993) found that the

5 phosphatase encoded by CL100 has dual specificity for tyrosine and threonine and that it specifically inactivates mitogen-activated protein kinase in vitro. Brondello et al. (1999) determined that DUSP1, which they called MKP1, is a labile protein with a half-life of approximately 45 minutes in CCL39 hamster fibroblasts. Its degradation was attenuated by inhibitors of the ubiquitin-directed proteasome complex. MKP1 was a target in vivo and in vitro for p42MAPK (176948) or p44MAPK (601795), which phosphorylates MKP1 on 2 C-terminal serine residues, ser359 and ser364. This phosphorylation did not modify MKP1's intrinsic ability to dephosphorylate p44MAPK, but led to stabilization of the protein. Brondello et al. (1999) concluded that these results illustrated the importance of regulated protein degradation in the control of mitogenic signaling.

10 The protein similarity information, expression pattern, and map location for the NOV9 protein and nucleic acid disclosed herein suggest that it may have important structural and/or physiological functions characteristic of the family. Therefore, the nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool.

15 These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) biological defense weapon.

20 The nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications implicated in various diseases and disorders described below and/or other pathologies. For example, the compositions of the present invention will have efficacy for treatment of patients suffering from: brain disorders including epilepsy, eating disorders, schizophrenia, ADD, and cancer; heart disease; blood disorders, kidney disorders, liver diseases, inflammation and autoimmune disorders including Crohn's disease, IBD, allergies, rheumatoid

and osteoarthritis, inflammatory skin disorders, allergies, blood disorders; psoriasis; colon-, ovarian-, testicular-, lymphatic-, brain-, and pancreatic cancers; leukemia AIDS; thalamus disorders; metabolic disorders including diabetes and obesity; lung diseases such as asthma, emphysema, cystic fibrosis, and cancer; pancreatic disorders including pancreatic insufficiency; 5 and prostate disorders including prostate cancer and other diseases, disorders and conditions of the like.

NOVX Nucleic Acids and Polypeptides

One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.

An NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps as they may take place within the cell, or host cell, in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having

residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

The term "probes", as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as approximately, *e.g.*, 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

The term "isolated" nucleic acid molecule, as utilized herein, is one, which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (*e.g.*, brain, heart, liver, spleen, etc.). Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or a complement of this aforementioned nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29 as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning

techniques (e.g., as described in Sambrook, *et al.*, (eds.), MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

5 A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

10 As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or a complement thereof.

15 20 Oligonucleotides may be chemically synthesized and may also be used as probes.

25 In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or a portion of this nucleotide sequence (*e.g.*, a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of an NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence shown NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39 or 41 is one that is sufficiently complementary to the nucleotide sequence shown NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39 or 41 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, thereby forming a stable duplex.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

10 Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice.

15 Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic

20 activity compared to wild type. Homologs are nucleic acid sequences or amino acid sequences of a particular gene that are derived from different species.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately

10
15
20
25
30

stringent, or low stringent conditions. See e.g. Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below.

A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for an NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, *e.g.*, frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.

An NOVX polypeptide is encoded by the open reading frame ("ORF") of an NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG "start" codon and terminates with one of the three "stop" codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a *bona fide* cellular protein, a minimum size requirement is often set, *e.g.*, a stretch of DNA that would encode a protein of 50 amino acids or more.

The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, *e.g.* from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The

oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29; or an anti-sense strand nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29; or of a naturally occurring mutant of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29.

5 Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express an NOVX protein, such as by measuring a level of an NOVX-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.

10 “A polypeptide having a biologically-active portion of an NOVX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a “biologically-active portion of NOVX” can be prepared by isolating a portion SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, that encodes a polypeptide having an NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of NOVX.

NOVX Nucleic Acid and Polypeptide Variants

25 The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29 due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30.

In addition to the human NOVX nucleotide sequences shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame (ORF) encoding an NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from the human SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29 are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high

stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5 °C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in Ausubel, *et al.*, (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions 5 are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well-known within the art. *See, e.g.*, Ausubel, et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990; GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 15 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (*e.g.*, as employed for cross-species hybridizations). *See, e.g.*, Ausubel, et al. (eds.), 1993, CURRENT 20 PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981. *Proc Natl Acad Sci USA* 78: 6789-6792.

Conservative Mutations

In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the 25 population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, thereby leading to changes in the amino acid sequences of the encoded NOVX proteins, without altering the functional ability of said NOVX proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the 30 sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX

proteins without altering their biological activity, whereas an "essential" amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are predicted to be particularly non-amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.

5 Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29 yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 45% homologous to the amino acid sequences SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30; more preferably at least about 70% homologous SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30; still more preferably at least about 80% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30; even more preferably at least about 90% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30; and most preferably at least about 95% homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30.

10 An isolated nucleic acid molecule encoding an NOVX protein homologous to the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30 can be created by 20 introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, such that one or 25 more amino acid substitutions, additions or deletions are introduced into the encoded protein.

25 Mutations can be introduced into SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted, non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. 30 These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine,

asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved "strong" residues or fully conserved "weak" residues. The "strong" group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the "weak" group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, VLIM, HFY, wherein the letters within each group represent the single letter amino acid code.

In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and an NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g. avidin proteins).

In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).

Antisense Nucleic Acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or fragments, analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein (e.g., complementary to the coding

strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, 5 homologs, derivatives and analogs of an NOVX protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30, or antisense nucleic acids complementary to an NOVX nucleic acid sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an NOVX protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding the NOVX protein. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to 20 only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For 25 example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (*e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used).

30 Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine,

5

4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil,

10

3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

20

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an NOVX protein to thereby inhibit expression of the protein (*e.g.*, by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (*e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

25

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific

double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other. *See, e.g.*, Gaultier, *et al.*, 1987. *Nucl. Acids Res.* **15**: 6625-6641. The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (*See, e.g.*, Inoue, *et al.* 1987. *Nucl. Acids Res.* **15**: 6131-6148) or a chimeric RNA-DNA analogue (*See, e.g.*, Inoue, *et al.*, 1987. *FEBS Lett.* **215**: 327-330.

Ribozymes and PNA Moieties

Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes as described in Haselhoff and Gerlach 1988. *Nature* 334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for an NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of an NOVX cDNA disclosed herein (*i.e.*, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an NOVX-encoding mRNA. *See, e.g.*, U.S. Patent 4,987,071 to Cech, *et al.* and U.S. Patent 5,116,742 to Cech, *et al.* NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. *See, e.g.*, Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (*e.g.*, the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. *See, e.g.*, Helene, 1991. *Anticancer Drug Des.* 6: 569-84; Helene, *et al.* 1992. *Ann. N.Y. Acad. Sci.* 660: 27-36; Maher, 1992. *Bioassays* 14: 807-15.

In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. *See, e.g.*, Hyrup, *et al.*, 1996. *Bioorg Med Chem* 4: 5-23. As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics (*e.g.*, DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, *et al.*, 1996. *supra*; Perry-O'Keefe, *et al.*, 1996. *Proc. Natl. Acad. Sci. USA* 93: 14670-14675.

PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (*e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S₁ nucleases (*See, Hyrup, et al., 1996. supra*); or as probes or primers for DNA sequence and hybridization (*See, Hyrup, et al., 1996, supra; Perry-O'Keefe, et al., 1996. supra*).

In another embodiment, PNAs of NOVX can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (*e.g.*, RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (*see, Hyrup, et al., 1996. supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, *et al.*, 1996. *supra* and Finn, *et al.*, 1996. *Nucl Acids Res* 24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.*,

5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA. *See, e.g.,* Mag, *et al.*, 1989. *Nucl Acid Res* 17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. *See, e.g.,* Finn, *et al.*, 1996. *supra*. Alternatively, chimeric 5 molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. *See, e.g.,* Petersen, *et al.*, 1975. *Bioorg. Med. Chem. Lett.* 5: 1119-1124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (*see, e.g.,* Letsinger, *et al.*, 1989. *Proc. Natl. Acad. Sci. U.S.A.* 86: 6553-6556; Lemaitre, *et al.*, 1987. *Proc. Natl. Acad. Sci.* 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (*see, e.g.,* PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (*see, e.g.,* Krol, *et al.*, 1988. *BioTechniques* 6:958-976) or intercalating agents (*see, e.g.,* Zon, 1988. *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.

NOVX Polypeptides

A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in SEQ ID NOS:2, 4, 6, 8, 10, 12, 20 14, 16, 18, 20, 22, 24, 26, 28 and 30. The invention also includes a mutant or variant protein any 25 of whose residues may be changed from the corresponding residues shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30 while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.

In general, an NOVX variant that preserves NOVX-like function includes any variant in 25 which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined 30 above.

One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate 5 purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, an NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language "substantially free of cellular material" includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.

Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence shown in SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30) that include fewer amino acids than the full-length NOVX proteins, and 5 exhibit at least one activity of an NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of an NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.

Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.

In an embodiment, the NOVX protein has an amino acid sequence shown SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30, and retains the functional activity of the protein of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30, and 20 retains the functional activity of the NOVX proteins of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30.

Determining Homology Between Two or More Sequences

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the 25 sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970. *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

Chimeric and Fusion Proteins

The invention also provides NOVX chimeric or fusion proteins. As used herein, an NOVX "chimeric protein" or "fusion protein" comprises an NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An "NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an NOVX protein SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 and 30, whereas a "non-NOVX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, *e.g.*, a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within an NOVX fusion protein the NOVX polypeptide can

correspond to all or a portion of an NOVX protein. In one embodiment, an NOVX fusion protein comprises at least one biologically-active portion of an NOVX protein. In another embodiment, an NOVX fusion protein comprises at least two biologically-active portions of an NOVX protein. In yet another embodiment, an NOVX fusion protein comprises at least three biologically-active portions of an NOVX protein. Within the fusion protein, the term "operatively-linked" is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.

In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.

In another embodiment, the fusion protein is an NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.

In yet another embodiment, the fusion protein is an NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between an NOVX ligand and an NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction *in vivo*. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of an NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (*e.g.* promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with an NOVX ligand.

An NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to

provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that

5 give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, *et al.* (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.

NOVX Agonists and Antagonists

The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (*e.g.*, discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.

Variants of the NOVX proteins that function as either NOVX agonists (*i.e.*, mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (*e.g.*, truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion

proteins (e.g., for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an
5 appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. *See, e.g.,* Narang, 1983. *Tetrahedron* 39: 3; Itakura, *et al.*, 1984. *Annu. Rev. Biochem.* 53: 323; Itakura, *et al.*, 1984. *Science* 198: 1056; Ike, *et al.*, 1983. *Nucl. Acids Res.* 11: 477.

10 Polypeptide Libraries

In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of an NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S₁ nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes
20 N-terminal and internal fragments of various sizes of the NOVX proteins.

Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely
25 used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new
30 technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. *See, e.g.,* Arkin and Yourvan,

1992. *Proc. Natl. Acad. Sci. USA* 89: 7811-7815; Delgrave, *et al.*, 1993. *Protein Engineering* 6:327-331.

Anti-NOVX Antibodies

Also included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab} , $F_{ab'}$ and $F_{(ab')2}$ fragments, and an F_{ab} expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated NOVX-related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX-related protein that is located on the surface of the protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of the human NOVX-related protein sequence will indicate which regions of a NOVX-related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a

means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation.

See, e.g., Hopp and Woods, 1981, *Proc. Nat. Acad. Sci. USA* 78: 3824-3828; Kyte and Doolittle

5 1982, *J. Mol. Biol.* 157: 105-142, each of which is incorporated herein by reference in its entirety.

Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow and Lane, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lyssolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental

cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., MONOCLONAL ANTIBODY PRODUCTION TECHNIQUES AND APPLICATIONS, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium.

Alternatively, the hybridoma cells can be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the

invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, *Nature* 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., *Nature*, 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science*, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human

immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).

Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991); Marks et al., *J. Mol. Biol.*, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (*Bio/Technology* 10, 779-783 (1992)); Lonberg et al. (*Nature* 368 856-859 (1994)); Morrison (*Nature* 368, 812-13 (1994)); Fishwild et al., (*Nature Biotechnology* 14, 845-51 (1996)); Neuberger (*Nature Biotechnology* 14, 826 (1996)); and Lonberg and Huszar (*Intern. Rev. Immunol.* 13 65-93 (1995)).

Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous

antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast 5 artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the XenomouseTM as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which 10 secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be 15 further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the 20 locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in 25 U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

30 In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds

immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

F_{ab} Fragments and Single Chain Antibodies

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see e.g., Huse, et al., 1989 *Science* 246: 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F_{(ab')2} fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_{(ab')2} fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker *et al.*, 1991 *EMBO J.*, 10:3655-3659.

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of

the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable 5 host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the 10 CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers. 15

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., *Science* 229:81 (1985) describe a procedure 20 wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then 25 reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby et al., *J. Exp. Med.* 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment 30 was separately secreted from *E. coli* and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells

overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., *J. Immunol.* 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc γ R), such as Fc γ RI (CD64), Fc γ RII (CD32) and Fc γ RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention.

Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent 5 No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., *J. Exp Med.*, 176: 1191-1195 (1992) and Shopes, *J. Immunol.*, 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. *Cancer Research*, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., *Anti-Cancer Drug Design*, 3: 219-230 (1989).

Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a 25 cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include 30 diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from

Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, saponaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the trichothecenes. A variety of radionuclides are 5 available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See 10 WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to 20 the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection 25 of antibodies that are specific to a particular domain of an NOVX protein is facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Anti-NOVX antibodies may be used in methods known within the art relating to the 30 localization and/or quantitation of an NOVX protein (e.g., for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in

imaging the protein, and the like). In a given embodiment, antibodies for NOVX proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds (hereinafter "Therapeutics").

An anti-NOVX antibody (*e.g.*, monoclonal antibody) can be used to isolate an NOVX polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-NOVX antibody can facilitate the purification of natural NOVX polypeptide from cells and of recombinantly-produced NOVX polypeptide expressed in host cells. Moreover, an anti-NOVX antibody can be used to detect NOVX protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the NOVX protein. Anti-NOVX antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

NOVX Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are

integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be

expressed in bacterial cells such as *Escherichia coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated

5 *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *Escherichia coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. *Gene* 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRITS (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

20 Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant 25 protein. *See, e.g.*, Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (*see, e.g.*, Wada, *et al.*, 1992. *Nucl. Acids Res.* 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be 30 carried out by standard DNA synthesis techniques.

In another embodiment, the NOVX expression vector is a yeast expression vector.

Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYEpSec1 (Baldari, *et al.*, 1987. *EMBO J.* 6: 229-234), pMFA (Kurjan and Herskowitz, 1982. *Cell* 30: 933-943), pJRY88 (Schultz *et al.*, 1987. *Gene* 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

5 Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, SF9 cells) include the pAc series (Smith, *et al.*, 1983. *Mol. Cell. Biol.* 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. *Virology* 170: 31-39).

10 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. *Nature* 329: 840) and pMT2PC (Kaufman, *et al.*, 1987. *EMBO J.* 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, *e.g.*, Chapters 16 and 17 of Sambrook, *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

15 In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, *et al.*, 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, *et al.*, 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, *et al.*, 1985. *Science* 230: 912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also

encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the α -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, 5 the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, *et al.*, "Antisense RNA as a molecular tool for genetic analysis," 10 *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular 20 subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be 25 expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and 30 "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride

co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

5 For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

10 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.

Transgenic NOVX Animals

15 The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of 20 NOVX protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of

the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (*e.g.*, by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of an NOVX gene into which a deletion, addition or substitution has been introduced to

thereby alter, *e.g.*, functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29 can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. *See, e.g.*, Thomas, *et al.*, 1987. *Cell* 51: 503 for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. *See, e.g.*, Li, *et al.*, 1992. *Cell* 69: 915.

The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. *See, e.g.*, Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol.* 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, *See, e.g.*, Lakso, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 6232-6236.

5 Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae*. *See, O'Gorman, et al.*, 1991. *Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, *e.g.*, by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, *et al.*, 1997. *Nature* 385: 810-813. In brief, a cell (*e.g.*, a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, *e.g.*, through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (*e.g.*, the somatic cell) is isolated.

20 **Pharmaceutical Compositions**

The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes

and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into

5 the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (*i.e.*, topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include

isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

5 Sterile injectable solutions can be prepared by incorporating the active compound (e.g., an NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

10 Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the 20 like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

25 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

30 Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.

Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional 5 suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible 10 polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit 20 form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the 25 limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene 30 therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Patent No. 5,328,470) or by stereotactic injection (see, e.g., Chen, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded.

Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express NOVX protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (*e.g.*, in a biological sample) or a genetic lesion in an NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (*e.g.*; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.

The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, *supra*.

Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, *e.g.*, NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of an NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. *See, e.g.,* Lam, 1997. *Anticancer Drug Design* 12: 145.

A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, *e.g.*, nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, *et al.*, 1993. *Proc. Natl. Acad. Sci. U.S.A.* 90: 6909; Erb, *et al.*, 1994. *Proc. Natl. Acad. Sci. U.S.A.* 91: 11422; Zuckermann, *et al.*, 1994. *J. Med. Chem.* 37: 2678; Cho, *et al.*, 20 1993. *Science* 261: 1303; Carell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2059; Carell, *et al.*, 1994. *Angew. Chem. Int. Ed. Engl.* 33: 2061; and Gallop, *et al.*, 1994. *J. Med. Chem.* 37: 1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten, 1992. *Biotechniques* 13: 412-421), or on beads (Lam, 1991. *Nature* 354: 82-84), on chips (Fodor, 1993. *Nature* 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 25 5,233,409), plasmids (Cull, *et al.*, 1992. *Proc. Natl. Acad. Sci. USA* 89: 1865-1869) or on phage (Scott and Smith, 1990. *Science* 249: 386-390; Devlin, 1990. *Science* 249: 404-406; Cwirla, *et al.*, 1990. *Proc. Natl. Acad. Sci. U.S.A.* 87: 6378-6382; Felici, 1991. *J. Mol. Biol.* 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

30 In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell

surface is contacted with a test compound and the ability of the test compound to bind to an NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that 5 binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule. As used 20 herein, a "target molecule" is a molecule with which an NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses an NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. An NOVX target molecule can be a non-NOVX molecule or an NOVX protein or polypeptide of the 25 invention. In one embodiment, an NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding 30

of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.

Determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with an NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular Ca^{2+} , diacylglycerol, IP_3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising an NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting an NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.* stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to an NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test

compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate an NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, *supra*.

5 In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with an NOVX protein, wherein determining the ability of the test compound to interact with an NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of an NOVX target molecule.

10 The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)_n, N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

15 In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed 20 onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either

the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for 5 example, as described, *supra*. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or 10 target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX 15 protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.

20 In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then 25 be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the 30 presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein

expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.

In yet another aspect of the invention, the NOVX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos, *et al.*, 5 1993. *Cell* 72: 223-232; Madura, *et al.*, 1993. *J. Biol. Chem.* 268: 12046-12054; Bartel, *et al.*, 1993. *Biotechniques* 14: 920-924; Iwabuchi, *et al.*, 1993. *Oncogene* 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX ("NOVX-binding proteins" or "NOVX-bp") and modulate NOVX activity. Such NOVX-binding proteins are also likely to be involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming an NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., 20 LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.

The invention further pertains to novel agents identified by the aforementioned screening 25 assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a 30 chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an

individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

Chromosome Mapping

Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences, SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.

Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. *See, e.g., D'Eustachio, et al., 1983. Science 220: 919-924.* Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a

single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.

Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step.

5 Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, *see*, Verma, *et al.*, HUMAN CHROMOSOMES: A MANUAL OF BASIC TECHNIQUES (Pergamon Press, New York 1988).

15 Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

20 Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, *e.g.*, in McKusick, MENDELIAN INHERITANCE IN MAN, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, *e.g.*, Egeland, *et al.*, 1987. *Nature*, 325: 783-787.

25 Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected

individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from

5 polymorphisms.

Tissue Typing

The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such 20 identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once 25 per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual 30 identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NOS:1, 3, 5, 7, 9,

11, 13, 15, 17, 19, 21, 23, 25, 27 and 29 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine

The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in an NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials.

These and other agents are described in further detail in the following sections.

Diagnostic Assays

An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., 5 mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody 20 using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as 25 *in vivo*. For example, *in vitro* techniques for detection of NOVX mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of NOVX protein include 30 introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be

labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or 5 genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.

Prognostic Assays

20 The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic 25 assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease 30 or disorder associated with aberrant NOVX expression or activity. As used herein, a "test

sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).

The methods of the invention can also be used to detect genetic lesions in an NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding an NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from an NOVX gene; (ii) an addition of one or more nucleotides to an NOVX gene; (iii) a substitution of one or more nucleotides of an NOVX gene, (iv) a chromosomal rearrangement of an NOVX gene; (v) an alteration in the level of a messenger RNA transcript of an NOVX gene, (vi) aberrant modification of an NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of an NOVX gene, (viii) a non-wild-type level of an NOVX protein, (ix) allelic loss of an NOVX gene, and (x) inappropriate post-translational modification of an NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in an NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, *et al.*, 1988. *Science* 241: 1077-1080; and Nakazawa, *et al.*, 1994. *Proc. Natl. Acad. Sci. USA* 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, *et al.*, 1995. *Nucl. Acids Res.* 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to an NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (see, Guatelli, *et al.*, 1990. *Proc. Natl. Acad. Sci. USA* 87: 1874-1878), transcriptional amplification system (see, Kwoh, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA* 86: 1173-1177); Q β Replicase (see, Lizardi, *et al.*, 1988. *BioTechnology* 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in an NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds

or thousands of oligonucleotides probes. See, e.g., Cronin, *et al.*, 1996. *Human Mutation* 7: 244-255; Kozal, *et al.*, 1996. *Nat. Med.* 2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, *et al.*, *supra*. Briefly, a first hybridization array of probes can be used to scan through 5 long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977. *Proc. Natl. Acad. Sci. USA* 74: 560 or Sanger, 1977. *Proc. Natl. Acad. Sci. USA* 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, *et al.*, 1995. *Biotechniques* 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, *et al.*, 1996. *Adv. Chromatography* 36: 127-162; and Griffin, *et al.*, 1993. *Appl. Biochem. Biotechnol.* 38: 147-159).

Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, *et al.*, 1985. *Science* 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA 25 or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S₁ nuclease to enzymatically digesting the 30 mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest

mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. *See, e.g.,* Cotton, *et al.*, 1988. *Proc. Natl. Acad. Sci. USA* 85: 4397; Saleeba, *et al.*, 1992. *Methods Enzymol.* 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

5 In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. *See, e.g.,* Hsu, *et al.*, 1994. *Carcinogenesis* 15: 1657-1662. According to an exemplary embodiment, a probe based on an NOVX sequence, *e.g.*, a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. *See, e.g.,* U.S. Patent No. 5,459,039.

10 In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. *See, e.g.,* Orita, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA*: 86: 2766; Cotton, 1993. *Mutat. Res.* 285: 125-144; Hayashi, 1992. *Genet. Anal. Tech. Appl.* 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more 20 sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. *See, e.g.,* Keen, *et al.*, 1991. *Trends Genet.* 7: 5.

25 In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). *See, e.g.,* Myers, *et al.*, 1985. *Nature* 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for

example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. *Biophys. Chem.* 265: 12753.

5 Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, *et al.*, 1986. *Nature* 324: 163; Saiki, *et al.*, 1989. *Proc. Natl. Acad. Sci. USA* 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

10 Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, *et al.*, 1989. *Nucl. Acids Res.* 17: 2437-2448) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. *Tibtech.* 11: 238). In addition it may be desirable to introduce a novel restriction site in the region 15 of the mutation to create cleavage-based detection. See, e.g., Gasparini, *et al.*, 1992. *Mol. Cell Probes* 6: 1. It is anticipated that in certain embodiments amplification may also be performed using *Taq* ligase for amplification. See, e.g., Barany, 1991. *Proc. Natl. Acad. Sci. USA* 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' 20 sequence, making it possible to detect the presence of a known mutation at a specific site by 25 looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving an NOVX gene.

30 Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any

biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.) In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See *e.g.*, Eichelbaum, 1996. *Clin. Exp. Pharmacol. Physiol.*, 23: 983-985; Linder, 1997. *Clin. Chem.*, 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after

ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with an NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene

expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trials of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in 5 clinical trials of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. 20 Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described 25 herein) comprising the steps of (*i*) obtaining a pre-administration sample from a subject prior to administration of the agent; (*ii*) detecting the level of expression of an NOVX protein, mRNA, or genomic DNA in the preadministration sample; (*iii*) obtaining one or more post-administration samples from the subject; (*iv*) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (*v*) comparing the level of 30 expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or

samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, *i.e.*, to increase the effectiveness of the agent.

Alternatively, decreased administration of the agent may be desirable to decrease expression or 5 activity of NOVX to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn's disease; multiple sclerosis, treatment of Albright Hereditary Osteodystrophy, and other diseases, disorders and conditions of the like.

These methods of treatment will be discussed more fully, below.

Disease and Disorders

20 Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (*see, e.g.*, Capecchi, 1989. 25 *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including

additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with

5 Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, and the like).

Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the 20 subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, 25 alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, an NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

Therapeutic Methods

Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of an NOVX protein, a peptide, an NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of an NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering an NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.

Stimulation of NOVX activity is desirable *in situations* in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).

25 **Determination of the Biological Effect of the Therapeutic**

In various embodiments of the invention, suitable *in vitro* or *in vivo* assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable

animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

Prophylactic and Therapeutic Uses of the Compositions of the Invention

5 The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders including, but not limited to: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers.

10 As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from: metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias.

15 Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as 20 an anti-bacterial molecule (*i.e.*, some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.

25 The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

Examples

EXAMPLE 1: Identification of NOVX Nucleic Acids

30 TblastN using CuraGen Corporation's sequence file for polypeptides or homologs was run against the Genomic Daily Files made available by GenBank or from files downloaded from the

individual sequencing centers. Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

The novel NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. PCR primer sequences were used for obtaining different clones. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the predicted exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain - amygdala, brain - cerebellum, brain - hippocampus, brain - substantia nigra, brain - thalamus, brain -whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma - Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation's database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.

Physical clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.

Example 2: Identification of Single Nucleotide Polymorphisms in NOVX nucleic acid sequences

Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.

SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for

similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.

Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation's human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools™ program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.

The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence (Alderborn et al., Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. *Genome Research.* 10 (8) 1249-1265, 2000).

Example 3. Quantitative expression analysis of clones in various cells and tissues

The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/5I (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoimmune diseases), Panel CNSD.01 (containing central nervous system samples from normal and diseased brains) and

CNS_neurodegeneration_panel (containing samples from normal and Alzheimer's diseased brains).

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β -actin and GAPDH). Normalized RNA (5 μ l) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions.

In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 μ g of total RNA were performed in a volume of 20 μ l and incubated for 60 minutes at 42°C. This reaction can be scaled up to 50 μ g of total RNA in a final volume of 100 μ l. sscDNA samples are then normalized to reference nucleic acids as described previously, using 1X TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions.

Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM, primer melting temperature (Tm) range = 58°-60°C, primer optimal Tm = 59°C, maximum primer difference = 2°C, probe does not have 5'G, probe Tm must be 10°C greater than primer Tm, amplicon size 75bp to 100bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and

3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900nM each, and probe, 200nM.

PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer's instructions. Reverse transcription was performed at 48°C for 30 minutes followed by amplification/PCR cycles as follows: 95°C 10 min, then 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100.

When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1X TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification was performed as follows: 95°C 10 min, then 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. Results were analyzed and processed as described previously.

Panels 1, 1.1, 1.2, and 1.3D

The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended

by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the 5 spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.

In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:

ca. = carcinoma,
* = established from metastasis,
met = metastasis,
s cell var = small cell variant,
non-s = non-sm = non-small,
squam = squamous,
pl. eff = pl effusion = pleural effusion,
glio = glioma,
astro = astrocytoma, and
neuro = neuroblastoma.

General_screening_panel_v1.4

The plates for Panel 1.4 include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in Panel 1.4 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian 25 cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panel 1.4 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panel 1.4 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the 30 following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.

Panels 2D and 2.2

The plates for Panels 2D and 2.2 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have "matched margins" obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in the results below. The tumor tissue and the "matched margins" are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI or CHTN). This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated "NAT", for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

Panel 3D

The plates of Panel 3D are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D and 1.3D are of the most common cell lines used in the scientific literature.

30 Panels 4D, 4R, and 4.1D

Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5ng/ml, TNF alpha at approximately 5-10ng/ml, IFN gamma at approximately 20-50ng/ml, IL-4 at approximately 5-10ng/ml, IL-9 at approximately 5-10ng/ml, IL-13 at approximately 5-10ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 20 100 μ M non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10 $^{-5}$ M (Gibco), and 10mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20ng/ml PMA and 1-2 μ g/ml ionomycin, 25 IL-12 at 5-10ng/ml, IFN gamma at 20-50ng/ml and IL-18 at 5-10ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10 $^{-5}$ M (Gibco), and 10mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at 30 approximately 5 μ g/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2x10 6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non

essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10^{-5} M) (Gibco), and 10mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10mM Hepes (Gibco), 50ng/ml GMCSF and 5ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μ g/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10mM Hepes (Gibco) and plated at 10^6 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μ g/ml anti-CD28 (Pharmingen) and 3 μ g/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours

after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10⁻⁵M (Gibco), and 10mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

5 To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resuspended at 10⁶cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10⁻⁵M (Gibco), and 10mM Hepes (Gibco). To activate the cells, we used PWM at 5 μ g/ml or anti-CD40 (Pharmingen) at approximately 10 μ g/ml and IL-4 at 5-10ng/ml. Cells were harvested for RNA preparation at 24,48 and 72 hours.

20 To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μ g/ml anti-CD28 (Pharmingen) and 2 μ g/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, MD) were cultured at 10⁵-10⁶cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10⁻⁵M (Gibco), 10mM Hepes (Gibco) and IL-2 (4ng/ml). IL-12 (5ng/ml) and anti-IL4 (1 μ g/ml) were used to direct to Th1, while IL-4 (5ng/ml) and anti-IFN gamma (1 μ g/ml) were used to direct to Th2 and IL-10 at 5ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5x10⁻⁵M (Gibco), 10mM Hepes (Gibco) and IL-2 (1ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μ g/ml) to prevent apoptosis. After 4-5 days, the 25 Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1mM dbcAMP at 5×10^5 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10^5 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10ng/ml and ionomycin at 1 μ g/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5ng/ml IL-4, 5ng/ml IL-9, 5ng/ml IL-13 and 25ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately 10^7 cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropene (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15ml Falcon Tube. An equal volume of isopropanol was added and left at -20°C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μ l of RNase-free water and 35 μ l buffer (Promega) 5 μ l DTT, 7 μ l RNAsin and 8 μ l DNase were added. The tube was incubated at 37°C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at -80°C.

AI_comprehensive panel_v1.0

The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, MD). Total RNA was extracted from tissue

samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.

Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.

Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.

Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn's patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.

Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-1 anti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.

In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:

AI = Autoimmunity

Syn = Synovial

Normal = No apparent disease

Rep22 /Rep20 = individual patients

RA = Rheumatoid arthritis
Backus = From Backus Hospital
OA = Osteoarthritis
(SS) (BA) (MF) = Individual patients
5 Adj = Adjacent tissue
Match control = adjacent tissues
-M = Male
-F = Female
COPD = Chronic obstructive pulmonary disease

10 Panels 5D and 5I

The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.

In the Gestational Diabetes study subjects are young (18 - 40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample sample (<1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:

	Patient 2	Diabetic Hispanic, overweight, not on insulin
	Patient 7-9	Nondiabetic Caucasian and obese (BMI>30)
	Patient 10	Diabetic Hispanic, overweight, on insulin
30	Patient 11	Nondiabetic African American and overweight
	Patient 12	Diabetic Hispanic on insulin

35 Adipocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al.,

Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr 2 1999: 143-147.

Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:

5 Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose

Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated

Donor 2 and 3 AD: Adipose, Adipose Differentiated

Human cell lines were generally obtained from ATCC (American Type Culture

Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.

10 Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.

15 In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:

20 GO Adipose = Greater Omentum Adipose

SK = Skeletal Muscle

UT = Uterus

PL = Placenta

AD = Adipose Differentiated

AM = Adipose Midway Differentiated

25 U = Undifferentiated Stem Cells

Panel CNSD.01

The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer's disease, Parkinson's disease, Huntington's disease, Progressive Supranuclear Palsy, Depression, and "Normal controls". Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus pallidus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington's disease is characterized in part by neurodegeneration in the globus pallidus, thus this region is impossible to obtain from confirmed Huntington's cases. Likewise Parkinson's disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.

In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:

PSP = Progressive supranuclear palsy
Sub Nigra = Substantia nigra
Glob Palladus= Globus pallidus
Temp Pole = Temporal pole
Cing Gyr = Cingulate gyrus
BA 4 = Brodman Area 4

Panel CNS_Neurodegeneration_V1.0

The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at -80°C in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.

Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer's disease (AD) patients, and eight brains from "Normal controls" who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer's like pathology (Controls) and controls

with no dementia but evidence of severe Alzheimer's like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0 = no evidence of plaques, 3 = severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodmann Area 21), parietal cortex (Brodmann area 7), and occipital cortex (Brodmann area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a "control" region within AD patients. Not all brain regions are represented in all cases.

In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:

AD = Alzheimer's disease brain; patient was demented and showed AD-like pathology upon autopsy

Control = Control brains; patient not demented, showing no neuropathology

Control (Path) = Control brains; patient not demented but showing severe AD-like pathology

Sup Temporal Ctx = Superior Temporal Cortex

Inf Temporal Ctx = Inferior Temporal Cortex

A. NOV1a: Delta serrate ligand receptor (also known as MEGF)

Expression of the NOV1a gene (COR87920446_A) was assessed using the primer-probe set Ag3978, described in Table A1. Results of the RTQ-PCR runs are shown in Tables A2, A3 and A4.

Table A1. Probe Name Ag3978

Primers	Sequences	Length	Start Position	Seq ID No.
Forward	5'-ctggaccgaagctacagctata-3'	22	2605	86
Probe	TET-5'-atggcccaggcccattctacaataaa-3'-TAMRA	26	2636	87
Reverse	5'-cgagctcttcagagatga-3'	21	2666	88

Table A2. CNS neurodegeneration v1.0

Tissue Name	Rel. Exp.(%) Ag3978, Run 206880050	Tissue Name	Rel. Exp.(%) Ag3978, Run 206880050
AD 1 Hippo	21.2	Control (Path) 3 Temporal Ctx	17.9
AD 2 Hippo	43.5	Control (Path) 4 Temporal Ctx	42.9
AD 3 Hippo	7.5	AD 1 Occipital Ctx	22.4

AD 4 Hippo	8.9	AD 2 Occipital Ctx (Missing)	0.0
AD 5 Hippo	20.2	AD 3 Occipital Ctx	6.4
AD 6 Hippo	100.0	AD 4 Occipital Ctx	8.7
Control 2 Hippo	13.6	AD 5 Occipital Ctx	65.1
Control 4 Hippo	8.3	AD 6 Occipital Ctx	40.3
Control (Path) 3 Hippo	10.4	Control 1 Occipital Ctx	6.6
AD 1 Temporal Ctx	21.6	Control 2 Occipital Ctx	20.7
AD 2 Temporal Ctx	26.2	Control 3 Occipital Ctx	18.0
AD 3 Temporal Ctx	0.0	Control 4 Occipital Ctx	4.2
AD 4 Temporal Ctx	9.2	Control (Path) 1 Occipital Ctx	36.1
AD 5 Inf Temporal Ctx	24.5	Control (Path) 2 Occipital Ctx	30.6
AD 5 Sup Temporal Ctx	17.7	Control (Path) 3 Occipital Ctx	16.5
AD 6 Inf Temporal Ctx	84.7	Control (Path) 4 Occipital Ctx	60.7
AD 6 Sup Temporal Ctx	79.6	Control 1 Parietal Ctx	6.7
Control 1 Temporal Ctx	2.5	Control 2 Parietal Ctx	13.7
Control 2 Temporal Ctx	17.9	Control 3 Parietal Ctx	23.2
Control 3 Temporal Ctx	17.8	Control (Path) 1 Parietal Ctx	32.8
Control 3 Temporal Ctx	9.2	Control (Path) 2 Parietal Ctx	41.5
Control (Path) 1 Temporal Ctx	79.6	Control (Path) 3 Parietal Ctx	24.8
Control (Path) 2 Temporal Ctx	23.3	Control (Path) 4 Parietal Ctx	31.0

Table A3. General screening panel v1.4

Tissue Name	Rel. Exp.(%) Ag3978, Run 217525358	Tissue Name	Rel. Exp.(%) Ag3978, Run 217525358
Adipose	3.1	Renal ca. TK-10	5.4
Melanoma* Hs688(A).T	3.9	Bladder	1.2
Melanoma* Hs688(B).T	10.0	Gastric ca. (liver met.) NCI-N87	0.2

Melanoma* M14	0.0	Gastric ca. KATO III	0.3
Melanoma* LOXIMVI	3.2	Colon ca. SW-948	0.4
Melanoma* SK- MEL-5	0.0	Colon ca. SW480	1.1
Squamous cell carcinoma SCC-4	1.1	Colon ca.* (SW480 met) SW620	0.1
Testis Pool	2.4	Colon ca. HT29	0.1
Prostate ca.* (bone met) PC-3	4.8	Colon ca. HCT-116	1.6
Prostate Pool	1.1	Colon ca. CaCo-2	0.3
Placenta	1.8	Colon cancer tissue	2.0
Uterus Pool	1.1	Colon ca. SW1116	0.6
Ovarian ca. OVCAR- 3	0.1	Colon ca. Colo-205	0.0
Ovarian ca. SK-OV-3	92.7	Colon ca. SW-48	0.1
Ovarian ca. OVCAR- 4	0.1	Colon Pool	4.2
Ovarian ca. OVCAR- 5	11.5	Small Intestine Pool	5.6
Ovarian ca. IGROV- 1	0.1	Stomach Pool	92.7
Ovarian ca. OVCAR- 8	0.5	Bone Marrow Pool	1.7
Ovary	1.1	Fetal Heart	1.5
Breast ca. MCF-7	0.1	Heart Pool	1.3
Breast ca. MDA-MB- 231	1.0	Lymph Node Pool	6.5
Breast ca. BT 549	0.0	Fetal Skeletal Muscle	1.8
Breast ca. T47D	21.3	Skeletal Muscle Pool	1.5
Breast ca. MDA-N	0.0	Spleen Pool	2.1
Breast Pool	100.0	Thymus Pool	3.1
Trachea	1.9	CNS cancer (glio/astro) U87-MG	0.1
Lung	0.5	CNS cancer (glio/astro) U-118-MG	0.3
Fetal Lung	4.9	CNS cancer (neuro;met) SK-N-AS	3.8
Lung ca. NCI-N417	91.4	CNS cancer (astro) SF- 539	0.0
Lung ca. LX-1	1.1	CNS cancer (astro)	0.2

		SNB-75	
Lung ca. NCI-H146	0.0	CNS cancer (glio) SNB-19	0.0
Lung ca. SHP-77	0.1	CNS cancer (glio) SF-295	0.0
Lung ca. A549	0.5	Brain (Amygdala) Pool	0.3
Lung ca. NCI-H526	0.0	Brain (cerebellum)	0.3
Lung ca. NCI-H23	0.1	Brain (fetal)	0.8
Lung ca. NCI-H460	88.3	Brain (Hippocampus) Pool	0.6
Lung ca. HOP-62	0.5	Cerebral Cortex Pool	0.5
Lung ca. NCI-H522	0.3	Brain (Substantia nigra) Pool	0.8
Liver	0.3	Brain (Thalamus) Pool	0.5
Fetal Liver	2.9	Brain (whole)	95.9
Liver ca. HepG2	0.0	Spinal Cord Pool	0.6
Kidney Pool	8.0	Adrenal Gland	2.3
Fetal Kidney	2.9	Pituitary gland Pool	0.6
Renal ca. 786-0	0.0	Salivary Gland	0.4
Renal ca. A498	0.5	Thyroid (female)	1.1
Renal ca. ACHN	2.0	Pancreatic ca. CAPAN2	0.8
Renal ca. UO-31	2.2	Pancreas Pool	3.0

Table A4. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3978, Run 170737278	Tissue Name	Rel. Exp.(%) Ag3978, Run 170737278
Secondary Th1 act	0.0	HUVEC IL-1beta	33.4
Secondary Th2 act	0.0	HUVEC IFN gamma	28.1
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	25.9
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	46.7
Secondary Th2 rest	0.0	HUVEC IL-11	23.3
Secondary Tr1 rest	0.0	Lung Microvascular EC none	100.0
Primary Th1 act	0.0	Lung Microvascular EC TNFalpha + IL-1beta	39.0
Primary Th2 act	0.0	Microvascular Dermal EC none	66.9
Primary Tr1 act	0.0	Microvascular Dermal EC TNFalpha + IL-1beta	36.3

Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	7.8
Primary Th2 rest	0.0	Small airway epithelium none	1.5
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	22.7
CD45RA CD4 lymphocyte act	1.2	Coronery artery SMC rest	14.5
CD45RO CD4 lymphocyte act	0.0	Coronery artery SMC TNFalpha + IL-1beta	9.0
CD8 lymphocyte act	0.0	Astrocytes rest	0.9
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	1.4
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	2.3
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	1.6
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	0.3
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	0.0	Liver cirrhosis	0.9
LAK cells IL-2+IL-12	0.0	NCI-H292 none	1.3
LAK cells IL-2+IFN gamma	0.0	NCI-H292 IL-4	3.4
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-9	3.1
LAK cells PMA/ionomycin	0.3	NCI-H292 IL-13	3.4
NK Cells IL-2 rest	0.0	NCI-H292 IFN gamma	2.9
Two Way MLR 3 day	0.0	HPAEC none	49.7
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1 beta	40.9
Two Way MLR 7 day	0.0	Lung fibroblast none	4.8
PBMC rest	0.0	Lung fibroblast TNF alpha + IL-1 beta	2.7
PBMC PWM	0.0	Lung fibroblast IL-4	2.8
PBMC PHA-L	0.0	Lung fibroblast IL-9	7.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	2.0
Ramos (B cell) ionomycin	0.0	Lung fibroblast IFN gamma	2.4
B lymphocytes PWM	0.0	Dermal fibroblast	5.1

B lymphocytes CD40L and IL-4	0.0	CCD1070 rest Dermal fibroblast CCD1070 TNF alpha	0.5
EOL-1 dbcAMP	0.6	Dermal fibroblast CCD1070 IL-1 beta	1.6
EOL-1 dbcAMP PMA/ionomycin	1.1	Dermal fibroblast IFN gamma	0.0
Dendritic cells none	0.3	Dermal fibroblast IL-4	0.0
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.4
Dendritic cells anti-CD40	0.0	Neutrophils TNFa+LPS	0.3
Monocytes rest	0.0	Neutrophils rest	0.6
Monocytes LPS	0.0	Colon	0.2
Macrophages rest	0.3	Lung	4.5
Macrophages LPS	0.0	Thymus	2.1
HUVEC none	42.9	Kidney	2.2
HUVEC starved	56.6		

CNS_neurodegeneration_v1.0 Summary: [Ag3978](#) This panel confirms expression of the COR87920446_A gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.4 for a discussion of the potential utility of this gene in the treatment of central nervous system disorders.

General_screening_panel_v1.4 Summary: [Ag3978](#) Expression of the COR87920446_A gene is highest in samples derived from normal breast, stomach and brain tissues (CTs = 26.6). Thus, the expression of this gene could be used to distinguish these samples from the other samples in the panel. In addition, there is substantial expression of this gene associated with an ovarian cancer cell line and two lung cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of lung cancer or ovarian cancer.

In addition, this gene is expressed at low levels in all CNS regions examined, including amygdala, cerebellum, hippocampus, cerebral cortex, substantia nigra, thalamus and spinal cord (CTs =33-35). Interestingly, COR87920446_A gene expression is significantly higher in adult brain (CT = 26.6) than in fetal brain (CT = 33.5), suggesting that expression of this gene may be

used to distinguish between adult and fetal brain. This gene encodes a protein with homology to the MEGF protein, and may therefore possibly interact with Notch receptors in neurodevelopment. This protein could therefore be of use in directing compensatory synaptogenesis in clinical conditions involving neuronal death such as stroke and head trauma, 5 and neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's diseases.

This gene is also expressed at low to moderate levels in a number of tissues with metabolic or endocrine function, including adipose, adrenal gland, gastrointestinal tract, pancreas, skeletal muscle and thyroid. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as Type II diabetes.

Panel 4.1D Summary: Ag3978 The COR87920446_A gene is expressed at low to moderate levels in endothelial cells (HUVEC, HPAEC) as well as in epithelium (CTs = 30-32). Activation with a variety of cytokines does not significantly change expression. This gene may encode a ligand for Notch; Notch-ligand interactions play an essential role during limb, craniofacial, and thymic development in mice. Multiple ligands that activate Notch and related receptors have been identified, including Serrate and Delta in Drosophila and JAG1 in vertebrates [602570; OMIM]. This family of molecules is also important in fate determination and development. Therefore, therapeutics designed with the protein encoded for by this transcript could be important for wound healing and organogenesis. Such therapeutics could be important in the treatment of emphysema, psoriasis, arthritis, cirrhosis and inflammatory bowel disease, where 20 there is considerable damage due to inflammation or aberrant wound healing.

References:

1. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblangre GA, Kintner CR, Stark KL. Dll4, a novel Notch ligand expressed in arterial endothelium. *Genes Dev* 2000 Jun 1;14(11):1313-8

We report the cloning and characterization of a new member of the Delta family of Notch 25 ligands, which we have named Dll4. Like other Delta genes, Dll4 is predicted to encode a membrane-bound ligand, characterized by an extracellular region containing several EGF-like domains and a DSL domain required for receptor binding. *In situ* analysis reveals a highly selective expression pattern of Dll4 within the vascular endothelium. The activity and expression

of Dll4 and the known actions of other members of this family suggest a role for Dll4 in the control of endothelial cell biology.

PMID: 10837024

B. NOV2: Novel Kinase

5 Expression of the NOV2 gene (COR87940554) was assessed using the primer-probe set Ag3979, described in Table B1. Results of the RTQ-PCR runs are shown in Tables B2, B3, and B4.

Table B1. Probe Name Ag3979

Primers	Sequences	Length	Start Position	Seq ID No.
Forward	5'-gctccttcaagacggtgtatc-3'	21	612	89
Probe	TET-5'-ctagacaccgacaccacagtggaggt-3'-TAMRA	26	638	90
Reverse	5'-ccgctcagctctagacagttt-3'	21	689	91

Table B2. General screening panel v1.4

Tissue Name	Rel. Exp.(%) Ag3979, Run 217534174	Tissue Name	Rel. Exp.(%) Ag3979, Run 217534174
Adipose	1.3	Renal ca. TK-10	14.5
Melanoma* Hs688(A).T	20.7	Bladder	0.6
Melanoma* Hs688(B).T	91.4	Gastric ca. (liver met.) NCI-N87	6.7
Melanoma* M14	8.6	Gastric ca. KATO III	0.3
Melanoma* LOXIMVI	4.2	Colon ca. SW-948	3.4
Melanoma* SK- MEL-5	0.8	Colon ca. SW480	4.5
Squamous cell carcinoma SCC-4	0.5	Colon ca.* (SW480 met) SW620	5.9
Testis Pool	0.8	Colon ca. HT29	24.3
Prostate ca.* (bone met) PC-3	100.0	Colon ca. HCT-116	5.1
Prostate Pool	15.4	Colon ca. CaCo-2	39.8
Placenta	0.0	Colon cancer tissue	24.1
Uterus Pool	0.3	Colon ca. SW1116	0.6
Ovarian ca. OVCAR- 3	0.5	Colon ca. Colo-205	0.2
Ovarian ca. SK-OV-3	0.7	Colon ca. SW-48	15.8
Ovarian ca. OVCAR-	0.5	Colon Pool	0.0

4			
Ovarian ca. OVCAR-5	11.5	Small Intestine Pool	2.9
Ovarian ca. IGROV-1	1.3	Stomach Pool	0.5
Ovarian ca. OVCAR-8	2.4	Bone Marrow Pool	0.6
Ovary	3.2	Fetal Heart	0.5
Breast ca. MCF-7	0.8	Heart Pool	0.1
Breast ca. MDA-MB-231	6.1	Lymph Node Pool	0.3
Breast ca. BT 549	21.8	Fetal Skeletal Muscle	0.0
Breast ca. T47D	16.0	Skeletal Muscle Pool	0.0
Breast ca. MDA-N	0.9	Spleen Pool	0.3
Breast Pool	0.2	Thymus Pool	0.1
Trachea	6.3	CNS cancer (glio/astro) U87-MG	0.3
Lung	1.2	CNS cancer (glio/astro) U-118-MG	0.3
Fetal Lung	2.9	CNS cancer (neuro;met) SK-N-AS	0.1
Lung ca. NCI-N417	0.0	CNS cancer (astro) SF-539	0.0
Lung ca. LX-1	6.9	CNS cancer (astro) SNB-75	1.7
Lung ca. NCI-H146	0.1	CNS cancer (glio) SNB-19	0.7
Lung ca. SHP-77	1.0	CNS cancer (glio) SF-295	11.4
Lung ca. A549	5.4	Brain (Amygdala) Pool	0.3
Lung ca. NCI-H526	0.1	Brain (cerebellum)	1.7
Lung ca. NCI-H23	3.1	Brain (fetal)	2.1
Lung ca. NCI-H460	0.8	Brain (Hippocampus) Pool	1.3
Lung ca. HOP-62	12.8	Cerebral Cortex Pool	0.5
Lung ca. NCI-H522	5.6	Brain (Substantia nigra) Pool	0.2
Liver	0.0	Brain (Thalamus) Pool	0.3
Fetal Liver	52.5	Brain (whole)	1.0
Liver ca. HepG2	28.7	Spinal Cord Pool	0.4
Kidney Pool	0.0	Adrenal Gland	0.2

Fetal Kidney	24.5	Pituitary gland Pool	0.6
Renal ca. 786-0	0.9	Salivary Gland	0.6
Renal ca. A498	1.6	Thyroid (female)	0.0
Renal ca. ACHN	32.1	Pancreatic ca. CAPAN2	1.5
Renal ca. UO-31	20.7	Pancreas Pool	1.6

Table B3. Panel 2.1

Tissue Name	Rel. Exp.(%) Ag3979, Run 170721574	Tissue Name	Rel. Exp.(%) Ag3979, Run 170721574
Normal Colon	9.9	Kidney Cancer 9010320	0.0
Colon cancer (OD06064)	0.2	Kidney margin 9010321	44.4
Colon cancer margin (OD06064)	2.6	Kidney Cancer 8120607	1.5
Colon cancer (OD06159)	3.5	Kidney margin 8120608	8.7
Colon cancer margin (OD06159)	2.4	Normal Uterus	0.0
Colon cancer (OD06298- 08)	30.8	Uterus Cancer	0.6
Colon cancer margin (OD06298-018)	12.7	Normal Thyroid	0.0
Colon Cancer Gr.2 ascend colon (ODO3921)	4.7	Thyroid Cancer	0.0
Colon Cancer margin (ODO3921)	4.1	Thyroid Cancer A302152	0.0
Colon cancer metastasis (OD06104)	0.8	Thyroid margin A302153	0.0
Lung margin (OD06104)	1.2	Normal Breast	3.2
Colon mets to lung (OD04451-01)	9.5	Breast Cancer	3.4
Lung margin (OD04451- 02)	0.0	Breast Cancer	2.9
Normal Prostate	9.3	Breast Cancer (OD04590-01)	1.3
Prostate Cancer (OD04410)	6.4	Breast Cancer Mets (OD04590-03)	2.3
Prostate margin (OD04410)	9.0	Breast Cancer Metastasis	100.0
Normal Lung	0.2	Breast Cancer	0.0
Invasive poor diff. lung	0.3	Breast Cancer	2.8

adeno 1 (ODO4945-01)		9100266		
Lung margin (ODO4945-03)	0.0	Breast margin 9100265		2.9
Lung Malignant Cancer (OD03126)	2.8	Breast Cancer A209073		0.5
Lung margin (OD03126)	0.6	Breast margin A2090734		3.5
Lung Cancer (OD05014A)	0.0	Normal Liver		0.0
Lung margin (OD05014B)	0.0	Liver Cancer 1026		2.6
Lung Cancer (OD04237-01)	0.0	Liver Cancer 1025		0.3
Lung margin (OD04237-02)	0.0	Liver Cancer 6004-T		0.6
Ocular Mel Met to Liver (ODO4310)	3.9	Liver Tissue 6004-N		1.4
Liver margin (ODO4310)	0.0	Liver Cancer 6005-T		4.4
Melanoma Mets to Lung (OD04321)	13.9	Liver Tissue 6005-N		0.0
Lung margin (OD04321)	0.0	Liver Cancer		1.7
Normal Kidney	19.9	Normal Bladder		0.0
Kidney Ca, Nuclear grade 2 (OD04338)	76.8	Bladder Cancer		6.7
Kidney margin (OD04338)	1.5	Bladder Cancer		0.0
Kidney Ca Nuclear grade 1/2 (OD04339)	0.7	Normal Ovary		1.8
Kidney margin (OD04339)	19.1	Ovarian Cancer		0.0
Kidney Ca, Clear cell type (OD04340)	0.0	Ovarian cancer (OD06145)		0.0
Kidney margin (OD04340)	15.4	Ovarian cancer margin (OD06145)		0.0
Kidney Ca, Nuclear grade 3 (OD04348)	0.0	Normal Stomach		1.8
Kidney margin (OD04348)	20.7	Gastric Cancer 9060397		2.5
Kidney Cancer (OD04450-01)	1.4	Stomach margin 9060396		1.2
Kidney margin (OD04450-03)	42.9	Gastric Cancer 9060395		1.0
Kidney Cancer 8120613	0.0	Stomach margin 9060394		2.2
Kidney margin 8120614	9.9	Gastric Cancer		1.0

Table B4. Panel 4.1D

Tissue Name	Rel. Exp.(%) Ag3979, Run 170721251	Tissue Name	Rel. Exp.(%) Ag3979, Run 170721251
Secondary Th1 act	0.0	HUVEC IL-1beta	1.2
Secondary Th2 act	0.0	HUVEC IFN gamma	1.8
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.2
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.3
Secondary Th2 rest	0.0	HUVEC IL-11	0.9
Secondary Tr1 rest	0.0	Lung Microvascular EC none	100.0
Primary Th1 act	0.1	Lung Microvascular EC TNFalpha + IL-1beta	58.2
Primary Th2 act	0.0	Microvascular Dermal EC none	72.2
Primary Tr1 act	0.0	Microvasular Dermal EC TNFalpha + IL-1beta	48.0
Primary Th1 rest	0.0	Bronchial epithelium TNFalpha + IL1beta	3.4
Primary Th2 rest	0.0	Small airway epithelium none	0.0
Primary Tr1 rest	0.0	Small airway epithelium TNFalpha + IL-1beta	0.7
CD45RA CD4 lymphocyte act	5.2	Coronery artery SMC rest	39.5
CD45RO CD4 lymphocyte act	0.0	Coronery artery SMC TNFalpha + IL-1beta	40.6
CD8 lymphocyte act	0.0	Astrocytes rest	12.1
Secondary CD8 lymphocyte rest	0.0	Astrocytes TNFalpha + IL-1beta	27.5
Secondary CD8 lymphocyte act	0.0	KU-812 (Basophil) rest	0.0
CD4 lymphocyte none	0.0	KU-812 (Basophil) PMA/ionomycin	0.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.0	CCD1106 (Keratinocytes) none	1.7
LAK cells rest	0.0	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	1.3
LAK cells IL-2	0.0	Liver cirrhosis	0.6

LAK cells IL-2+IL-12	0.0	NCI-H292 none	0.5
LAK cells IL-2+IFN gamma	0.0	NCI-H292 IL-4	0.8
LAK cells IL-2+ IL-18	0.0	NCI-H292 IL-9	1.2
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-13	0.3
NK Cells IL-2 rest	0.0	NCI-H292 IFN gamma	0.6
Two Way MLR 3 day	0.0	HPAEC none	3.4
Two Way MLR 5 day	0.0	HPAEC TNF alpha + IL-1 beta	7.5
Two Way MLR 7 day	0.2	Lung fibroblast none	0.3
PBMC rest	0.0	Lung fibroblast TNF alpha + IL-1 beta	0.1
PBMC PWM	0.0	Lung fibroblast IL-4	0.0
PBMC PHA-L	0.0	Lung fibroblast IL-9	0.0
Ramos (B cell) none	0.0	Lung fibroblast IL-13	0.6
Ramos (B cell) ionomycin	0.4	Lung fibroblast IFN gamma	0.9
B lymphocytes PWM	0.0	Dermal fibroblast CCD1070 rest	14.3
B lymphocytes CD40L and IL-4	0.0	Dermal fibroblast CCD1070 TNF alpha	9.9
EOL-1 dbcAMP	0.9	Dermal fibroblast CCD1070 IL-1 beta	11.2
EOL-1 dbcAMP PMA/ionomycin	1.8	Dermal fibroblast IFN gamma	0.9
Dendritic cells none	0.0	Dermal fibroblast IL-4	0.2
Dendritic cells LPS	0.0	Dermal Fibroblasts rest	0.0
Dendritic cells anti-CD40	0.3	Neutrophils TNFa+LPS	0.3
Monocytes rest	0.0	Neutrophils rest	0.3
Monocytes LPS	0.0	Colon	2.0
Macrophages rest	0.0	Lung	0.0
Macrophages LPS	0.0	Thymus	4.5
HUVEC none	3.5	Kidney	29.1
HUVEC starved	1.5		

CNS_neurodegeneration_v1.0 Summary: Ag3979 Expression of the COR87940554 gene is low/undetectable (CTs > 35) across all of the samples on this panel (data not shown).

General_screening_panel_v1.4 Summary: Ag3979 Expression of the COR87940554 gene is highest in prostate cancer cell line PC-3 and a melanoma cell line (CT = 28). Thus, the expression of this gene could be used to distinguish these cells from the other samples in the panel. In addition, there is substantial expression of this gene associated with kidney cancer cell lines and colon cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be of benefit in the treatment of kidney cancer, prostate cancer, colon cancer or melanoma. Finally, expression of this gene is much higher in fetal liver (CT = 29) than adult liver (CT = 40), as well as in fetal kidney (CT = 30) than adult kidney (CT = 40). This observation suggests that expression of this gene may be used to distinguish fetal from adult liver or kidney.

This gene encodes a protein with homology to kinases and is expressed at very low levels in the fetal brain, hippocampus, and cerebellum. This gene is predominantly expressed in fetal tissues and in cancer cell lines, suggesting that it plays a role in cell division or differentiation. Thus, this gene may therefore be of use in regulation of the cell cycle in stem cell research or therapy.

Panel 2.1 Summary: Ag3979 Expression of the COR87940554 gene is highest in a sample derived from a metastatic breast cancer (CT = 30.9). Thus, the expression of this gene could be used to distinguish this metastatic breast cancer specimen from other samples in the panel. In addition, there appears to be substantial expression of this gene associated with a number of normal kidney tissue samples adjacent to malignant kidney. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be of benefit in the treatment of breast and kidney cancer.

Panel 4.1D Summary: Ag3979 Expression of this gene is highest in lung microvascular endothelial cells (CT = 29.7). The COR87940554 gene is also expressed in fibroblasts, 25 endothelium, and smooth muscle cells. This gene encodes a putative protein kinase that localizes to the nucleus based on PSORT analysis. The protein encoded for by this transcript may be important in the normal function of the fibroblasts, endothelial cells and smooth muscle cells. Therefore, therapies designed with the protein encoded for by this transcript could be used to regulate fibroblast, endothelium and smooth muscle cell function and may be important in the 30 treatment of asthma, emphysema, arthritis, and inflammatory bowel disease.

C. NOV8a and NOV8b: GPCR

Expression of the NOV8a gene (CG56663-01) and its variant NOV8b (CG56663-02) was assessed using the primer-probe set Ag2971, described in Table C1. Results of the RTQ-PCR runs are shown in Tables C2, C3 and C4. NOV8b represents a full-length physical clone of the NOV8a gene, validating the prediction of the gene sequence.

5

Table C1. Probe Name Ag2971

Primers	Sequences	Length	Start Position	Seq ID No.
Forward	5'-gtaaaggcatctccacctgact-3'	22	947	92
Probe	TET-5'-tcacttccatccagggccactgg-3'-TAMRA	23	969	93
Reverse	5'-gggctaatacagctggaaattc-3'	22	1009	94

Table C2. CNS neurodegeneration v1.0

Tissue Name	Rel. Exp.(%) Ag2971, Run 209778983	Tissue Name	Rel. Exp.(%) Ag2971, Run 209778983
AD 1 Hippo	6.5	Control (Path) 3 Temporal Ctx	1.2
AD 2 Hippo	31.6	Control (Path) 4 Temporal Ctx	51.4
AD 3 Hippo	1.8	AD 1 Occipital Ctx	14.9
AD 4 Hippo	15.1	AD 2 Occipital Ctx (Missing)	0.0
AD 5 hippo	52.9	AD 3 Occipital Ctx	0.8
AD 6 Hippo	19.6	AD 4 Occipital Ctx	20.9
Control 2 Hippo	18.9	AD 5 Occipital Ctx	11.9
Control 4 Hippo	3.9	AD 6 Occipital Ctx	26.1
Control (Path) 3 Hippo	3.8	Control 1 Occipital Ctx	2.8
AD 1 Temporal Ctx	9.5	Control 2 Occipital Ctx	46.3
AD 2 Temporal Ctx	22.1	Control 3 Occipital Ctx	13.2
AD 3 Temporal Ctx	3.1	Control 4 Occipital Ctx	4.4
AD 4 Temporal Ctx	28.5	Control (Path) 1 Occipital Ctx	100.0
AD 5 Inf Temporal Ctx	82.4	Control (Path) 2 Occipital Ctx	7.3
AD 5 SupTemporal Ctx	46.0	Control (Path) 3 Occipital Ctx	5.5
AD 6 Inf Temporal Ctx	30.4	Control (Path) 4 Occipital Ctx	23.3

AD 6 Sup Temporal Ctx	28.3	Control 1 Parietal Ctx	8.4
Control 1 Temporal Ctx	3.6	Control 2 Parietal Ctx	25.3
Control 2 Temporal Ctx	33.7	Control 3 Parietal Ctx	22.2
Control 3 Temporal Ctx	32.3	Control (Path) 1 Parietal Ctx	81.8
Control 4 Temporal Ctx	7.1	Control (Path) 2 Parietal Ctx	9.2
Control (Path) 1 Temporal Ctx	80.7	Control (Path) 3 Parietal Ctx	3.2
Control (Path) 2 Temporal Ctx	10.5	Control (Path) 4 Parietal Ctx	80.7

Table C3. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag2971, Run 166219829	Tissue Name	Rel. Exp.(%) Ag2971, Run 166219829
Liver adenocarcinoma	4.2	Kidney (fetal)	1.0
Pancreas	0.0	Renal ca. 786-0	0.0
Pancreatic ca. CAPAN 2	0.0	Renal ca. A498	0.0
Adrenal gland	0.0	Renal ca. RXF 393	0.0
Thyroid	3.4	Renal ca. ACHN	0.0
Salivary gland	0.0	Renal ca. UO-31	0.0
Pituitary gland	4.3	Renal ca. TK-10	0.0
Brain (fetal)	33.4	Liver	0.0
Brain (whole)	45.7	Liver (fetal)	21.0
Brain (amygdala)	18.2	Liver ca. (hepatoblast) HepG2	1.9
Brain (cerebellum)	1.5	Lung	0.0
Brain (hippocampus)	7.5	Lung (fetal)	1.1
Brain (substantia nigra)	17.8	Lung ca. (small cell) LX-1	0.0
Brain (thalamus)	14.9	Lung ca. (small cell) NCI-H69	0.0
Cerebral Cortex	22.1	Lung ca. (s.cell var.) SHP-77	0.0
Spinal cord	4.9	Lung ca. (large cell) NCI-H460	0.0
glio/astro U87-MG	0.0	Lung ca. (non-sm. cell) A549	0.0

glio/astro U-118-MG	0.0	Lung ca. (non-s.cell) NCI-H23	0.0
astrocytoma SW1783	0.0	Lung ca. (non-s.cell) HOP-62	3.9
neuro*; met SK-N-AS	0.9	Lung ca. (non-s.cl) NCI-H522	0.0
astrocytoma SF-539	0.0	Lung ca. (squam.) SW 900	0.0
astrocytoma SNB-75	0.0	Lung ca. (squam.) NCI-H596	0.0
glioma SNB-19	0.0	Mammary gland	5.9
glioma U251	0.0	Breast ca.* (pl.ef) MCF-7	0.0
glioma SF-295	0.0	Breast ca.* (pl.ef) MDA-MB-231	0.0
Heart (fetal)	15.1	Breast ca.* (pl.ef) T47D	0.0
Heart	0.0	Breast ca. BT-549	0.0
Skeletal muscle (fetal)	3.3	Breast ca. MDA-N	0.0
Skeletal muscle	0.8	Ovary	0.5
Bone marrow	100.0	Ovarian ca. OVCAR-3	0.0
Thymus	0.0	Ovarian ca. OVCAR-4	0.0
Spleen	2.0	Ovarian ca. OVCAR-5	0.0
Lymph node	0.0	Ovarian ca. OVCAR-8	7.3
Colorectal	4.2	Ovarian ca. IGROV-1	0.0
Stomach	0.0	Ovarian ca.* (ascites) SK-OV-3	57.0
Small intestine	1.1	Uterus	0.9
Colon ca. SW480	0.9	Placenta	27.9
Colon ca.* SW620(SW480 met)	0.0	Prostate	0.0
Colon ca. HT29	0.0	Prostate ca.* (bone met)PC-3	4.5
Colon ca. HCT-116	0.0	Testis	12.8
Colon ca. CaCo-2	0.0	Melanoma Hs688(A).T	0.0
Colon ca.	0.0	Melanoma* (met)	0.0

tissue(ODO3866)		Hs688(B).T	
Colon ca. HCC-2998	0.0	Melanoma UACC-62	9.0
Gastric ca.* (liver met)	0.0	Melanoma M14	1.1
NCI-N87			
Bladder	0.0	Melanoma LOX IMVI	0.0
Trachea	0.0	Melanoma* (met) SK-MEL-5	0.0
Kidney	0.0	Adipose	2.5

Table C4. Panel 4D

Tissue Name	Rel. Exp.(%) Ag2971, Run 164403109	Tissue Name	Rel. Exp.(%) Ag2971, Run 164403109
Secondary Th1 act	0.6	HUVEC IL-1beta	0.0
Secondary Th2 act	0.4	HUVEC IFN gamma	0.7
Secondary Tr1 act	0.0	HUVEC TNF alpha + IFN gamma	0.0
Secondary Th1 rest	0.0	HUVEC TNF alpha + IL4	0.0
Secondary Th2 rest	0.0	HUVEC IL-11	0.0
Secondary Tr1 rest	0.0	Lung Microvascular EC none	0.0
Primary Th1 act	0.3	Lung Microvascular EC TNFalpha + IL-1beta	0.0
Primary Th2 act	0.0	Microvascular Dermal EC none	0.0
Primary Tr1 act	0.0	Microvasular Dermal EC TNFalpha + IL-1beta	0.0
Primary Th1 rest	1.5	Bronchial epithelium TNFalpha + IL1beta	0.0
Primary Th2 rest	2.2	Small airway epithelium none	0.0
Primary Tr1 rest	0.4	Small airway epithelium TNFalpha + IL-1beta	0.0
CD45RA CD4 lymphocyte act	0.0	Coronery artery SMC rest	3.1
CD45RO CD4 lymphocyte act	0.8	Coronery artery SMC TNFalpha + IL-1beta	0.5
CD8 lymphocyte act	0.0	Astrocytes rest	0.0
Secondary CD8 lymphocyte rest	0.4	Astrocytes TNFalpha + IL- 1beta	0.0
Secondary CD8	0.0	KU-812 (Basophil) rest	47.0

lymphocyte act			
CD4 lymphocyte none	0.1	KU-812 (Basophil) PMA/ionomycin	100.0
2ry Th1/Th2/Tr1_anti-CD95 CH11	0.1	CCD1106 (Keratinocytes) none	0.0
LAK cells rest	0.2	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	0.0
LAK cells IL-2	1.1	Liver cirrhosis	2.3
LAK cells IL-2+IL-12	1.4	Lupus kidney	0.0
LAK cells IL-2+IFN gamma	0.5	NCI-H292 none	0.0
LAK cells IL-2+ IL-18	0.6	NCI-H292 IL-4	0.0
LAK cells PMA/ionomycin	0.0	NCI-H292 IL-9	0.0
NK Cells IL-2 rest	0.5	NCI-H292 IL-13	0.0
Two Way MLR 3 day	0.2	NCI-H292 IFN gamma	0.0
Two Way MLR 5 day	0.0	HPAEC none	0.0
Two Way MLR 7 day	0.0	HPAEC TNF alpha + IL-1 beta	0.0
PBMC rest	0.6	Lung fibroblast none	0.3
PBMC PWM	1.4	Lung fibroblast TNF alpha + IL-1 beta	0.2
PBMC PHA-L	1.1	Lung fibroblast IL-4	0.2
Ramos (B cell) none	0.0	Lung fibroblast IL-9	0.8
Ramos (B cell) ionomycin	0.0	Lung fibroblast IL-13	0.0
B lymphocytes PWM	0.8	Lung fibroblast IFN gamma	0.2
B lymphocytes CD40L and IL-4	1.1	Dermal fibroblast CCD1070 rest	0.0
EOL-1 dbcAMP	1.1	Dermal fibroblast CCD1070 TNF alpha	4.5
EOL-1 dbcAMP PMA/ionomycin	0.0	Dermal fibroblast CCD1070 IL-1 beta	0.0
Dendritic cells none	0.0	Dermal fibroblast IFN gamma	0.0
Dendritic cells LPS	0.0	Dermal fibroblast IL-4	0.0
Dendritic cells anti-CD40	0.3	IBD Colitis 2	0.2
Monocytes rest	2.5	IBD Crohn's	0.0
Monocytes LPS	0.2	Colon	0.9
Macrophages rest	0.2	Lung	0.3

Macrophages LPS	0.2	Thymus	0.9
HUVEC none	0.0	Kidney	2.0
HUVEC starved	0.0		

CNS_neurodegeneration_v1.0 Summary: Ag2971 This panel confirms the expression of the CG56663-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.3D for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

Panel 1.3D Summary: Ag2971 Expression of the CG56663-01 gene is highest in bone marrow (CT = 31.6). Interestingly, expression of this gene is significantly higher in fetal heart (CT = 34.3) than adult heart (CT = 40) as well as in fetal liver (CT = 33.8) than adult liver (CT = 40). This observation suggests that expression of this gene may be used to distinguish fetal from adult heart and liver.

This gene is also expressed at low levels in several regions of the CNS examined, including amygdala, substantia nigra, thalamus and cerebral cortex. This gene encodes a novel G-protein coupled receptor (GPCR). The GPCR family of receptors contains a large number of neurotransmitter receptors, including the dopamine, serotonin, α and β -adrenergic, acetylcholine muscarinic, histamine, peptide, and metabotropic glutamate receptors. GPCRs are excellent drug targets in various neurologic and psychiatric diseases. All antipsychotics have been shown to act at the dopamine D2 receptor; similarly novel antipsychotics also act at the serotonergic receptor, and often the muscarinic and adrenergic receptors as well. While the majority of antidepressants can be classified as selective serotonin reuptake inhibitors, blockade of the 5-HT1A and α 2 adrenergic receptors increases the effects of these drugs. The GPCRs are also of use as drug targets in the treatment of stroke. Blockade of the glutamate receptors may decrease the neuronal death resulting from excitotoxicity; further more the purinergic receptors have also been implicated as drug targets in the treatment of cerebral ischemia. The α -adrenergic receptors have been implicated in the treatment of ADHD with Ritalin, while the β -adrenergic receptors have been implicated in memory. Therefore, this gene may be of use as a small molecule target for the treatment of any of the described diseases.

References:

1. El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeois JM. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. *Br J Pharmacol* 2001 Sep;134(1):68-77

5 1. Adenosine, an ubiquitous neuromodulator, and its analogues have been shown to produce 'depressant' effects in animal models believed to be relevant to depressive disorders, while adenosine receptor antagonists have been found to reverse adenosine-mediated 'depressant' effect. 2. We have designed studies to assess whether adenosine A2A receptor antagonists, or genetic inactivation of the receptor would be effective in established screening procedures, such as tail suspension and forced swim tests, which are predictive of clinical antidepressant activity. 3. Adenosine A2A receptor knockout mice were found to be less sensitive to 'depressant' challenges than their wildtype littermates. Consistently, the adenosine A2A receptor blockers SCH 58261 (1 - 10 mg kg(-1), i.p.) and KW 6002 (0.1 - 10 mg kg(-1), p.o.) reduced the total immobility time in the tail suspension test. 4. The efficacy of adenosine A2A receptor antagonists in reducing immobility time in the tail suspension test was confirmed and extended in two groups of mice. Specifically, SCH 58261 (1 - 10 mg kg(-1)) and ZM 241385 (15 - 60 mg kg(-1)) were effective in mice previously screened for having high immobility time, while SCH 58261 at 10 mg kg(-1) reduced immobility of mice that were selectively bred for their spontaneous 'helplessness' in this assay. 5. Additional experiments were carried out using the forced swim test. SCH 58261 at 10 mg kg(-1) reduced the immobility time by 61%, while KW 6002 decreased the total immobility time at the doses of 1 and 10 mg kg(-1) by 75 and 79%, respectively. 6. Administration of the dopamine D2 receptor antagonist haloperidol (50 - 200 microg kg(-1) i.p.) prevented the antidepressant-like effects elicited by SCH 58261 (10 mg kg(-1) i.p.) in forced swim test whereas it left unaltered its stimulant motor effects. 7. In conclusion, these data support the hypothesis that 20 A2A receptor antagonists prolong escape-directed behaviour in two screening tests for antidepressants. Altogether the results support the hypothesis that blockade of the adenosine A2A receptor might be an interesting target for the development of effective antidepressant agents.

25 2. Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. *Clin Psychiatry* 2001;62 Suppl 15:12-7

Although selective serotonin reuptake inhibitors (SSRIs) block serotonin (5-HT) reuptake rapidly, their therapeutic action is delayed. The increase in synaptic 5-HT activates feedback mechanisms mediated by 5-HT1A (cell body) and 5-HT1B (terminal) autoreceptors, which, respectively, reduce the firing in 5-HT neurons and decrease the amount of 5-HT released per action potential resulting in attenuated 5-HT neurotransmission. Long-term treatment desensitizes the inhibitory 5-HT1 autoreceptors, and 5-HT neurotransmission is enhanced. The time course of these events is similar to the delay of clinical action. The addition of pindolol, which blocks 5-HT1A receptors, to SSRI treatment decouples the feedback inhibition of 5-HT neuron firing and accelerates and enhances the antidepressant response. The neuronal circuitry of the 5-HT and norepinephrine (NE) systems and their connections to forebrain areas believed to be involved in depression has been dissected. The firing of 5-HT neurons in the raphe nuclei is driven, at least partly, by alpha1-adrenoceptor-mediated excitatory inputs from NE neurons. Inhibitory alpha2-adrenoceptors on the NE neuroterminals form part of a feedback control mechanism. Mirtazapine, an antagonist at alpha2-adrenoceptors, does not enhance 5-HT neurotransmission directly but disinhibits the NE activation of 5-HT neurons and thereby increases 5-HT neurotransmission by a mechanism that does not require a time-dependent desensitization of receptors. These neurobiological phenomena may underlie the apparently faster onset of action of mirtazapine compared with the SSRIs.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

3. Tranquillini ME, Reggiani A. Glycine-site antagonists and stroke. *Expert Opin Investig Drugs* 1999 Nov;8(11):1837-1848

The excitatory amino acid, (S)-glutamic acid, plays an important role in controlling many neuronal processes. Its action is mediated by two main groups of receptors: the ionotropic receptors (which include NMDA, AMPA and kainic acid subtypes) and the metabotropic receptors (mGluR(1-8)) mediating G-protein coupled responses. This review focuses on the strychnine insensitive glycine binding site located on the NMDA receptor channel, and on the possible use of selective antagonists for the treatment of stroke. Stroke is a devastating disease caused by a sudden vascular accident. Neurochemically, a massive release of glutamate occurs in neuronal tissue; this overactivates the NMDA receptor, leading to increased intracellular calcium influx, which causes neuronal cell death through necrosis. NMDA receptor activation strongly depends upon the presence of glycine as a co-agonist. Therefore, the administration of a glycine antagonist can block overactivation of NMDA receptors, thus preserving neurones from damage.

The glycine antagonists currently identified can be divided into five main categories depending on their chemical structure: indoles, tetrahydroquinolines, benzoazepines, quinoxalinediones and pyrida-zinoquinolines.

4. Monopoli A, Lozza G, Forlani A, Mattavelli A, Ongini E. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 1998 Dec 1;9(17):3955-9

Blockade of adenosine receptors can reduce cerebral infarct size in the model of global ischaemia. Using the potent and selective A2A adenosine receptor antagonist, SCH 58261, we assessed whether A2A receptors are involved in the neuronal damage following focal cerebral ischaemia as induced by occluding the left middle cerebral artery. SCH 58261 (0.01 mg/kg either i.p. or i.v.) administered to normotensive rats 10 min after ischaemia markedly reduced cortical infarct volume as measured 24 h later (30% vs controls, $p < 0.05$). Similar effects were observed when SCH 58261 (0.01 mg/kg, i.p.) was administered to hypertensive rats (28% infarct volume reduction vs controls, $p < 0.05$). Neuroprotective properties of SCH 58261 administered after ischaemia indicate that blockade of A2A adenosine receptors is a potentially useful biological target for the reduction of brain injury.

Panel 4D Summary: Ag2971 The CG56663-01 gene is expressed exclusively in the basophil cell line KU-812, irrespective of treatment with PMA and ionomycin. Thus, expression of this gene may be used to distinguish basophils from the other samples on this panel. This gene encodes a putative GPCR and it is known that GPCR-type receptors are important in multiple physiological responses mediated by basophils (ref. 1). Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene could block or inhibit inflammation or tissue damage due to basophil activation in response to asthma, allergies, hypersensitivity reactions, psoriasis, and viral infections.

25 Reference:

1. Heinemann A., Hartnell A., Stubbs V.E., Murakami K., Soler D., LaRosa G., Askenase P.W., Williams T.J., Sabroe I. (2000) Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling. *J. Immunol.* 165: 7224-7233.

To investigate human basophil responses to chemokines, we have developed a sensitive assay that uses flow cytometry to measure leukocyte shape change as a marker of cell responsiveness. PBMC were isolated from the blood of volunteers. Basophils were identified as a single population of cells that stained positive for IL-3Ralpha (CDw123) and negative for HLA-DR, and their increase in forward scatter (as a result of cell shape change) in response to chemokines was measured. Shape change responses of basophils to chemokines were highly reproducible, with a rank order of potency: monocyte chemoattractant protein (MCP) 4 (peak at /=
5 eotaxin-2 = eotaxin-3 >= eotaxin > MCP-1 = MCP-3 > macrophage-inflammatory protein-1alpha > RANTES = MCP-2 = IL-8. The CCR4-selective ligand macrophage-derived chemokine did not elicit a response at concentrations up to 10 nM. Blocking mAbs to CCR2 and CCR3 demonstrated that responses to higher concentrations (>10 nM) of MCP-1 were mediated by CCR3 rather than CCR2, whereas MCP-4 exhibited a biphasic response consistent with sequential activation of CCR3 at lower concentrations and CCR2 at 10 nM MCP-4 and above. In contrast, responses to MCP-3 were blocked only in the presence of both mAbs, but not after pretreatment with either anti-CCR2 or anti-CCR3 mAb alone. These patterns of receptor usage were different from those seen for eosinophils and monocytes. We suggest that cooperation between CCRs might be a mechanism for preferential recruitment of basophils, as occurs in tissue hypersensitivity responses in vivo.

PMID: 11120855

20 **D. NOV9: Dual Specificity Phosphatase**

Expression of the NOV9 gene (CG56787-01) was assessed using the primer-probe set Ag3021, described in Table D1. Results of the RTQ-PCR runs are shown in Tables D2, D3 and D4.

25 **Table D1. Probe Name Ag3021**

Primers	Sequences	Length	Start Position	Seq ID No.
Forward	5'-aattgttggcaagaacactgt-3'	22	512	95
Probe	TET-5'-ccagtggaaatgatccctgacatcta-3'-TAMRA	26	550	96
Reverse	5'-atcatcaaacggacttccttct-3'	22	578	97

Table D2. CNS neurodegeneration v1.0

Tissue Name	Rel. Exp.(%) Ag3021, Run 209821073	Tissue Name	Rel. Exp.(%) Ag3021, Run 209821073
AD 1 Hippo	3.3	Control (Path) 3	1.0

		Temporal Ctx	
AD 2 Hippo	5.8	Control (Path) 4	5.5
AD 3 Hippo	2.7	Temporal Ctx	
AD 4 Hippo	1.2	AD 1 Occipital Ctx	3.0
AD 5 Hippo	12.6	AD 2 Occipital Ctx (Missing)	0.0
AD 6 Hippo	10.3	AD 3 Occipital Ctx	2.5
Control 2 Hippo	3.3	AD 4 Occipital Ctx	100.0
Control 4 Hippo	3.9	AD 5 Occipital Ctx	4.2
Control (Path) 3 Hippo	2.7	AD 6 Occipital Ctx	5.3
AD 1 Temporal Ctx	4.3	Control 1 Occipital Ctx	1.4
AD 2 Temporal Ctx	5.1	Control 2 Occipital Ctx	5.0
AD 3 Temporal Ctx	1.8	Control 3 Occipital Ctx	2.7
AD 4 Temporal Ctx	4.2	Control 4 Occipital Ctx	3.0
AD 5 Inf Temporal Ctx	18.8	Control (Path) 1 Occipital Ctx	13.4
AD 5 Sup Temporal Ctx	13.3	Control (Path) 2 Occipital Ctx	1.6
AD 6 Inf Temporal Ctx	13.0	Control (Path) 3 Occipital Ctx	1.1
AD 6 Sup Temporal Ctx	12.2	Control (Path) 4 Occipital Ctx	3.0
Control 1 Temporal Ctx	1.4	Control 1 Parietal Ctx	1.5
Control 2 Temporal Ctx	3.1	Control 2 Parietal Ctx	8.2
Control 3 Temporal Ctx	2.2	Control 3 Parietal Ctx	2.9
Control 3 Temporal Ctx	0.2	Control (Path) 1 Parietal Ctx	9.1
Control (Path) 1 Temporal Ctx	10.7	Control (Path) 2 Parietal Ctx	5.9
Control (Path) 2 Temporal Ctx	4.5	Control (Path) 3 Parietal Ctx	0.6
		Control (Path) 4 Parietal Ctx	6.8

Table D3. Panel 1.3D

Tissue Name	Rel. Exp.(%) Ag3021, Run 167966916	Tissue Name	Rel. Exp.(%) Ag3021, Run 167966916
Liver adenocarcinoma	14.2	Kidney (fetal)	24.3
Pancreas	4.4	Renal ca. 786-0	15.0
Pancreatic ca. CAPAN 2	6.0	Renal ca. A498	10.0
Adrenal gland	2.6	Renal ca. RXF 393	15.2
Thyroid	5.7	Renal ca. ACHN	2.8
Salivary gland	3.4	Renal ca. UO-31	10.2
Pituitary gland	15.7	Renal ca. TK-10	13.5
Brain (fetal)	60.7	Liver	2.1
Brain (whole)	11.5	Liver (fetal)	0.7
Brain (amygdala)	11.9	Liver ca. (hepatoblast) HepG2	2.5
Brain (cerebellum)	5.8	Lung	10.7
Brain (hippocampus)	10.0	Lung (fetal)	19.1
Brain (substantia nigra)	22.1	Lung ca. (small cell) LX-1	21.8
Brain (thalamus)	10.9	Lung ca. (small cell) NCI-H69	20.2
Cerebral Cortex	10.7	Lung ca. (s.cell var.) SHP-77	31.6
Spinal cord	11.5	Lung ca. (large cell)NCI-H460	1.8
glio/astro U87-MG	26.8	Lung ca. (non-sm. cell) A549	20.0
glio/astro U-118-MG	23.5	Lung ca. (non-s.cell) NCI-H23	16.0
astrocytoma SW1783	24.0	Lung ca. (non-s.cell) HOP-62	9.3
neuro*; met SK-N-AS	9.7	Lung ca. (non-s.cl) NCI-H522	12.0
astrocytoma SF-539	9.5	Lung ca. (squam.) SW 900	17.6
astrocytoma SNB-75	20.4	Lung ca. (squam.) NCI-H596	24.3
glioma SNB-19	6.5	Mammary gland	11.0
glioma U251	16.2	Breast ca.* (pl.ef) MCF-7	16.6
glioma SF-295	29.9	Breast ca.* (pl.ef) MDA-MB-231	8.7

Heart (fetal)	6.6	Breast ca.* (pl.ef) T47D	40.1
Heart	6.1	Breast ca. BT-549	7.0
Skeletal muscle (fetal)	4.6	Breast ca. MDA-N	0.9
Skeletal muscle	4.0	Ovary	9.5
Bone marrow	6.4	Ovarian ca. OVCAR-3	8.4
Thymus	17.2	Ovarian ca. OVCAR-4	7.3
Spleen	6.6	Ovarian ca. OVCAR-5	100.0
Lymph node	17.1	Ovarian ca. OVCAR-8	5.9
Colorectal	20.7	Ovarian ca. IGROV-1	4.3
Stomach	6.7	Ovarian ca.* (ascites) SK-OV-3	47.3
Small intestine	5.5	Uterus	8.1
Colon ca. SW480	5.3	Placenta	0.0
Colon ca.* SW620(SW480 met)	27.7	Prostate	1.6
Colon ca. HT29	12.5	Prostate ca.* (bone met)PC-3	9.8
Colon ca. HCT-116	12.1	Testis	14.2
Colon ca. CaCo-2	20.4	Melanoma Hs688(A).T	3.8
Colon ca. tissue(ODO3866)	18.3	Melanoma* (met) Hs688(B).T	2.7
Colon ca. HCC-2998	19.8	Melanoma UACC-62	11.5
Gastric ca.* (liver met) NCI-N87	44.4	Melanoma M14	3.5
Bladder	10.9	Melanoma LOX IMVI	9.7
Trachea	12.4	Melanoma* (met) SK-MEL-5	15.1
Kidney	5.8	Adipose	11.0

Table D4. Panel 4D

Tissue Name	Rel. Exp.(%) Ag3021, Run 164528127	Tissue Name	Rel. Exp.(%) Ag3021, Run 164528127
Secondary Th1 act	15.1	HUVEC IL-1beta	11.1

Secondary Th2 act	16.5	HUVEC IFN gamma	20.0
Secondary Tr1 act	15.5	HUVEC TNF alpha + IFN gamma	25.9
Secondary Th1 rest	4.5	HUVEC TNF alpha + IL4	22.2
Secondary Th2 rest	8.2	HUVEC IL-11	18.3
Secondary Tr1 rest	7.6	Lung Microvascular EC none	24.3
Primary Th1 act	6.6	Lung Microvascular EC TNFalpha + IL-1beta	27.7
Primary Th2 act	10.1	Microvascular Dermal EC none	33.2
Primary Tr1 act	15.6	Microvascular Dermal EC TNFalpha + IL-1beta	27.7
Primary Th1 rest	34.4	Bronchial epithelium TNFalpha + IL1beta	16.4
Primary Th2 rest	14.3	Small airway epithelium none	8.4
Primary Tr1 rest	7.1	Small airway epithelium TNFalpha + IL-1beta	100.0
CD45RA CD4 lymphocyte act	4.4	Coronery artery SMC rest	10.4
CD45RO CD4 lymphocyte act	16.3	Coronery artery SMC TNFalpha + IL-1beta	4.9
CD8 lymphocyte act	9.0	Astrocytes rest	8.7
Secondary CD8 lymphocyte rest	15.4	Astrocytes TNFalpha + IL-1beta	13.3
Secondary CD8 lymphocyte act	6.7	KU-812 (Basophil) rest	3.9
CD4 lymphocyte none	6.4	KU-812 (Basophil) PMA/ionomycin	19.8
2ry Th1/Th2/Tr1_anti-CD95 CH11	11.6	CCD1106 (Keratinocytes) none	6.8
LAK cells rest	18.2	CCD1106 (Keratinocytes) TNFalpha + IL-1beta	4.6
LAK cells IL-2	16.6	Liver cirrhosis	3.1
LAK cells IL-2+IL-12	11.7	Lupus kidney	3.0
LAK cells IL-2+IFN gamma	25.9	NCI-H292 none	7.1
LAK cells IL-2+ IL-18	18.3	NCI-H292 IL-4	7.2
LAK cells PMA/ionomycin	8.8	NCI-H292 IL-9	8.8

NK Cells IL-2 rest	12.2	NCI-H292 IL-13	5.0
Two Way MLR 3 day	15.4	NCI-H292 IFN gamma	4.0
Two Way MLR 5 day	11.8	HPAEC none	20.2
Two Way MLR 7 day	8.3	HPAEC TNF alpha + IL-1 beta	27.2
PBMC rest	7.1	Lung fibroblast none	4.9
PBMC PWM	55.5	Lung fibroblast TNF alpha + IL-1 beta	4.1
PBMC PHA-L	25.9	Lung fibroblast IL-4	19.1
Ramos (B cell) none	9.9	Lung fibroblast IL-9	12.5
Ramos (B cell) ionomycin	33.4	Lung fibroblast IL-13	12.8
B lymphocytes PWM	38.7	Lung fibroblast IFN gamma	28.7
B lymphocytes CD40L and IL-4	15.0	Dermal fibroblast CCD1070 rest	16.4
EOL-1 dbcAMP	5.8	Dermal fibroblast CCD1070 TNF alpha	37.9
EOL-1 dbcAMP PMA/ionomycin	17.0	Dermal fibroblast CCD1070 IL-1 beta	6.2
Dendritic cells none	26.8	Dermal fibroblast IFN gamma	14.8
Dendritic cells LPS	16.2	Dermal fibroblast IL-4	29.1
Dendritic cells anti-CD40	21.8	IBD Colitis 2	0.5
Monocytes rest	30.8	IBD Crohn's	1.4
Monocytes LPS	24.1	Colon	23.5
Macrophages rest	35.1	Lung	14.8
Macrophages LPS	23.0	Thymus	19.6
HUVEC none	27.9	Kidney	33.0
HUVEC starved	40.1		

CNS_neurodegeneration_v1.0 Summary: [Ag3021](#) This panel confirms the expression of the CG56787-01 gene at low levels in the brain in an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer's diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.3D for a discussion of the potential utility of this gene in treatment of central nervous system disorders.

Panel 1.3D Summary: [Ag3021](#) Expression of the CG56787-01 gene is highest in a sample derived from ovarian cancer cell line OVCAR-5 (CT = 30). In addition, there is

substantial expression of this gene associated with other ovarian cancer cell lines as well as a breast cancer cell line. Thus, the expression of this gene could be used to distinguish OVCAR-5 cells from other samples in the panel. Moreover, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or

5 antibodies, might be beneficial for the treatment of ovarian or breast cancer.

This gene is expressed at low levels in all regions of the CNS examined, including amygdala, cerebellum, hippocampus, substantia nigra, cerebral cortex, thalamus and spinal cord. This gene encodes a protein with homology to dual-specificity phosphatases. Dual-specificity phosphatases comprise a family of MAP kinase-regulating enzymes that are upregulated in brains subjected to insults such as ischemia and seizure activity. MAP kinases are known to regulate neurotrophic and neurotoxic pathways. Consequently, agents that modulate the activity of CG56787-01 may have utility in attenuating the apoptotic and neurodegenerative processes following brain insults.

This gene is also expressed at low levels (CTs = 33-34) in pancreas, thyroid, pituitary gland, adult and fetal heart, adult and fetal skeletal muscle, and adipose. Thus, this novel protein phosphatase may be a target for small molecule drugs in the treatment of metabolic and endocrine diseases, including obesity and diabetes.

References:

1. Wiessner C. The dual specificity phosphatase PAC-1 is transcriptionally induced in the rat brain following transient forebrain ischemia. *Brain Res Mol Brain Res* 1995 Feb;28(2):353-6

PAC-1 mRNA has previously been found only in activated T-cells in vitro and in vivo. The gene encodes a dual specificity protein phosphatase that regulates MAP kinase activity. Here, I describe that PAC-1 mRNA is induced also in neurons in the rat brain following 30 min of forebrain ischemia. At 6, 12 and 24 h after ischemia, PAC-1 mRNA was found most prominently 25 in hippocampal cells which are resistant to 30 min of forebrain ischemia, but not in the selectively vulnerable CA1 sector. At later time points and in control animals no PAC-1 mRNA could be detected in any brain region. The protein-tyrosine/threonine phosphatase PAC-1, therefore, may be involved in adaptational responses of hippocampal cells resistant to ischemic injury.

2. Boschert U, Muda M, Camps M, Dickinson R, Arkinstall S. Induction of the dual specificity phosphatase PAC1 in rat brain following seizure activity. *Neuroreport* 1997 Sep 29;8(14):3077-80

Recurrent seizure activity leads to delayed neuronal death as well as to inflammatory responses involving microglia in hippocampal subfields CA1, CA3 and CA4. Since mitogen activated protein (MAP) kinases control neuronal apoptosis and trigger generation of inflammatory cytokines, their activation state could determine seizure-related brain damage. PAC1 is a dual specificity protein phosphatase inactivating MAP kinases which we have found to be undetectable in normal brain. Despite this, kainic acid-induced seizure activity lead to rapid (approximately 3 h) but transient appearance of PAC1 mRNA in granule cells of the dentate gyrus as well as in pyramidal CA1 neurons. This pattern changed with time and after 2-3 days PAC1 was induced in dying CA1 and CA3 neurons. At this time PAC1 mRNA was also expressed in white matter microglia as well as in microglia invading the damaged hippocampus. PAC1 may play an important role controlling MAP kinase involvement in both neuronal death and neuroinflammation following excitotoxic damage.

3. Muda M, Boschert U, Dickinson R, Martinou JC, Martinou I, Camps M, Schlegel W, Arkinstall S. MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. *J Biol Chem* 1996 Feb 23;271(8):4319-26

MKP-1 (also known as CL100, 3CH134, Erp, and hVH-1) exemplifies a class of dual-specificity phosphatase able to reverse the activation of mitogen-activated protein (MAP) kinase family members by dephosphorylating critical tyrosine and threonine residues. We now report the cloning of MKP-3, a novel protein phosphatase that also suppresses MAP kinase activation state. The deduced amino acid sequence of MKP-3 is 36% identical to MKP-1 and contains the characteristic extended active-site sequence motif VXVHCXXGXSRSXTXXXAYLM (where X is any amino acid) as well as two N-terminal CH2 domains displaying homology to the cell cycle regulator Cdc25 phosphatase. When expressed in COS-7 cells, MKP-3 blocks both the phosphorylation and enzymatic activation of ERK2 by mitogens. Northern analysis reveals a single mRNA species of 2.7 kilobases with an expression pattern distinct from other dual-specificity phosphatases. MKP-3 is expressed in lung, heart, brain, and kidney, but not

significantly in skeletal muscle or testis. *In situ* hybridization studies of MKP-3 in brain reveal enrichment within the CA1, CA3, and CA4 layers of the hippocampus.

Panel 4D Summary: Ag3021 The CG56787-01 gene is expressed at low to moderate levels in all tissues examined except IBD colitis and Crohn's. This gene encodes a putative dual specificity phosphatase that may be important in maintaining normal cellular homeostasis in a wide range of tissues. Therapies designed with the protein encoded for by this transcript could be important in the treatment of diseases, such as IBD and Crohn's disease that show reduce the expression of this transcript.

OTHER EMBODIMENTS

Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims.